

Sheet 1 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY: DOCKET NO. 10165-042-999

APPLICATION NO. 10/573,905

APPLICANT

Coleman et al.

FILING DATE
May 30, 2006

ART UNIT 1647

*EXAMINER					PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
INITIAL	A01	4,343,782	8/10/982	NAME Shapiro	FIGURES APPEAR
	A01	4,377,513	03/22/83	Sugimoto et al.	-
	A02	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	-
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
- 2. .	A10	5,292,654	3/08/94	Yoshimura	
	All	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin .	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	A21	5,696,080	12/09/97	O' Brien	
	A22	5,700,909	12/23/97	O'Brien	
	A23	5,714,459	02/03/98	O'Brien	
	A24	5,750,376	5/12/98	Weiss et al.	
	A25	5,756,349	05/26/98	Lin	
	A26	5,763,198	6/09/98	Hirth et al	
	A27	5,767,078	06/16/98	Johnson et al.	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 2 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT Coleman et al.

FILING DATE ART UNIT May 30, 2006 1647

*EXAMINER					PAGES, COLUMNS, LINES, WHERE
INITIAL		DOCUMENT NUMBER	DATE	NAME	RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A28	5,773,569	06/30/98	Wrighton et al.	
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	A46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
· · ·	A48	6,531,121	3/11/03	Brines et al.	
	A49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
 	A51	7,214,532	5/08/07	Stern et al.	
	A52	7,309,687	12/18/07	Brines et al.	
	A53	7,345,019	3/18/08	Brines et al.	
	A54	2002/0031806	3/14/02	Lee	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 3 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10/573,905 APPLICANT Coleman et al.

*EXAMINER					PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
INITIAL	1.55	DOCUMENT NUMBER 2002/0052309	5/02/02	NAME Anagnostou et al.	FIGURES APPEAR
	A55			Nielsen et al.	
	A56	2002/0061849	5/23/02	1	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	A72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
· · · ·	A74	2004/0009902	1/15/04	Boime	
	A75	2004/0018978	1/29/04	Campana et al.	
	A76	2004/0091961	5/13/04	Evans et al.	
	A77	2004/0096447	5/20/04	Yasuda et al.	
	A78	2004/0122216	6/24/04	Nielsen et al.	
	A79	2004/0209812	10/21/04	Farrell et al.	
	A80	2004/0214236	10/28/04	Brines et al.	
	A80	2005/0176627	8/11/05	Cerami et al.	

EXAMINER NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO. 10/573,905		
10165-042-999			
APPLICANT			
Coleman et al.			
FILING DATE	ART UNIT		
May 30, 2006	1647		

	U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	
-	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
-	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	-

	FOREIGN PATENT DOCUMENTS						
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	Т		
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh				
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)				
В03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.				
B04	EP 0640619	1/03/95	Amgen Inc.				
B05	EP 0668 351	8/23/95	Amgen, Inc.				
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG	-			
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)				
. B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)				

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER,			PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
		KIND CODE (IF KNOWN)	DATE	NAME	RELEVANT FIGURES APPEAR	L
	B09	WO 00/032772	6/8/00	Eli Lilly & Co.		
	B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		
	B11	WO 00/24893	5/4/00	Amgen, Inc.		
	B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)		
	B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		
	B14	WO 01/81405	1/11/01	Amgen Inc.		
	B15	WO 01/82952	11/08/01	Action Pharma APS		T
	B16	WO 01/82953	11/08/01	Action Pharma APS		
	B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		T
	B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		T
	B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		Τ
	B20	WO 02/14356	2/21/02	Althoff, Claudia		
	B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		
	B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		
	B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
	B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
	B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		T
	B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
	B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		
	B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		1
	B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		T
***************************************	B32	WO 06/002646	1/12/06	Lundbeck A/S		1
	B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		Ť

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 6 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

			FOREIG	N PATENT DOCUMENTS		
		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	т
	B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S		
	B35	WO 91/05867	5/02/91	Amgen Inc.		
	B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		
	B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		
	B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		
	B39	WO 95/05465	02/23/95	Amgen, Inc.		Γ
	B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		
	B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.	,	T
	B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		
	B43	WO 97/32895	9/12/97	Regents of the University of California		
	B44	WO 98/10650	3/19/98	East Carolina University		
	B45	WO 98/18926	05/07/98	G.D. Searle & Co.		
•	B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
	B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		
	B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		T
	B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		T
	B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		T
	B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		
	B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		
	B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		T
	B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		T
	B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		
	B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		1

EXAMINER	
NYI-4088719v3)

Sheet 7 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999	APPLICATION NO.		
APPLICANT	10/573,905		
Coleman et al.			
FILING DATE	ART UNIT		
May 30, 2006	1647		

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
nitials	<u> </u>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of	
		claims, and Ehrenreich clean copy of claims (10/02/06)	<u> </u>
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	
		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	
		alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	
		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	ļ
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	
		Natl. Acad. Sci. USA 91:3974-3978	↓
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	
		for Bioassay," Bull. Org. mond. Sante, 47:99-112.	_
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	
		der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	<u> </u>
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	
		Glycoproteins," Meth. Enzymol., 50:287-291.	╀-
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	
		Cerebrovascular Disease, Vol. 9:131-135	_
	C11	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	
		premature rabbits," Pediatric Res., Vol. 40(3):381-387	↓_
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	
	_	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	+
	C13	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	1
	_	Cell. Biol. 14(10):6506-6514	1
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	
	<u> </u>	function relationships," J. Biol. Chem. 272(8):4985-4992	-
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	
		murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	╄
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	
		traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	╁-
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	
		12.	+
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
	1	prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
		Commun. 164(2):788-795	1_
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
		artery occulsion in rats," Brain Research, Vol. 739:88-96	1_
	C20	BENIT et al., 1993, "The 'WS motif common to v-mpl and members of the cytokine receptor superfamily is	
		dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	\perp

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 8 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905				
APPLICANT Coleman et al.					
FILING DATE May 30, 2006	ART UNIT				

		NON PATENT LITERATURE DOCUMENTS	
Examiner (CANITAL LETTERS) Title Date Date of the Canital Letters of		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
Initials	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	1
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 9 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	<u> </u>		T.
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	17
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With	
		Erythrocytosis," Blood, 81(6):1593-1597.	4
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat	
		model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding	
		to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci.,	Ι
		149:40-45.	1
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-	Τ
	"	241	
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	丁
			+
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure:	
		angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	+
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through	
		separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	4
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res,	1
		Vol. 81, pp. 29-42	┵
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil.,	1
		65:370-374.	_
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a	
		Reduced Pressure," Nature, 191:1065-1067.	
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante,	
		35:751-760.	
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of	Т
		Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-	Т
		scanning mutagenesis," Science, Vol. 244:1081-1085	İ
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the	1
	057	mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	-
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors:	┪
	033	insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by	十
	C30	expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest.	
		102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the	+
	(2)	cell surface," Nature, Vol. 415, pp. 175-179	1
		DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and	+
	C58	neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	 	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.	+
	C59		
		86(3):681-687	\perp

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 10 of 26 of List of References

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
FILING DATE	ART UNIT			
May 30, 2006	1647			

		NON PATENT LITERATURE DOCUMENTS		
Examiner				
nitials	ļ	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation	1	
		to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem.		
		Vol. 10(1):32-7	+	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist,		
	 	Vol. 3:314-318 DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the	┿	
	C62	tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277		
	 	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's	╁	
	C63			
	 	disease," Pharm. Res. 15(3):386-98 STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley &	╄	
	C64	Sons, p. 122, p. 508	1	
	+	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple	+-	
	C65	sclerosis," Brain, Vol. 128, pp. 375-385	-	
	-	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and	+	
	C66	platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360		
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the	t	
	C67	mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	ı	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant	╁	
	C08	erythropoietin treatment", ASAIO J. 38:M477-M480		
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation:	\dagger	
	109	prelude to apoptosis. Cardiovasc Res. 43(4): 947-957		
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global	1	
	1070	ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78		
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	T	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	+	
	- C/2		1	
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New		
		York, 1993	4	
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion,		
		and Biological Function," J. Biol. Chem., 263(33):17516-17521.	+	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance,"		
		Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55 EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP),"	+	
	C76			
		Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13 EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med.	+	
	C77			
		8(8):495-505 EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular	+	
	C78	Psychiatry, 9:42-54		
		EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	+	
	C79			
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	T	
			1	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 11 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.				
10165-042-999	10/573,905				
APPLICANT					
Coleman et al.					
FILING DATE	ART UNIT				
	· ·				
May 30, 2006	1647				

		NON PATENT LITERATURE DOCUMENTS	
Examiner	<u> </u>		T
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury,"	
		Transplantation Proceedings, Vol. 36, pp. 2935-2938	╀-
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective	
		activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	_
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury,"	ı
		www.molmed.org. July 2006	4
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by	
	000	severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd	T
	1007	Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	İ
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine,	T
	1 600	path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007,	T
	(6)	http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	+-
	1 0 90	Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl	+-
	(5)	tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology	\dagger
	C92	and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but	十
	C93	how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY	+
	C94	1983	1
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics	+
	(693	across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal	+
	C96	of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and	+
	(097	erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of	╁
	C98	Carbohydrates," Blood, 73(1):84-89.	-
-	G00	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal	╁
	C99	transduction," Semin. Immunol. 2:119-128	
	6:00	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol.	+
	C100	269(10):7224-7230	
	716:	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	+-
	C101	OARCIA et al., 1990, Ischemic shoke and incomplete illiarction, Shoke, vol. 27(4):701-703	ŀ

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 12 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
EH DIC DATE	ADTUNET
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T -	(finally name of the makes (in CARITAL LETTERS) Title Date Restinant Pages Etc.)	Т
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	+-
	C102		
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	┿
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	Ϊ
		Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,	
		Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	
		Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97(2):315-	
		323.	L
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	
		neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental	
		spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in	
		rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	C111	CDETAL 1000 "Cl. add at 1 (7 dags) in a data days and a Dagingham and bird and days and	
	0	clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	Τ
	"	therapy. J Sleep Res. 4(S1): 130-134	1
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating	Τ
	0.13	bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	Τ
		Kidney Intl. 38:480-486	1
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal	Ī
	0113	degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	CROTTOLOGO AND CONTROL OF THE CONTRO	Т
	0110	1592:215-223	1
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	T
	0117	antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	T
	0.110	granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119		T
	10117	Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	T
	10120	receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	\dagger
	1 (121	Bioengineering, Vol. 16:1069-1079	1
	C122	TIANOTHI A L COCO MA L L L LLL L L L L L L L L L L L L L	+
	C122		⊥

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 13 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

	1					
ATTY. DOCKET NO.	APPLICATION NO.					
10165-042-999	10/573,905					
APPLICANT						
Coleman et al.						
FILING DATE	ART UNIT					
May 30, 2006	1647					

		NON PATENT LITERATURE DOCUMENTS	
Examiner (1.1 Language Color of the Color of the Date Post of the Date Pos			
Initials	 	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	T
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209	
	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	111 000 1 11 000 1 10 1 1 1 1 1 1 1 1 1	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	<u> </u>
***	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	Γ
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	T
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	ľ
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	Γ
	C133	THE PROPERTY OF THE PROPERTY O	T
	C134	THE ALTERNATION OF THE PROPERTY OF THE PROPERT	
	C135	DAAL LI 1000 (DI C. I. L. I.	Ī
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients, "Nephron, Vol. 72, pp. 30-36	T
	C137		T
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	11110 1 1000 (10 1 1)	
	C140	10) 150 - 1 1000 411 - 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	T

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 14 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.					
10165-042-999	10/573,905					
APPLICANT						
Coleman et al.						
FILING DATE	ART UNIT					
May 30, 2006	1647					

NON PATENT LITERATURE DOCUMENTS			
Examiner		(1.1.) (1. (1. (1. (1. (1. (1. (1. (1. (1. (1.	T_{x}
nitials	 	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	
	 -		╫
,	C142	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paraoxonase active site," Chem Biol Interact, Vol. 119-120:79-84	
	C143	JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis," Chem Biol Interact, Vol. 119-120:71-78	
		JUBINSKY et al., 1996, "The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-	+
	C144	CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence	
		proliferation and beta-globin mRNA expression," Mol. Med. 2(6):766-773	┸
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor," Blood 90(5):1867-1873	
	C146	TIDUE - 1 0000 //D -1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	\top
	C146	injury", Proc. Natl. Acad. Sci. USA 99(16):10659-10664	
	C147	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous	1
	10147	system", Pediatr. Res. 43(1):40-49	
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	1
	6110	fetus", Early Human Devel. 52(3):235-249	
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	Т
		sheep", Soc. for Neuroscience Abstracts 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San	
	<u> </u>	Diego, CA Nov. 10-15, 2001)	\perp
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	
		damage," Acta Paediatr. Supp. Vol. 438, pp. 36-42	\perp
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate	
	<u> </u>	of avidin and a monoclonal antibody to the transferrin receptor," Drug Metab Dispos. Vol. 22(1):99-105	╀
	C152	KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin," Glycobiology, Vol. 11(12):1043-1049	
		KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	+-
	C153	therapy of heart failure-induced mitral regurgitation. Circulation 108:1795-1797	
	0154	WEIGHT BY 1000 (F. d. B. d. St. A. B. d. St.	+
	C154	York Acad. Sci., 149:18-24.	
	C155	TATIONNA MILL I COOL WALL I I I I I I I I I I I I I I I I I I	+
	(133	Ann. Neurol. Vol. 56(6):815-826	
-	C156	MIDITO A LAGOR WILL SEE ALL CALLS AND ALL CA	
	0130	activation," Blood 99(1):102-110	
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	T
		Am J Anat. Vol. 178:241-9.	\perp
	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant erythropoietin and cepharanthin in a girl	
		with refractory anemia," Japanese J. Clin. Hematology, Vol. 35(7):694-6988 (w/English abstract)	\perp
	C159	KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1," Blood, Vol 73(2):375-80	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 15 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.				
10165-042-999	10/573,905				
APPLICANT					
Coleman et al.					
FILING DATE	ART UNIT				
May 30, 2006	1647				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
muais	C160	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96(5):826-828.	Ė
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons <i>in vitro</i> and <i>in vivo</i> ", Brain Res. 609:29-35	
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31(4):601-608	
	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A. 95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol. 305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol. 93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation <i>in vitro</i> ," Exp. Hematol. 32:36-44	
	C172	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40(3):376-380	
	C173	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	C174	http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	C175	glycans," Anal. Biochem. 219:207-217	
	C176	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
·	C179	1.11. 1.100. (MT	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 16 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905
APPLICANT Coleman et al.	
FILING DATE May 30, 2006	ART UNIT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C180	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182		
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	10.2+ 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C188	14.001. 1.4001. 11.001.	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
-	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	14. (2004)	
	C197		
	C198	1,000,000,000,000,000,000,000,000,000,0	
	C199	1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to	T
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	T

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 17 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

NO.				
5				
Coleman et al.				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin	
	C202	on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465 MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	314774341794 (1 1000 WDL) (11 1 C) (1 1 1 C) (1 1 C) (1 1 C)	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
.,,	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218		
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOCHOLI - 1 1001 (CI : CI I - I :: :	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 18 of 26 of List of References

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT May 30, 2006 1647

	NON PATENT LITERATURE DOCUMENTS		
Examiner			
Initials	-	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	
		OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid	1
	chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11		
	C223 OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestio		—
57:328-332			
		ON-LINE MEDICAL DICTIONARY Lysozyme entry; website http://cancerweb.ncl.ac.uk/omd . Published at	1
		the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB	
		Project.	
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the	
		rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the	
		rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development	
factor or thrombopoietin," Cytokine 8(1):66-69			ļ
C228 PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through			
 		introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	
C229 PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through t			
barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60		D 111 WW 1000 "CNG 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	┼
C230 Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." Vol. 70:1781-92.			
D. D. D. D. D. C.		PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	+-
0231			ļ
C232 PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by			
recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699			-
	C233		
		carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635 PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major	_
	C234	histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta	
	'	2m," Eur. J. Immunol. 25:1609-16	
	0225	DEDUCE A LOOSE WILD CITED AND A LANGE TO A LOCAL DISTRICT AND A LOCAL DI	+
		oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-	
		773	
	C236		1
	C230	11(4):974-980	1
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral	1
	2257	infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol.	
		260(5 Pt 2): H1406-1414	
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525	
		and 2125-2131	

Sheet 19 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ΑT	TTY. DOCKET NO.	APPLICATION NO.				
10	0165-042-999	10/573,905				
AI	APPLICANT					
C	oleman et al.					
FI	LING DATE	ART UNIT				
	4 20 2006	1647				
1 10	1av 30. 2006	1 104 /				

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Π
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C240	PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company, Montvale, NJ), pp.1765-1769	
C241 PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid horn			
C242 PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Chem. 246(4):939-45			
C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers"		PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8			
C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Sc 283:990-993			
C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunoger conformation," J. Biol. Chem. 250(18):7435-42			
C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endoth		ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
	C252	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistr 67(8):1442-1452			
with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32		with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	Natl. Acad. Sci. USA 95:4635-4640	
	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 20 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

Case Case	
C259 SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-2 C260 SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", 74(1):103-109 C261 SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) or prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100 C262 SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift fur Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only) C263 SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with rece erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 C264 SHIKAMA et al., 1996, "Gonstitutively activated chimeric cytokine receptor confers factor-independe growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma vivo and in vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 2968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 S1REN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone ma Ultrastruct Res. Vol. 88(1):18-29 S7PAK et al., 1960, "Reactions of the Cyanate Present i	
ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27- C260 SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythropoietin (PHU-EPO) of Tyti) 103-109 C261 SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (PHU-EPO) of prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100 C262 SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift fur Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only) C263 SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with rece erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 C264 SHIRAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independe growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIEN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone ma Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteir Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification o	T
C260 SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", 74(1):103-109 C261 SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) of prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100 C262 SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift fur Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only) C263 SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with rece erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 C264 SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independe growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone ma Ultrastruct Res. Vol. 88(1):18-29 S7PIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo 73:90-99. S7PIVAK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 S7TARK, 19	
 C261 SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) of revented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100 C262 SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift fur Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only) C263 SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with rece erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 C264 SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independe growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIREN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone ma Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo 73:90-99. C272 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C273 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: G	
prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100 C263 SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift für Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only) C263 SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with rece erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 C264 SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independe growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 3168, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines," J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone ma Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteir Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma ar Inflammation, pp. 897-898, 1865-1866 C375	
Neonatologie (202)(2), pp 64-68 (Abstract Only) C263 SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with rece erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 C264 SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independe growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines," J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone ma Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteir Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma ar Inflammation, pp. 897-898, 1865-1866 C275 STECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Re	ı be
C263 SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with rece erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 C264 SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independe growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone ma Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma an Inflammation, pp. 897-898, 1865-1866 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with rece erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 C264 SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independe growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone ma Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma ar Inflammation, pp. 897-898, 1865-1868 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	hain
C264 SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independe growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic seproc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone may Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blomator of Stark et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
growth in hematopoietic cell lines," Blood 88(2):455-464 C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma (Vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic sproc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone matultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo. 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
C265 SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic seproc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone matabolic seproce. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo. 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866 C275 STECCE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
Vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic seproc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone may complete the complex of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	elle in
C266 SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46- C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic seproc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone made Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo. 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma ar Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	,115 III
C268 SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic sproc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone matultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo. 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma ar Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	3.
dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone mate Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blog 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
C269 SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic s Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone may Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blor 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma ar Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone many Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blom 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	ess",
 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blo 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma ar Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: 	ow," J
 C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Protein Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma ar Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: 	i,
C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma ar Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	"J.
Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
Natl. Acad. Sci. U. S. A. 99(22):13972-4 C276 STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
	roc.
Collaborative Study of Four Decombinant DNA derived Emythropoieting and Two Highly Durified Hum	
Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
C277 STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions	a
Biological Properties," British J. Haematology, 100:79-89.	
C278 STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," Euro of Clinical Investigation, Vol. 35, pp. 711-717	an J.

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 21 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

	ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999		10/573,905
APPLICANT		
	Coleman et al.	
	Colonian of an	
	FILING DATE	ARTUNIT
	May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Ι_
Initials	ļ	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C279	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral	1
	blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216		╄
C280 SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and			1
		Erythrocytosis," British J. Haematology, 113:49-51.	<u> </u>
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol.	İ
		73:1525-1535	_
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor	\vdash
	C283	orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by	1
	1 0204	inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in	1
	10283	vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	1
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol.	†
	C280	81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood	t
	C287	flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on	+
	C200	chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	1
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys.	\top
	1 0209	Res. Commun. 148(1):443-448	
	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis,"	╁
	C290	Press Medicale, Vol. 31(11):505-514 (Abstract only)	
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats	╁
	(291	with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
•	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced	+
	C292	anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- β Immunoreactivity and microglia are enhanced in the rat hippocampus	+-
	(293	by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol	
		19(12):5054-65	ł
 -		VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures	+
	C294	but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological	
assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63			1
		VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone	╁
	C295	morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	9201	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	╁
	C296		\perp
· · · · · · · · · · · · · · · · · · ·	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins,"	1
		Blut, 44:173-175.	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	

EXAMINER NYI-4088719v2	DATE CONSIDERED

Sheet 22 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
FILING DATE	ART UNIT			
FILING DATE	AKTONII			
May 30, 2006	1647			

NON PATENT LITERATURE DOCUMENTS				
Examiner		(1 - 1 - 1 - 1 - CADITAL LETTERS) Tide Day Bering Born Eq.	T_	
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	T	
	C299		lacksquare	
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin		
		receptors", Kidney Intl. 55:808-820	-	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol.		
-		23, pp. 61-70 WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	+	
	C302		<u> </u>	
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling,"		
		Semin. Immunol. 5(5):337-344		
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30		
	C205	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and	╁╌	
	C305	infarction," Circulation 85 Suppl. 1:1-32-1-42		
	C306	WOLGUONGUL LOVOLVE 1000 (P) C LV LV LV LV LV LV LV LV LV LV LV LV LV	T	
	0300	utility as receptor ligands," Blood, Vol. 74(3):952-958		
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and		
		cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	L	
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs,"		
		Thromb. Haemost. 78:1505-1509	1	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous		
		injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83		
	6210	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	+	
	C310			
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J.	1	
		Clin Invest. Vol. 101(5):1184-1194	-	
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500		
		YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and	╁	
	C313	interleukin-2 receptor," EMBO J. 11(13):4909-4915		
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion	+	
	C314	in rats," Stroke, Vol. 25(8):1658-1665		
	C315	14. NO. 1 2002 (FCC + C + 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1	
		Biotechnol. Prog. 18:129-38		
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with		
		erythropoietin," Blood 82(6):1713-1719	\perp	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds		
	_	to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	_	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines		
		through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	+	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	1	

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 23 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Oncologist 1(5):337-339	Т	
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7		
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51		
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7		
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002		
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002		
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002		
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003		
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003		
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	\top	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	1	
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	T	
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	Ţ-	
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	T	
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	T	
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	\top	
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004		
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004		
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	1	
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	\dagger	
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	T	
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	\top	
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	\dagger	
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	\top	
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003		
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	+	
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	+	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647
	10165-042-999 APPLICANT Coleman et al.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
imuais	C346	Office Action, Application No. 09/716,963, date mailed: March 18, 2005	
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
·	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
•••	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	-
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 25 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
IIIItiais	C374	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	
*	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	
	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

EXAMINER
NY1-4088719v2

DATE CONSIDERED

Sheet 26 of 26 of List of References

1647

APPLICATION NO.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912	
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008	

EXAMINER NYI-4088719v2

Sheet 1 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT May 30, 2006 1647

JUL 2 9 2008

U.S. PATENT DOCUMENTS

*EXAMINER	SK.				PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
INITIAL		DOCUMENT NUMBER	DATE	NAME	FIGURES APPEAR
	A01	4,343,782	8/10/982	Shapiro	
	A02	4,377,513	03/22/83	Sugimoto et al.	
•	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	A11	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	· ·
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	A21	5,696,080	12/09/97	O' Brien	
	A22	5,700,909	12/23/97	O'Brien	
	A23	5,714,459	02/03/98	O'Brien	
	A24	5,750,376	5/12/98	Weiss et al.	
	A25	5,756,349	05/26/98	Lin	
	A26	5,763,198	6/09/98	Hirth et al	
	A27	5,767,078	06/16/98	Johnson et al.	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 2 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET NO. 10165-042-999 APPLICATION NO. 10/573,905

APPLICANT

(Use several sheets if necessary)

Coleman et al.

FILING DATE May 30, 2006 ART UNIT

1647

			U.S. P .	ATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INITIAL	A28	5,773,569	06/30/98	Wrighton et al.	HOURES ATTEAN
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
· · · · · · · · · · · · · · · · · · ·	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	A46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
······································	A48	6,531,121	3/11/03	Brines et al.	
	A49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
·	A51	7,214,532	5/08/07	Stern et al.	
	A52	7,309,687	12/18/07	Brines et al.	
	A53	7,345,019	3/18/08	Brines et al.	
	A54	2002/0031806	3/14/02	Lee	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 26 of List of References

LIST OF	REFERENCES	CITED BY	APPLICANT
	TELL ETTEL TODO	ULLED DI	THE DICTION

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

			U.S. P.	ATENT DOCUMENTS	
*EXAMINER		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
INITIAL	A55	DOCUMENT NUMBER 2002/0052309	5/02/02	NAME Anagnostou et al.	FIGURES APPEAR
	A56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
-	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
<u> </u>	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
•	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	A72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	A74	2004/0009902	1/15/04	Boime	
	A75	2004/0018978	1/29/04	Campana et al.	
	A76	2004/0091961	5/13/04	Evans et al.	
. .	A77	2004/0096447	5/20/04	Yasuda et al.	
··	A78	2004/0122216	6/24/04	Nielsen et al.	
	A79	2004/0209812	10/21/04	Farrell et al.	
	A80	2004/0214236	10/28/04	Brines et al.	
	A81	2005/0176627	8/11/05	Cerami et al.	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.	
10165-042-999	10/573,905	
APPLICANT		
Coleman et al.		
	· · · · · · · · · · · · · · · · · · ·	
FILING DATE	ART UNIT	
May 30, 2006	1647	

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	i.
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER,			PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
	KIND CODE (IF KNOWN)	DATE	NAME	RELEVANT FIGURES APPEAR	Т
B0	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh		
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		
В0:	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
B0-	EP 0640619	1/03/95	Amgen Inc.		
B0	EP 0668 351	8/23/95	Amgen, Inc.		
B0	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		
В0	7 JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
В0	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

APPLICATION NO.

	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		
	Coleman et al.		

Coleman et al.

FILING DATE ART UNIT
May 30, 2006 1647

COREIGN PATENT DOCUMENTS

ATTY. DOCKET NO.

		FOREIGI	N PATENT DOCUMENTS	
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME .	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
 B09	WO 00/032772	6/8/00	Eli Lilly & Co.	
 B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories	
 B11	WO 00/24893	5/4/00	Amgen, Inc.	
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)	
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG	
B14	WO 01/81405	1/11/01	Amgen Inc.	
B15	WO 01/82952	11/08/01	Action Pharma APS	
B16	WO 01/82953	11/08/01	Action Pharma APS	
 B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG	
 B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.	
 B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.	
 B20	WO 02/14356	2/21/02	Althoff, Claudia	
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG	
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG	
 B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.	
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.	
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.	
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.	
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.	
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.	
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B32	WO 06/002646	1/12/06	Lundbeck A/S	
 B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 6 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	- "
Coleman et al.	
FILING DATE	ART UNIT
TIEING DATE	AKI OIIII
May 30, 2006	1647

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	Т
B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S		
 B35	WO 91/05867	5/02/91	Amgen Inc.		
B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		
 B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		
 B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		
 B39	WO 95/05465	02/23/95	Amgen, Inc.		
 B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		
 B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.		
 B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		
B43	WO 97/32895	9/12/97	Regents of the University of California		
 B44	WO 98/10650	3/19/98	East Carolina University		
 B45	WO 98/18926	05/07/98	G.D. Searle & Co.		
B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		
 B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		
 B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		
B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		
 B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		
B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		
 B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		T
 B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		
B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		T
 B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		T

EXAMINER
EXAMINER NYI-4088719v2

Sheet 7 of 26 of List of References

APPLICATION NO.

1647

	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	

ATTY. DOCKET NO.

May 30, 2006

Evenines	1		т
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	lη
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of	Ť
	Cor	claims, and Ehrenreich clean copy of claims (10/02/06)	ı
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	T
	C02	myocardial ischemia," Shock, Vol. 22(1), pp 63-69	
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	t
	C03	experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	十
	104	alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	T
	1003	Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	t
	1 000	Natl. Acad. Sci. USA 91:3974-3978	
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	†
	07	for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	$^{+}$
	100	der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	t
	109	Glycoproteins," Meth. Enzymol., 50:287-291.	ı
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	t
	1010	Cerebrovascular Disease, Vol. 9:131-135	1
	C11	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	T
	1011	premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	T
	1012	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	C13	BARBER et al.,1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	Ť
	1013	Cell. Biol. 14(10):6506-6514	1
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	T
		function relationships," J. Biol. Chem. 272(8):4985-4992	
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	T
	1013	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	T
	0.0	traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	T
	017	12.	İ
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	Ť
	"	prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
		Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	T
	17	artery occulsion in rats," Brain Research, Vol. 739:88-96	
	C20	BENIT et al., 1993, "The 'WS motif common to <i>v-mpl</i> and members of the cytokine receptor superfamily is	T
	C20	dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 8 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647
LIVEAV NO. ZOUO	1 104 /

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		
Initials	<u> </u>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-15993	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	1

l	EXAMINER
l	EXAMINER NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 9 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS			
Examiner					
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T		
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With			
		Erythrocytosis," Blood, 81(6):1593-1597.	\perp		
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat			
	<u> </u>	model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417			
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding			
		to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	<u> </u>		
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci.,			
		149:40-45.			
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-			
		241			
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401			
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure:	1		
	1040	angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325			
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through	1		
	(47	separate endosomes," J Cell Biol. Vol. 114(6):1149-58.			
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res,	+-		
	C40	Vol. 81, pp. 29-42			
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil.,	\top		
	(49	65:370-374.			
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a	+		
	C30	Reduced Pressure," Nature, 191:1065-1067.			
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante,	+		
	CSI	35:751-760.			
	G52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of	╁		
	C52	Erythropoietin, Annals New York Acad. Sci., 149:12-17.			
		CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-	+		
	C53	scanning mutagenesis," Science, Vol. 244:1081-1085			
		CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the	+		
	C54	mouse," Arthritis & Rheumatism, Vol. 52(3):940-950			
	+	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors:	+-		
	C55	insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243			
		D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by	+-		
	C56	expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest.			
		102(11):1951-1960			
	 	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the	+		
	C57	cell surface," Nature, Vol. 415, pp. 175-179			
		DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and	+-		
	C58				
		neuroprotective potential," Biology of the Neonate, 79(304):228-35	+		
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.			
		86(3):681-687	_L.		

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 10 of 26 of List of References

LIST OF	REFERENCES	CITED BY	APPLICANT
LIGI OI	ICLI LICLIACES	CILLD DI	III I DICITIVI

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905	
APPLICANT Coleman et al.		
FILING DATE May 30, 2006	ART UNIT	

		NON PATENT LITERATURE DOCUMENTS		
Examiner (C. CADITAL LETTERS) Tide Date Date See				
Initials	C60	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	T	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318		
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277		
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98		
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508		
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385		
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360		
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720		
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480		
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957		
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78		
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76		
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.		
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993		
-	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.		
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55		
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13		
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505		
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54		
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	1	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	T	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Express Mail No.: <u>EV 654 895 272 US</u>
Express Mail No.: <u>EV 654 895 286 US</u>
Express Mail No.: <u>EV 654 895 290 US</u>
Express Mail No.: <u>EV 654 895 290 US</u>

Sheet 11 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
nitials	 	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> ," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org, July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Coleman et al.		
	FILING DATE May 30, 2006	ART UNIT 1647	

NON PATENT LITERATURE DOCUMENTS			
examiner Capital Capital LETTERS Title Data Portinent Pages Etc.)			
Initials	C102	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	T
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer. Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology, Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97(2):315-323.	
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	C111	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-x _L expression", Blood 94:87-96	
,	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin", Kidney Intl. 38:480-486	
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta. 1592:215-223	
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	†

EXAMINER
EXAMINER NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 13 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

atty. docket no. 10165-042-999	APPLICATION NO. 10/573,905	
APPLICANT Coleman et al.		
FILING DATE May 30, 2006	art unit 1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
		in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209	
······································	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
·	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	194:457-462.	
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients, "Nephron, Vol. 72, pp. 30-36	
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139		
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER	
NYI-4088719v2	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 14 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
14 20 2006	1647
l May 30 2006	1.1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials	_	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following	
	 	delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	╁╌
	C142		
·	-	Chem Biol Interact, Vol. 119-120:79-84 JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino acid residues by	+
	C143		
	+	group-selective labelling and site-directed mutagenesis," Chem Biol Interact, Vol. 119-120:71-78	╁
	C144	JUBINSKY et al., 1996, "The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-	
		CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence	
		proliferation and beta-globin mRNA expression," Mol. Med. 2(6):766-773	+-
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor," Blood 90(5):1867-1873	1
	+	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion	+-
	C146	injury", Proc. Natl. Acad. Sci. USA 99(16):10659-10664	
		JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous	+
	C147	system", Pediatr. Res. 43(1):40-49	
	+		╁
	C148	fetus", Early Human Devel. 52(3):235-249	1
		JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	+
	C149	sheep", Soc. for Neuroscience Abstracts 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San	
	ł	Diego, CA Nov. 10-15, 2001)	
	0150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	+-
	C150	damage," Acta Paediatr. Supp. Vol. 438, pp. 36-42	1
	0151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate	+
	C151	of avidin and a monoclonal antibody to the transferrin receptor," Drug Metab Dispos. Vol. 22(1):99-105	
	01.50	WANGE CARE A L 0001 (60) A L L L C 10 A 13 L L L L L L L L L L L L L L L L L L	╁
	C152	Glycobiology, Vol. 11(12):1043-1049	1
	0152	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	+
	C153	therapy of heart failure-induced mitral regurgitation. Circulation 108:1795-1797	
·	CISA	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New	+
	C154	York Acad. Sci., 149:18-24.	
	0166	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"	╁
	C155	Ann. Neurol. Vol. 56(6):815-826	
***	C156		+
	C136	activation," Blood 99(1):102-110	
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	
	C157	Am J Anat. Vol. 178:241-9.	
	0150	KITAJIMA et al., 1994, "Effective combination therapy by recombinant erythropoietin and cepharanthin in a girl	+
	C158	with refractory anemia," Japanese J. Clin. Hematology, Vol. 35(7):694-6988 (w/English abstract)	
	0150	KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell	+
	C159	line, TF-1," Blood, Vol 73(2):375-80	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 15 of 26 of List of References

ATTY. DOCKET NO. | APPLICATION NO. | 10165-042-999 | 10/573,905 | LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) Coleman et al. | ART UNIT | May 30, 2006 | 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T_
nitials	_	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C160	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis,"	1
		Obstetrics and Gynecology, 96(5):826-828.	┷
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic	1
	ļ	neurons in vitro and in vivo", Brain Res. 609:29-35	1_
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic	
		mechanism.", Behav. Neural Biol. 62:237-243	ļ
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in	
		patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	_
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following	
		neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle	
		cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional	T
	0.00	asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive	T
	10107	and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J.	
		Cardiovasc. Pharmacol. 31(4):601-608	1
	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A.	\top
	100	95:11371-11376	1
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol.	Ť
	103	305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol.	T
	10170	93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid	十
	(1/1	progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	0172	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human	+
	C172	fetuses", Pediatr. Res. 40(3):376-380	
		LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing	+
	C173	various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	1
		LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund,	+
	C174	http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
		1 DIGUEL 1 1004 (/4 1) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	+
	C175		
		glycans," Anal. Biochem. 219:207-217	+
	C176		
		Res. 692:143-153	_
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the	
	_	Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	_
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol.	
		166:159-169	\perp
	C179		
	1	hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 16 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the outbox (in CADITAL LETTERS) Title Date Portions Pages Etc.)	T
nitiais	C180	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	1
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	1.4.000 . 1.1000	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	1
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193		
	C194	14.015.	
,	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	AAA TOTAL TO MARKET AND A STATE OF THE STATE	
	C197	14 CULTURE 1 0004 (CULTURE 1)	
	C198	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C199		
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 17 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Vol. 51:220-222	Т
 .	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
· ·	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 18 of 26 of List of References

1647

APPLICATION NO.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials	ļ	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	<u> 1</u>
	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol.	
		9(1):suppl. 2:12-15	╀
	C222	OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid	
		chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	╁
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion	
		57:328-332	+
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website http://cancerweb.ncl.ac.uk/omd . Published at	
		the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB	
		Project.	+
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the	
	+	rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	╀
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	1
			+
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development	
		factor or thrombopoietin," Cytokine 8(1):66-69	╁
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the	
		introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	╀
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain	1
		barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	╁
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem.	
		Vol. 70:1781-92.	╂
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a	
		recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti-	
		carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major	
		histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta	
		2m," Eur. J. Immunol. 25:1609-16	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked	
	1	oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-	
		773	\perp
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics	
	<u> </u>	11(4):974-980	\perp
	C237		
		infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	\perp
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol.	
		260(5 Pt 2): H1406-1414	\perp
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525	1
		and 2125-2131	1

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 19 of 26 of List of References

1647

APPLICATION NO.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner	<u> </u>		1
Initials	<u> </u>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C240	PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company,	
	<u> </u>	Montvale, NJ), pp.1765-1769	↓_
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone- related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
-	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
	C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8	
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	DOL(4) YOUR WILL A 100 C (VII)	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
	C252	DOGDUNATE AND AND AND AND AND AND AND AND AND AND	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	0.11.11.11.11.11.11.11.11.11.11.11.11.11	
	C258	CATAVE : 1 1000 %Cl : 1 1'C :: C .1 .:: :	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 20 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10/573,905 APPLICANT Coleman et al.

NON PATENT LITERATURE DOCUMENTS			
Examiner		(Include name of the outbox (in CADITAL LETTEDS) Title Date Portinent Dages Etc.)	Т
mittais			<u> </u>
	C259		
C259 SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	ł		
Examiner Initials C259 SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37			
	C2(1		<u> </u>
	C201	prevented by indomethacin. Pathogenetic role of cytosolic calcium." Fur I. Med Res. Vol. 2:97-100	
	C2(2	SCHIISSI FR et al. 1998 "Frythropojetin and obstetrical influences". Zeitschrift für Geburtshilfe und	
	C262		
	C2(2	SCOTT et al. 2000 "Peassessment of interactions between hematopoletic recentors using common beta chain	
	C263	and interleukin-3-specific recentor beta-chain-null cells; no evidence of functional interactions with recentors for	
			
	C264		
	0265	SHIR AMIZU et al. 1994 "Constitutive Secretion of Frythropoietin by Human Renal Adenocarcinoma Cells in	
	C263		1
	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) C259 SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37 C260 SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100 C261 SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100 C262 SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift fur Geburtshilfe und Neonatologic (202)(2), pp. 64-68 (Abstract Only) C263 SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(3):1588-1590 C264 SHIRAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):458-464 C265 SHORE et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256. C266 SHORE et al., 1968, "Quantitative Setimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48. C267 SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 C268 SILVA et al., 1989, "Erythropoietin can induce the expression of Bel-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 C269 SIREN et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol.		
		<u> </u>	
			ļ
	C268		
·			-
	C269		
			-
	C270		
		CRITICAL LANG. (MILLS AV. L. L. L. CR. L. L. L. L. L. L. L. L. R. M. D. L. L. L. L. L. R. M. D. L. L. L. L. L. R. M. D. L. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. R. M. D. L. L. L. L. L. R. M. D. L. L. L. L. L. R. M. D. L. L. L. L. L. R. M. D. L. L. L. L. L. R. M. D. L. L. L. L. L. R. M. D. L. L. L. L. L. L. R. M. D. L. L. L. L. L. L. R. M. D. L. L. L. L. L. L. R. M. D. L. L. L. L. L. L. L. L. R. M. D. L. L. L. L. L. L. R. M. D. L. L. L. L. L. L. R. M. D. L. L. L. L. L. L. L. L. L. L. L. L. L.	┼—
	C271		
-	C272	CT 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	-
Proc. Natl. Acad. Sci. USA 98(7):4044-4049 C270 SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	ļ		
	C273		
		STEDMAN'S MEDICAL DICTIONARY 27th Ed. 2000. Linning Williams, and Wilkins: Trauma and	
	C2/4		
Ultrastruct Res. Vol. 88(1):18-29 C271 SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99. C272 STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181 C273 STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 C274 STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866 C275 STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc.	┼		
	C275		
	C276		t
	C276		
	C277		+
	(2//		
	0050	STURM et al. 2005 "Recombinant human erythronoietin: effects on fratavin expression in vitro" Furancen 1	+
	C278		
		or Chinear investigation, vol. 33, pp. 711-717	

EXAMINER	
NYI-4088719v2	•

DATE CONSIDERED

Sheet 21 of 26 of List of References

APPLICATION NO.

1647

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS		
Examiner				
initials	C279	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral	1	
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.		
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535		
	C282	SWISS ACCESSION No. P32927, October 1, 1993		
	C283	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) C279 SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216 C280 SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51. C281 SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535 C282 SWISS ACCESSION No. P32927, October 1, 1993		
	C284			
	C285	vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252		
	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) C279 SUZUK1 et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1, Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216 C280 SUZUK1 et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51. C281 SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535 C282 SWISS ACCESSION No. P32927, October 1, 1993 C283 SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516 C284 SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly/(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872 C285 TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252 C286 TAKAHASHI. 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402 C287 TEIEN et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738 C289 TOJO et al., 1987, "Identification of erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738 C290 URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale, Vol. 31(11):505-514 (Abstract only) VENA DER MEER et al., 2003, "Darbepoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) p			
	C287			
	C288			
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys.		
	C290			
	C291			
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced		
	C293	VEZANNI et al., 1999, "Interleukin-1- β Immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol 19(12):5054-65		
	C294	but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63		
	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) (279 SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Bert), Vol. 60:207-216 (280 SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51. (281 SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535 (282 SWISS ACCESSION No. P32927, October 1, 1993 (283 SYED et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872 (284 SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872 (285 TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252 (286 TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402 (287 TEIEN et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738 (280 TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738 (280 TEMPLE et al., 1985, "Recombinant erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133 (291 VERNA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator			
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.		
	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)			
C283 SWISS ACCESSION No. P32927, October 1, 1993 C284 SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516 C284 SZABO et al., 1998, "Frotection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872 C285 TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252 C286 TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402 C287 TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268 C288 TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738 C289 TOLO et al., 1987, "Identification of erythropoietin increase of fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448 C290 URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale, Vol. 31(11):595-514 (Abstract only) VAN DER MEER et al., 2003, "Darbepoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133 C292 VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508 C293 VEZANNI et al., 1999, "Interleukin-1-β Immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol 19(12):505-465 C294 VEZANI et al., 1986, "Anticonvulsant drugs effective against h				

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 22 of 26 of List of References

APPLICATION NO.

1647

	10165-042-999	10/573,905
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Coleman et al.	
	FILING DATE	ART UNIT

ATTY. DOCKET NO.

May 30, 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	C200	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) WEN et al. 1994 "Frythropoietin structure-function relationships" Riol Chem. 269(36):22839-22846	Т
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin	-
	(Include name of the author (in CAPITAL LETTERS). Title, Date, Pertinent Pages, Etc.) C299 WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846 C300 WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820 C301 WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70 C302 WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244 C303 WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling, Semin. Immunol. 5(5):337-344 C304 WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequen and assignment to chromosome 19p." Blood 76(1):24-30 C305 WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 11-32-1-42 C306 WOLFOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958 C307 WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485 C308 WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509 C309 WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenou injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83 C310 WU et al., 1999, "Feirnogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194 C312 YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eu	ļ	
	C302		
	C303		
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	infarction," Circulation 85 Suppl. 1:I-32-1-42	
	C306		
	C307		
	C308		
	C309	injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery	
	C310	With the 1 1000 (2) I also the time to the	
1 == 11	C311		
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA",	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms,"	
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines	
	C319		T

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 23 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905
APPLICANT Coleman et al.	
FILING DATE May 30, 2006	ART UNIT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Oncologist 1(5):337-339	Т
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	Г
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	Т
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	T
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	T
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	T
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	T
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	Ť
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	1
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	T
· · ·	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	1
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	\dagger
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	1
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	T
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	T
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	T
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	\dagger
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	\dagger
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	\dagger

EXAMINER	
NYI-4088719v2	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

	NON PATENT LITERATURE DOCUMENTS			
Examiner				
Initials	C346	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Office Action, Application No. 09/716,963, date mailed: March 18, 2005	T	
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005		
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006		
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007		
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002		
-	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	-	
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004		
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004		
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	- "	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006		
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007		
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007		
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007		
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008		
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002		
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002		
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003		
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004		
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004		
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005		
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006		
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006		
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007		
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002		
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002		
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003		
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003		
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 25 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

АТ	TY. DOCKET NO.	APPLICATION NO.
10	0165-042-999	10/573,905
AF	PPLICANT	
C	oleman et al.	
FII	LING DATE	ART UNIT
M	lay 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials	C374	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Office Action, Application No. 09/717,053, date mailed: May 3, 2005	T
	C374	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	
		Office Action, Application No. 09/717,053, date mailed: October 24, 2006	
	C376	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	_
	C377	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	_
	C378	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	ļ <u></u>
	C379	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	_
	C380	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C381		
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	Γ
•	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	T
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	T
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	T
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	\vdash
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	Π

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 26 of 26 of List of References

APPLICATION NO.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al.

10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

ATTY. DOCKET NO.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912		
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008		

EXAMINER NYI-4088719v2

DATE CONSIDERED

Sheet 1 of 26 of List of References

REFERENCES CITED BY APPLICANT Use several sheets if necessary)

JUL 2 9 2008

APPLICATION NO. ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE May 30, 2006

ART UNIT 1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	4,343,782	8/10/982	Shapiro	
	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
· · · · · ·	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	A11	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	A21	5,696,080	12/09/97	O' Brien	
	A22	5,700,909	12/23/97	O'Brien	
	A23	5,714,459	02/03/98	O'Brien	
	A24	5,750,376	5/12/98	Weiss et al.	
	A25	5,756,349	05/26/98	Lin	
	A26	5,763,198	6/09/98	Hirth et al	
	A27	5,767,078	06/16/98	Johnson et al.	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 2 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10/573,905 ART UNIT May 30, 2006

	1				PAGES, COLUMNS, LINES, WHERE
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A28	5,773,569	06/30/98	Wrighton et al.	
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	A46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	A48	6,531,121	3/11/03	Brines et al.	
	A49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
	A51	7,214,532	5/08/07	Stern et al.	
	A52	7,309,687	12/18/07	Brines et al.	
	A53	7,345,019	3/18/08	Brines et al.	
	A54	2002/0031806	3/14/02	Lee	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 3 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

			U.S. P.	ATENT DOCUMENTS	
*EXAMINER			DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
INITIAL	A55	DOCUMENT NUMBER 2002/0052309	5/02/02	NAME Anagnostou et al.	FIGURES APPEAR
	A56	2002/0061849	5/23/02	Nielsen et al.	-
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	·· · · · · · · · · · · · · · · · · · · ·
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	A72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	A74	2004/0009902	1/15/04	Boime	
	A75	2004/0018978	1/29/04	Campana et al.	
	A76	2004/0091961	5/13/04	Evans et al.	
	A77	2004/0096447	5/20/04	Yasuda et al.	
	A78	2004/0122216	6/24/04	Nielsen et al.	
	A79	2004/0209812	10/21/04	Farrell et al.	
	A80	2004/0214236	10/28/04	Brines et al.	
· · · · · ·	A81	2005/0176627	8/11/05	Cerami et al.	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

					PAGES, COLUMNS, LINES, WHERE
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

	FOREIGN PATENT DOCUMENTS					
		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	т
F	301	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh		
E	302	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		
1	B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
E	B04	EP 0640619	1/03/95	Amgen Inc.		
1	B05	EP 0668 351	8/23/95	Amgen, Inc.		
I	B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		
i	B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
I	B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

1	1	
ATTY. DOCKET NO.	APPLICATION NO.	
10165-042-999	10/573,905	
APPLICANT		
Coleman et al.		
FILING DATE	ART UNIT	
May 30, 2006	1647	

	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
B09	WO 00/032772	6/8/00	Eli Lilly & Co.	
B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories	
B11	WO 00/24893	5/4/00	Amgen, Inc.	
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)	
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG	
B14	WO 01/81405	1/11/01	Amgen Inc.	
B15	WO 01/82952	11/08/01	Action Pharma APS	
B16	WO 01/82953	11/08/01	Action Pharma APS	
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG	
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.	
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.	
B20	WO 02/14356	2/21/02	Althoff, Claudia	
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG	
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG	
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.	
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.	
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.	
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.	
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.	
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.	
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B32	WO 06/002646	1/12/06	Lundbeck A/S	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 6 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

			FOREIGN	N PATENT DOCUMENTS		
·		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
	B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	_	
	B35	WO 91/05867	5/02/91	Amgen Inc.		
	B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		T
	B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		
	B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		Т
	B39	WO 95/05465	02/23/95	Amgen, Inc.		
	B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		T
	B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.	***************************************	T
	B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		
	B43	WO 97/32895	9/12/97	Regents of the University of California		
	B44	WO 98/10650	3/19/98	East Carolina University		T
	B45	WO 98/18926	05/07/98	G.D. Searle & Co.		T
	B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
	B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		
	B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		T
	B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		T
	B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		T
	B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		
	B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		T
	B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		
	B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		T
	B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		T
	B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		1

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 7 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
FILING DATE	AKTUNII
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			<u> </u>
Initials	ļ	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of	
		claims, and Ehrenreich clean copy of claims (10/02/06)	_
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	┖
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	ł
		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	L
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	
		alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	l
		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	
		Natl. Acad. Sci. USA 91:3974-3978	
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	
		for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	
		der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	Τ
	007	Glycoproteins," Meth. Enzymol., 50:287-291.	1
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	\top
	10.0	Cerebrovascular Disease, Vol. 9:131-135	
	C11	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	†
	1011	premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	T
	C12	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	1
	C13	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	T
	1013	Cell. Biol. 14(10):6506-6514	
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	+
	1014	function relationships," J. Biol. Chem. 272(8):4985-4992	İ
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	╁
	C13	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
		BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	╁
	C16	traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	015	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	╁
	C17	12.	
		BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	+
	C18	prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
		Commun. 164(2):788-795	+
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
	_	artery occulsion in rats," Brain Research, Vol. 739:88-96	4
	C20	BENIT et al., 1993, "The 'WS motif common to v-mpl and members of the cytokine receptor superfamily is	
		dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 8 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

1				
ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
FILING DATE	ART UNIT			
May 30, 2006	1647			

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of	i
		the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-	
		1598	Ļ
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol.	1
		Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-	
		induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J.	
	1 024	Cereb. Blood Flow Metab. 19:643-651	
-	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that	
	1 023	involve the redox-state of the brain", Glia 30:271-278	
		BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac	\vdash
	C26	disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	1
		BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy,	╁
	C27		
	<u> </u>	PNAS, Vol. 101, pp. 823-828	┼
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc	
		Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal	
		antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	┖
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-	
		15993	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease	
		and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule	Τ
	032	agonists," Bioorg. & Med. Chem., 9:557-562	İ
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin	T
	[C33	and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	1
	-	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease,"	✝
	C34	Society for Experimental Biology & Medicine, pp. 337-345	
		BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-	╁
	C35		
		mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to	
	ļ	megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol.	
		98:549-559	┺
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement	
		of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol.,	
	05,	227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain	┪
	1038	injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
		BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	╁
	C39	The state of the s	1

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 9 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

APPLICATION NO. 10/573,905

APPLICANT (Use several sheets if necessary)

Coleman et al.

ATTY. DOCKET NO. 10165-042-999

FILING DATE May 30, 2006 ART UNIT 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T	(I I I I CHARLES CARREST AND A PART OF THE	
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With	
		Erythrocytosis," Blood, 81(6):1593-1597.	4
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat	
		model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	\bot
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding	
		to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	1
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-	
		241	\perp
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure:	†
	1040	angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through	+
	(47	separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res,	+
	C46	Vol. 81, pp. 29-42	
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil.,	╁
	C49	65:370-374.	1
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a	╁
	1030	Reduced Pressure," Nature, 191:1065-1067.	
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante,	\dagger
	1031	35:751-760.	
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of	+
	1 032	Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-	╁
	C33	scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the	+-
	C34	mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors:	+
	(33	insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
-	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by	+
	C36	expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest.	Ì
		102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the	+
	C57	cell surface," Nature, Vol. 415, pp. 175-179	
		DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and	+
	C58	neuroprotective potential," Biology of the Neonate, 79(304):228-35	
			+
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.	
		86(3):681-687	

EXAMINE	R
NYI-4088719)v2

DATE CONSIDERED

Sheet 10 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.				
10165-042-999	10/573,905				
APPLICANT					
Coleman et al.					
FILING DATE	ART UNIT				
May 30, 2006	1647				

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation	
		to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem.	
		Vol. 10(1):32-7	_
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist,	
	00.	Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the	1
	1 002	tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	
	C(2	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's	
	C63	disease," Pharm. Res. 15(3):386-98	
		STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley &	+
	C64		
		Sons, p. 122, p. 508	1
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple	
		sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and	Ţ
		platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	1
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the	\top
	1007	mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	2.0	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant	╫
	C68	erythropoietin treatment", ASAIO J. 38:M477-M480	
			+
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation:	
		prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	-
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global	
		ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	-
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	╁╌
		DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New	+
	C73		1
		York, 1993	_
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion,	
		and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance,"	
	0,5	Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP),"	T
	1070	Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
		EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med.	╫
	C77		
		8(8):495-505	+
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular	
		Psychiatry, 9:42-54	L
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	T
	C80	2223 Table 1 Table 2 T	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 11 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
1				
Coleman et al.				
FILING DATE	ART UNIT			
May 30, 2006	1647			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
miliais	C81	EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	<u> </u>
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> ," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100		
	C101	CARCIA 4 1 1000 W. L. C. Adda 4 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	T

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 12 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner		(Include many of the english (in CARITAL LETTERS). Title Date Regions Pages Fac.)	Т
Initials	C102	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	<u> </u>
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer. Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology, Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin <i>in Vitro</i> at the Milliunit Level," Endo., 97(2):315-323.	
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	C111	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin", Kidney Intl. 38:480-486	
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	CROTTINICED ACCOUNTS IN A STATE OF THE PARTY	
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	114314 70310 4 1 1007 45 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	T

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 13 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
		in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209	
	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C129	and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	194:457-462.	
	C136	Nephron, Vol. 72, pp. 30-36	
	C137	Science 247:324-327	
	C138	granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179	
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER	
NYI-4088719v2	2

DATE CONSIDERED

Sheet 14 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
initiais	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	'	
	C142	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paraoxonase active site," Chem Biol Interact, Vol. 119-120:79-84		
	C143	JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis," Chem Biol Interact, Vol. 119-120:71-78		
	C144	JUBINSKY et al., 1996, "The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and beta-globin mRNA expression," Mol. Med. 2(6):766-773		
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor," Blood 90(5):1867-1873		
	C146	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury", Proc. Natl. Acad. Sci. USA 99(16):10659-10664		
	C147	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system", Pediatr. Res. 43(1):40-49		
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus", Early Human Devel. 52(3):235-249		
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep", Soc. for Neuroscience Abstracts 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001)		
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage," Acta Paediatr. Supp. Vol. 438, pp. 36-42		
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor," Drug Metab Dispos. Vol. 22(1):99-105		
	C152	11.11.0.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.		
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the therapy of heart failure-induced mitral regurgitation. Circulation 108:1795-1797		
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New York Acad. Sci., 149:18-24.		
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration," Ann. Neurol. Vol. 56(6):815-826		
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation," Blood 99(1):102-110		
,	C157	LUIGHIN COTTO LA LOGGIUTE LA L'ILLE AND LA L'INDIANA CONTRA LA LINE DE LA LIN		
	C158	KITA III AA . 1 1004 (EDO)		
	C159			

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 15 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT	A
(Use several sheets if necessary)	10

ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FW 010 5 4 775	ADTIBUT
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner	1		
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C160	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96(5):826-828.	
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons <i>in vitro</i> and <i>in vivo</i> ", Brain Res. 609:29-35	
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31(4):601-608	
	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A. 95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol. 305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol. 93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	C172	Ll et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40(3):376-380	
	C173	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	C174	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund, http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," Anal. Biochem. 219:207-217	
	C176	LIPINSK1 et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
	C179	1.11. 1.100¢ (m	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 16 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

	•
ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

	NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
muais	C180	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	Ė
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
- 	C187	Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
1	C192	with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	cultured astrocytes", Brain Res. 746:63-70	
,	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C197	The column at a control of the column at the	
	C198	1.67.110 1.1004 (4.1111)	
	C199		
	C200		1

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 17 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
FILING DATE	AKTUNII
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210		
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	1
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	T-

EXAMINER
NYI-4088719v2

Sheet 18 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner			T_
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol.	
	<u> </u>	9(1):suppl. 2:12-15	+
	C222	OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid	
		chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	ł
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion	
		57:328-332 ON-LINE MEDICAL DICTIONARY Lysozyme entry; website http://cancerweb.ncl.ac.uk/omd . Published at	+
	C224	the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB	1
		Project.	L
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the	
		rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the	
		rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development	
		factor or thrombopoietin," Cytokine 8(1):66-69	
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the	
		introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	
	C229		
		barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	
	C230		
		Vol. 70:1781-92.	
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a	
	0202	recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti-	
	0200	carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major	
		histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta	Ì
		2m," Eur. J. Immunol. 25:1609-16	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked	
		oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-	
		773	┸
	C236		1
		11(4):974-980	
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral	
		infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol.	1
		260(5 Pt 2): H1406-1414	\perp
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525	
	5237	and 2125-2131	

	EXAMINER
l	NYI-4088719v2

DATE CONSIDERED

Sheet 19 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(1.1.1. C. CADITAL LETTERS) Tide Date Particular Properties	Т
Initials	<u> </u>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	+-
	C240	PHYSICIANS' DESK REFERENCE, 1995, 49th Edition (Medical Economics Data Production Company,	
		Montvale, NJ), pp.1765-1769	-
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone- related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
	C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8	
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
-	C252		
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	G + 1 TO G + 1 + 1000 (/D + C + + + + + + + + + + + + + + + + +	
	C257	C 11 11 20 20 20 20 20 20 20 20 20 20 20 20 20	
	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 20 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(I I I I C CAPITAL ASTERDO) THE D. D. C. (D. C.)	Т
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
	C259	SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives	
		ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	
	C260	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262	CONTROL 1 1000 (FD 4) 111 11 11 11 11 11 11 11 11 11 11 11 1	
	C262	Neonatologie (202)(2), pp 64-68 (Abstract Only)	
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464	
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267		
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin- dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29	
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	T
	C274	STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866	
	C275		
	C276	CERTIFICATION (IT) I A CONTROL	
	C277		T
	C278		-

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 21 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
Colonian of all				
FILING DATE	ART UNIT			
May 30, 2006	1647			

NON PATENT LITERATURE DOCUMENTS				
Examiner		(I I I I C CANITAL I STTERS) Till Day Paring Page (C)	Т	
Initials	C279	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216		
<u> </u>	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.		
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535		
	C282	SWISS ACCESSION No. P32927, October 1, 1993		
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516		
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872		
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252		
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402		
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268		
	C288			
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448		
_	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale, Vol. 31(11):505-514 (Abstract only)		
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133		
	C292	1.1.1.000000000000000000000000000000000		
	C293			
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63		
	C295	THREE CONTROL AND THE CONTROL OF THE		
	C296	WALLDEN DEN DIG 4 1 1000 WELL 1 C' 1 C 4 L' 1 L' 1 ND' 1 D 1 V 1 20 1 10 C 10		
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," Blut, 44:173-175.		
	C298		T	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 22 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
FILING DATE	ARTUNIT			
May 30, 2006	1647			

NON PATENT LITERATURE DOCUMENTS				
Examiner	T			
Initials	<u> </u>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T	
	C299	WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846		
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820		
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70		
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244		
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	ŀ	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30		
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42		
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958		
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485		
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509		
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83		
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	T	
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194		
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	T	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915		
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	1	
	C315	1/43/0 - 1 0000 (FDC) - C - : 1.1 - :		
	C316	1 1000 (m)	T	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	1	
	C318	LYOCHIN AUDA A 1 100C (9) A		
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	╁	

EXAMINER
NYI-4088719v2

DATE CONSIDERED



Sheet 1 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
HATTAL	A01	4,343,782	8/10/982	Shapiro	PIOORES ALTERA
.	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
•	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	A11	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	A21	5,696,080	12/09/97	O' Brien	
	A22	5,700,909	12/23/97	O'Brien	
	A23	5,714,459	02/03/98	O'Brien	
	A24	5,750,376	5/12/98	Weiss et al.	
	A25	5,756,349	05/26/98	Lin	
	A26	5,763,198	6/09/98	Hirth et al	
	A27	5,767,078	06/16/98	Johnson et al.	

EXAMINE	₹
NYI-4088719	v2

DATE CONSIDERED

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

	ATTY. DOCKET NO.	APPLICATION NO.			
	10165-042-999	10/573,905			
APPLICANT					
Coleman et al.					
	FILING DATE	ART UNIT			
		7			
	May 30, 2006	1647			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	C346	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Office Action, Application No. 09/716,963, date mailed: March 18, 2005	Т
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
 .	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
-	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 25 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

	ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905				
,	APPLICANT Coleman et al.					
	FILING DATE May 30, 2006	art unit 1647				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
mitiais	C374	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	Ė
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	Γ
·	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	
·	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	Г
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	Г
•	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	Т
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	T
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	Г
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	Γ
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	Γ
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	Γ
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	Π

EXAM	INER	
NYI-408	38719v2	

DATE CONSIDERED

Sheet 26 of 26 of List of References

1647

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999
10/573,905

APPLICANT
Coleman et al.

FILING DATE

ART UNIT

May 30, 2006

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т			
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912				
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008				

EXAMINER NYI-4088719v2

Sheet 2 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.	
10165-042-999	10/573,905	
APPLICANT		
Coleman et al.		
FILING DATE	ART UNIT	
May 30, 2006	1647	

	U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A28	5,773,569	06/30/98	Wrighton et al.	
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
1 (1 mm)	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	A46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	A48	6,531,121	3/11/03	Brines et al.	
	A49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
	A51	7,214,532	5/08/07	Stern et al.	
	A52	7,309,687	12/18/07	Brines et al.	
	A53	7,345,019	3/18/08	Brines et al.	
	A54	2002/0031806	3/14/02	Lee	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 23 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.					
10165-042-999 10/573,905						
APPLICANT						
Coleman et al.						
FILING DATE	ART UNIT					
May 30, 2006	1647					

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials]	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
mittais	 	Oncologist 1(5):337-339	Ť
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	\top
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
· · · · · ·	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	1
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	†
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	+-
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	+
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	+-
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	+
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	+
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	+
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	+
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	1
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	\top
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	+

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 3 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) Coleman

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

Filing date ART unit

May 30, 2006 1647

			U.S. PA	ATENT DOCUMENTS	
*EXAMINER			DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
INITIAL	A55	DOCUMENT NUMBER 2002/0052309	5/02/02	NAME Anagnostou et al.	FIGURES APPEAR
	A56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
_ · · · -· - ·	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	A72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	A74	2004/0009902	1/15/04	Boime	
	A75	2004/0018978	1/29/04	Campana et al.	
	A76	2004/0091961	5/13/04	Evans et al.	
	A77	2004/0096447	5/20/04	Yasuda et al.	
	A78	2004/0122216	6/24/04	Nielsen et al.	
	A79	2004/0209812	10/21/04	Farrell et al.	
	A80	2004/0214236	10/28/04	Brines et al.	
	A81	2005/0176627	8/11/05	Cerami et al.	

EXAM	INER
NYI-408	8719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

	_				D. 000 COLUMNIA I DITE COLUMNIA
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	
	A83	2006/0216757	9/28/06	Brines et al.	
, ,	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
-	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

	FOREIGN PATENT DOCUMENTS				
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	Т
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh		
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		
B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
B04	EP 0640619	1/03/95	Amgen Inc.		
B05	EP 0668 351	8/23/95	Amgen, Inc.		
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT Coleman et al.

FILING DATE ART UNIT
May 30, 2006 1647

FOREIGN PATENT DOCUMENTS FOREIGN PATENT PAGES, COLUMNS, LINES, WHERE DOCUMENT RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR COUNTRY CODE, NUMBER, т KIND CODE (IF KNOWN) DATE NAME 6/8/00 Eli Lilly & Co. WO 00/032772 B09 WO 00/061164 10/19/00 Kenneth S. Warren Laboratories B10 5/4/00 Amgen, Inc. WO 00/24893 B11 06/22/00 Ehrenreich, Hannelore (w/English WO 00/35475 B12 abstract) 1/11/01 F. Hoffmann-La Roche AG WO 01/02017 B13 WO 01/81405 1/11/01 Amgen Inc. B14 11/08/01 Action Pharma APS WO 01/82952 B15 WO 01/82953 11/08/01 Action Pharma APS B16 11/22/01 F. Hoffmann-La Roche AG WO 01/87329 B17 Kenneth S. Warren Institute, Inc. WO 02/053580 7/11/02 B18 2/07/02 Ortho-McNeil Pharmaceutical, Inc. WO 02/10743 B19 WO 02/14356 2/21/02 Althoff, Claudia B20 WO 02/49673 6/27/02 F. Hoffmann-La Roche AG B21 F. Hoffmann-La Roche AG 4/10/03 WO 03/029291 B22 1/8/04 The Kenneth S. Warren Institute, Inc. WO 04/003176 B23 and H. Lundbeck A/S WO 04/004656 1/15/04 The Kenneth S. Warren Institute, Inc. **B24** WO 04/022577 3/18/04 Warren Pharmaceuticals, Inc.; B25 Kenneth S. Warren Institute, Inc. The Kenneth S. Warren Institute, Inc. WO 04/096148 11/11/04 **B26** The Kenneth S. Warren Institute, Inc. 12/29/04 WO 04/112693 **B27** and H. Lundbeck A/S Warren Pharmaceuticals, Inc.; WO 05/025606 3/24/05 **B28** Kenneth S. Warren Institute, Inc. WO 05/032467 4/14/05 Warren Pharmaceuticals, Inc. B29 WO 05/084364 9/15/05 The Kenneth S. Warren Institute, Inc. B30 The Kenneth S. Warren Institute, Inc. 12/15/05 WO 05/117927 B31 and H. Lundbeck A/S WO 06/002646 1/12/06 Lundbeck A/S B32 2/9/06 WO 06/014349 The Kenneth S. Warren Institute, Inc., B33 et al.

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 6 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

	FOREIGN PATENT DOCUMENTS					
_		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	Т
	B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S		
	B35	WO 91/05867	5/02/91	Amgen Inc.		
	B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		
	В37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		
	B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		
	B39	WO 95/05465	02/23/95	Amgen, Inc.		\Box
	B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		T
	B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.		
	B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		
	B43	WO 97/32895	9/12/97	Regents of the University of California		
	B44	WO 98/10650	3/19/98	East Carolina University		
	B45	WO 98/18926	05/07/98	G.D. Searle & Co.		T
	B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
	B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		1
	· B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		1
	B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		T
	B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		T
	B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		
	B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		T
	B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		T
	B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		1
	B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		T
	B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		\top

EXAMINER
NYI-4088719v2

Sheet 7 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
	4.00.00
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		<u> </u>
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of	
		claims, and Ehrenreich clean copy of claims (10/02/06)	ļ
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	<u> </u>
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	
		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	ļ.,
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	
		alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	
		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	
		Natl. Acad. Sci. USA 91:3974-3978	
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	
		for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	Ī
		der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
-	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	
	1007	Glycoproteins," Meth. Enzymol., 50:287-291.	
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	1
	1010	Cerebrovascular Disease, Vol. 9:131-135	
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	1
	111	premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	
	1012	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	C13	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	
	1013	Cell. Biol. 14(10):6506-6514	
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	+
	C14	function relationships," J. Biol. Chem. 272(8):4985-4992	
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	+
	C13	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	CIC	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	✝
	C16	traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	017	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	╁╌
	C17	12.	
		BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	+-
	C18	prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
		Commun. 164(2):788-795	
			+
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
		artery occulsion in rats," Brain Research, Vol. 739:88-96	+-
	C20	BENIT et al., 1993, "The 'WS motif' common to <i>v-mpl</i> and members of the cytokine receptor superfamily is	
		dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 8 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
Initials	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-15993	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EX	ΑM	IN	ER
NY	1-408	887	19v2

DATE CONSIDERED

Sheet 9 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT Coleman et al.

FILING DATE ART UNIT May 30, 2006 1647

Examiner	$\overline{}$		\top
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With	
		Erythrocytosis," Blood, 81(6):1593-1597.	
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat	
		model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding	
		to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	4
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	
·	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	T
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure:	T
	0.0	angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through	
		separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res,	
		Vol. 81, pp. 29-42	┸
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil.,	
		65:370-374.	+
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a	
		Reduced Pressure," Nature, 191:1065-1067. COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante,	+-
	C51	35:751-760.	-
		COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of	╬
	C52	Erythropoietin, Annals New York Acad. Sci., 149:12-17.	ļ
•	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-	\dagger
	1 033	scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the	\dagger
	034	mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors:	\top
	055	insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
,	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by	
		expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest.	
	_	102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the	Τ
		cell surface," Nature, Vol. 415, pp. 175-179	\perp
	C58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and	
		neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.	
		86(3):681-687	⊥.

EXAMINER
NYI-4088719v2

Sheet 10 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			1
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	\dagger

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 11 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T_
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> ," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10	T
· · · · · · · · · · · · · · · · · · ·	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100	CAEDWIED 4 1 1004 (C)	T
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	T

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 12 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Include many of the author (In CADITAL LETTERS). Title Date Business Bases Fee.)	
Initials	+	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C102	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and	
_		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	├ ─
	C103	GENBANK No. M59941, 1994	
	C104 GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. A		
Chem Soc., Vol. 124(4):544-555			
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,	
	10.03	Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	
	100	Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97(2):315-	1
	10107	323.	
- ·	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	\top
	100	neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental	\vdash
	109	spinal cord injury," PNAS, Vol. 102(45):16379-84	
OD 1000 1 0000 (D 011 00 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		\vdash	
C110 GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietii rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631			
C111 GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemi		\vdash	
clinical efficacy," Pharm. Ther. Vol. 80(2):123-147			ł
	C112 GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of C		\vdash
	CHZ	therapy. J Sleep Res. 4(S1): 130-134	
	C113 GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulati		\vdash
	bcl-x _L expression", Blood 94:87-96		
			┼-
Kidney Intl. 38:480-486		╁	
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal	ļ
		degeneration," Nature Medicine, Vol. 8(7):718-724	╄
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.	
		1592:215-223	+
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	1
		antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	
		granule cells," Toxicological Sciences, Vol. 64:83-89	<u> </u>
	C119		1
		Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	1_
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	1
		receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	\perp
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	
		Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	1

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 13 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.		
10165-042-999	10/573,905		
APPLICANT			
Coleman et al.			
FILING DATE	ART UNIT		
May 30, 2006	1647		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
		in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209	
	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
-	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	71.00.131 - 1.00.5 (P. 1. 0. 1. 11.1.1.1.1.1.1.1.1.1.1.1.1.1.	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C129	and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	194:457-462.	
	C136	Nephron, Vol. 72, pp. 30-36	
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327	
	C138	granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179	
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 14 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
FILING DATE	ART UNIT			
14 20 2006	1645			
May 30, 2006	1 164 /			

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(I I I I CALL AL CONTENT DETERMINE THE DATE OF THE PROPERTY OF	T
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	
		JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paraoxonase active site,"	+
	C142	Chem Biol Interact, Vol. 119-120:79-84	
	C143	JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino acid residues by	
	C143	group-selective labelling and site-directed mutagenesis," Chem Biol Interact, Vol. 119-120:71-78	
	C144	JUBINSKY et al., 1996, "The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-	
	10177	CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence	
		proliferation and beta-globin mRNA expression," Mol. Med. 2(6):766-773	1
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the	+
	C145	erythropoietin receptor," Blood 90(5):1867-1873	
	GLAC	TRUE A LOOPE WE ALL THE LOOPE WE ALL THE COLUMN TO THE COLUMN THE	+
	C146	injury", Proc. Natl. Acad. Sci. USA 99(16):10659-10664	
		JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous	+
	C147	300L et al., 1996, Elytinopoietin and elytinopoietin receptor in the developing numan central nervous	
		system", Pediatr. Res. 43(1):40-49 JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	+
	C148		
		fetus", Early Human Devel. 52(3):235-249	+-
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	
		sheep", Soc. for Neuroscience Abstracts 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San	
		Diego, CA Nov. 10-15, 2001)	_
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	1
		damage," Acta Paediatr. Supp. Vol. 438, pp. 36-42	
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate	
		of avidin and a monoclonal antibody to the transferrin receptor," Drug Metab Dispos. Vol. 22(1):99-105	\perp
	C152	KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin,"	1
	1	Glycobiology, Vol. 11(12):1043-1049	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	Т
	0.55	therapy of heart failure-induced mitral regurgitation. Circulation 108:1795-1797	.
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New	
	0154	York Acad. Sci., 149:18-24.	
	C155		1
	(133	Ann. Neurol. Vol. 56(6):815-826	
	C156	WIDING . 1 0000 WIL . C. C. 1 1	†
	C156	activation," Blood 99(1):102-110	
	0.00	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	+-
	C157	Am J Anat. Vol. 178:241-9.	
	 	KITAJIMA et al., 1994, "Effective combination therapy by recombinant erythropoietin and cepharanthin in a girl	+
	C158		
	ļ	with refractory anemia," Japanese J. Clin. Hematology, Vol. 35(7):694-6988 (w/English abstract)	+
	C159	KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1," Blood, Vol 73(2):375-80	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 15 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.		
10165-042-999	10/573,905		
APPLICANT			
Coleman et al.			
FILING DATE	ART UNIT		
May 30, 2006	1647		

		NON PATENT LITERATURE DOCUMENTS	
xaminer			
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C160	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis,"	
	-	Obstetrics and Gynecology, 96(5):826-828.	_
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic	
	 	neurons <i>in vitro</i> and <i>in vivo</i> ", Brain Res. 609:29-35 KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic	
	C162		
-		mechanism.", Behav. Neural Biol. 62:237-243 GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in	
	C163	patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	10161	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following	\vdash
	C164	neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle	
	C165	cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional	┢
	C100	asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive	
	10107	and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J.	
	ŀ	Cardiovasc. Pharmacol. 31(4):601-608	
	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A.	
	100	95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol.	
		305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol.	
		93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid	
		progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	C172	Ll et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human	
		fetuses", Pediatr. Res. 40(3):376-380	<u> </u>
	C173	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing	
 		various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	<u> </u>
	C174	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund,	
	 	http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	├-
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," Anal. Biochem. 219:207-217	1
· · · · · · · · · · · · · · · · · · ·		1.17.10.11.11.11.11.11.11.11.11.11.11.11.11.	⊢
	C176	Res. 692:143-153	
	 		╁
	C177	Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
		1111 1 1004 ((m)) 100 1 101 11 11 11 11 11 11 11 11 11 11	┼-
	C178	166:159-169	
		LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct	\vdash
	C179	hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 16 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.				
10165-042-999	10/573,905				
APPLICANT					
Coleman et al.					
FILING DATE	ART UNIT				
May 30, 2006	1647				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CADITAL LETTERS) Title Date Partirent Dage Etc.)	T
muais	-	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem.	╀
	C180	272(51):32395-32400	
			╁
	C181	Blood, Vol. 110(7):2408-2413	
	0100	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand	╁
	C182	activation," Science 283:987-990	1
	C192	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS,	+
	C183	Vol. 101:777-783	1
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions,"	+
	10184	Nature, 185:102-103.	
	C185		┿
	C183	injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186		十
	C180	Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1",	\dagger
	C187	Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients",	\dagger
	100	Kidney Intl. 39:155-163	
	C189	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	\top
	(10)	8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the	T
	10.70	brain", Kidney Intl. 51:416-418	1
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison	†
	10172	with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193		1
	10.75	astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary	
	0.,,	cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular	Т
	""	Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS,	
		USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit,"	
		Cytokine 13(4):240-243	
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta:	T
		differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll.	Τ
		Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	Т

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 17 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.	
10165-042-999	10/573,905	
APPLICANT		
Coleman et al.		
FILING DATE	ART UNIT	
May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	ļ
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26 th ed. pp. 524-526, McGraw-Hill Co., .	T
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	12/4 W A 2 (1) 1 1 2 2 3 4 5 5 5 6 5 6 5 6 5 6 6 6 6 6 6 6 6 6 6	
	C214	114 D 4 1 D 4 1 D 4 1 D 4 1 D 4 D 4 D 4	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 18 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
FILING DATE	ART UNIT			
1.2				
May 30, 2006	1647			

NON PATENT LITERATURE DOCUMENTS				
Examiner	T		_	
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol.		
		9(1):suppl. 2:12-15	├	
	C222	OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid		
		chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	 	
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332		
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website http://cancerweb.ncl.ac.uk/omd. Published at		
		the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB Project.		
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the		
	0223	rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261		
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the		
	0220	rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	1	
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development		
	1 (22)	factor or thrombopoietin," Cytokine 8(1):66-69		
C228 PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhance		PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the		
	C226	introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	1	
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain	1	
		barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60		
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem.		
	0250	Vol. 70:1781-92.	1	
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731		
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a	T	
		recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704		
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti-		
		carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	1	
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major		
		histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta		
	_	2m," Eur. J. Immunol. 25:1609-16	<u>L</u>	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked		
		oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-		
		773	<u> </u>	
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics		
		11(4):974-980		
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral		
	.	infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	_	
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol.		
	260(5 Pt 2): H1406-1414			
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525		
		and 2125-2131		

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 19 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999 10/573,905				
APPLICANT				
Coleman et al.				
FILING DATE	ART UNIT			
May 30, 2006	1647			

NON PATENT LITERATURE DOCUMENTS				
Examiner			T_	
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T	
	C240	PHYSICIANS' DESK REFERENCE, 1995, 49th Edition (Medical Economics Data Production Company,		
	Montvale, NJ), pp.1765-1769		┼	
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone- related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720		
	C242	Chem. 246(4):939-45		
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709		
	C244	procedure," Diabetes, Vol. 32:1087-1091		
	C245	conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352		
	C246	Chem. 273(18):11173-11176		
	C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8		
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993		
	C249	conformation," J. Biol. Chem. 250(18):7435-42		
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253		
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030		
	C252			
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842		
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452		
	C255			
	C256			
	C257			
	C258			

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 20 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
FILING DATE	ART UNIT			
May 30, 2006	1647			

NON PATENT LITERATURE DOCUMENTS				
Examiner				
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T	
	C259	SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives		
		ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	<u> </u>	
	C260	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74(1):103-109		
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be		
	0201	prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100		
	C262	SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift für Geburtshilfe und	1	
	C202	Neonatologie (202)(2), pp 64-68 (Abstract Only)		
-	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain	T	
	1 0203	and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for		
		erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590		
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent	1	
	C204	growth in hematopoietic cell lines," Blood 88(2):455-464		
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in		
	C203	Vivo and in Vitro," Exp. Cell Res., 215:249-256.		
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.		
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107		
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-	1	
	C200	dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169		
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress",	T	
	1 0209	Proc. Natl. Acad. Sci. USA 98(7):4044-4049		
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J	✝	
	C270	Ultrastruct Res. Vol. 88(1):18-29		
	C271	CDUVALY A LICONOMINE LIVE AND LIVE CO. IN CO. IN CO. INC. IN CO. INC. INC. INC. INC. INC. INC. INC. INC	\vdash	
	C2/1	73:90-99.		
	C272		+-	
	C212	Biol. Chem. 235(11): 3177-3181		
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	${\dagger}$	
			╁	
	C274	Inflammation, pp. 897-898, 1865-1866		
			+	
	C275	Natl. Acad. Sci. U. S. A. 99(22):13972-4		
	+	CTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	-	
	C276	STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	1	
		Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human		
		Urinary Erythropoietins," J. Endocrinol., 134:459-484.	\vdash	
	C277			
	-	Biological Properties," British J. Haematology, 100:79-89.	╄	
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J.		
		of Clinical Investigation, Vol. 35, pp. 711-717	L	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 21 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
FILING DATE	ART UNIT			
May 30, 2006	1647			

Examiner			T
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C279		
	_	blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	4
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and	
		Erythrocytosis," British J. Haematology, 113:49-51.	_
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol.	
		73:1525-1535	ــــــ
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor	1
	C203	orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by	1
	C204	inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	1
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in	1
	C203	vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	THE COLUMN TO SERVICE AND ASSESSMENT OF THE CO	
	C280	81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood	1
	C287	flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	1
• •	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on	+
	C200	chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	İ
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys.	1
	C289	Res. Commun. 148(1):443-448	1
	C290	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	+
	C290	Press Medicale, Vol. 31(11):505-514 (Abstract only)	1
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats	
	C291	with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C202	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced	+
	C292	anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- β Immunoreactivity and microglia are enhanced in the rat hippocampus	╅╌
	C293	by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol	
		19(12):5054-65	
	+	117771211 1 1000 (14 11 11 11 11 11 11 11 11 11 11 11 11 1	
	C294	but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological	
		assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	1
		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	+
	C295		ļ
	+	morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	+
	C296		
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins,"	\top
	1 5277	Blut, 44:173-175.	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	1

EXAMINER NYI-4088719v2
NYI-4088719v2

DATE CONSIDERED

Sheet 22 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.
ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the surface (in CADITAL LETTERS). Title Date Desire AD- on Fa-)	Т
nitiais	C299	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	1
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin	
		receptors", Kidney Intl. 55:808-820	<u> </u>
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	
-	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42	
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83	
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	
	C312	77.7.4.17 . 1 . 20.4 (17. 1 . 11. 11. 11. 11. 11. 11. 11. 11.	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	
	C316	11777 1 1000 (177)	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C318	Treatment to the second	
,	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	T

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 23 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT.
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		Oncologist 1(5):337-339	
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	<u> </u>
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	1
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	+
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	Ť
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	十
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	1
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICATION NO. ATTY. DOCKET NO. 10/573,905 10165-042-999 APPLICANT Coleman et al. FILING DATE ART UNIT May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Include come of the mathew (in CADITAL LETTERS) Title Date Bestings Bases Fee	Т
Initials	C346	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Office Action, Application No. 09/716,963, date mailed: March 18, 2005	
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
<u> </u>	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
<u>.</u>	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
<u>-</u>	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 25 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
	AKTONI
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
ilitiais	C374	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	'
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	\vdash
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	\vdash
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	H
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	T
	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	<u> </u>
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	T
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	T
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	\vdash
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	┢╌
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	H
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	\vdash
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	1
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	T
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	T
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	T
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	T
·	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 26 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10165-042-999 10/573,905

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912	
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008	

EXAMINER
NYI-4088719v2

Sheet 1 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

ART UNIT

1647

		_	U.S. 1	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A01	4,343,782	8/10/982	Shapiro	FIGURES APPEAR
	A02	4,377,513	03/22/83	Sugimoto et al.	OIPE
	A03	4,658,019	04/14/87	Kung et al.	iso
	A04	4,703,008	10/27/87	Lin	1111 9.9 2008
	A05	4,806,524	02/21/89	Kawaguchi et al.	30L 10 2000 III
	A06	4,835,260	05/30/89	Shoemaker	& TRADEMARTH
	A07	4,992,419	2/12/91	Woog et al.	THE GALL
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	All	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	A21	5,696,080	12/09/97	O' Brien	
	A22	5,700,909	12/23/97	O'Brien	
	A23	5,714,459	02/03/98	O'Brien	
	Λ24	5,750,376	5/12/98	Weiss et al.	
	A25	5,756,349	05/26/98	Lin	
	Λ26	5,763,198	6/09/98	Hirth et al	
	Λ27	5,767,078	06/16/98	Johnson et al.	

EXAMINER
NYI-4088719v2

Sheet 2 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

APPLICATION NO.

10/573,905

APPLICANT

ART UNIT

1647

...

May 30, 2006

			U.S. 1	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
	A28	5,773,569	06/30/98	Wrighton et al.	FIGURES APPEAR
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	Λ46	6,489,293	12/3/02	Sytkowski et al.	
	Λ47	6,521,245	2/18/03	Zaharia	
	Λ48	6,531,121	3/11/03	Brines et al.	
	Λ49	6,583,272	6/24/03	Bailon	
	Λ50	6,645,522	11/11/03	Naeff et al.	
	A51	7.214,532	5/08/07	Stern et al.	
	Λ52	7,309,687	12/18/07	Brines et al.	
	A53	7.345,019	3/18/08	Brines et al.	
		2002/0031806	3/14/02	Lee	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

					1047
			U.S. 1	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
1.	A55	2002/0052309	5/02/02	Anagnostou et al.	FIGURES APPEAR
1	A56	2002/0061849	5/23/02	Nielsen et al.	
/	457	2002/0077294	6/20/02	Kay et al.	
1	458	2002/0081734	6/27/02	Choi et al.	
F	159	2002/0086816	7/04/02	Brines et al.	
F	160	2002/0142370	10/3/02	Paulson et al.	
A	161	2002/0160460	10/31/02	Paulson et al.	
A	162	2003/0003529	1/2/03	Bayer	
A	163	2003/0040037	2/27/03	Bayer	
A	64	2003/0072737	4/17/03	Brines	
Λ	65	2003/0077753	4/24/03	Tischer	
A	66	2003/0083251	5/01/03	Westfenfelder	
A	67	2003/0104988	6/5/03	Brines	
A	68	2003/0113871	6/19/03	Lee et al.	
A	69	2003/0118547	6/26/03	Vandenberg	
A	70	2003/0120045	6/26/03	Bailon	
A	71	2003/0124115	7/3/03	Lee et al.	
A'	72	2003/0134798	7/17/03	Brines et al.	
A	73	2003/0166566	9/04/03	Kinstler et al.	
A	74	2004/0009902	1/15/04	Boime	
Δ7	75	2004/0018978	1/29/04	Campana et al.	
A7	76	2004/0091961	5/13/04	Evans et al.	
Α7	77	2004/0096447	5/20/04	Yasuda et al.	
Α7	8	2004/0122216	6/24/04	Nielsen et al.	
Α7	9 :	2004/0209812	10/21/04	Farrell et al.	
/18	0 2	2004/0214236	10/28/04	Brines et al.	
Λ8	- + -	2005/0176627	8/11/05	Cerami et al.	

EXAMINER
NYI-4088719v2

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

				PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	PIGURES APPEAR
	A83	2006/0216757	9/28/06	Brines et al.	
· ·	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME:	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh	RELEVANT FIGURES APPEAR	-
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		
B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
B04	EP 0640619	1/03/95	Amgen Inc.		
B05	EP 0668 351	8/23/95	Amgen, Inc.		_
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>EV 654 895 309 US</u> Sheet 5 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B09	WO 00/032772	6/8/00	Eli Lilly & Co.	RELEVANT FIGURES APPEAR	╀
B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		-
B11	WO 00/24893	5/4/00	Amgen, Inc.		├-
B12		06/22/00	Ehrenreich, Hannelore (w/English abstract)		
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		\vdash
B14	WO 01/81405	1/11/01	Amgen Inc.		-
B15	WO 01/82952	11/08/01	Action Pharma APS		<u> </u>
B16	WO 01/82953	11/08/01	Action Pharma APS		L
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		_
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		
B20	WO 02/14356	2/21/02	Althoff, Claudia		
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		_
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		_
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B32	WO 06/002646	1/12/06	Lundbeck A/S		
B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		

EXAMINER NYI-4088719v2

DATE CONSIDERED

Sheet 6 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	I
B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	RECEVANT FIGURES AFFEAR	+
B35	WO 91/05867	5/02/91	Amgen Inc.		†
B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		1
B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		†
B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		†
B39	WO 95/05465	02/23/95	Amgen, Inc.		ł
B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		1
B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.		ł
B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		-
B43	WO 97/32895	9/12/97	Regents of the University of California		ł
B44	WO 98/10650	3/19/98	East Carolina University		ŀ
B45	WO 98/18926	05/07/98	G.D. Searle & Co.		ŀ
B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		ŀ
B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		ŀ
B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		-
B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		_
B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		-
B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		-
B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		-
B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		-
B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		-
B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		-
B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		_

EXAMINER
NYI-4088719v2

Sheet 7 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner			Τ
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	-
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1. Declaration, Brines clean copy of	Ť
		claims, and Ehrenreich clean copy of claims (10/02/06)	
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	+
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	l
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	╁
		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	╁
		alpha-crystallins," Current Eye Research, Vol. 18:270-276	ı
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	╁
		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	ľ
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	╀
		Natl. Acad. Sci. USA 91:3974-3978	
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	╀
	00,	for Bioassay," Bull. Org. mond. Sante, 47:99-112.	l
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	╀
	000	der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	l
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	⊢
	100	Glycoproteins," Meth. Enzymol., 50:287-291.	
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	┞
	1010	Cerebrovascular Disease, Vol. 9:131-135	
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	⊢
		premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	L
	C12	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	C13	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	_
	1013	Cell. Biol. 14(10):6506-6514	
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	_
	C14	function relationships," J. Biol. Chem. 272(8):4985-4992	
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	
	1013	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	614	RASKAVA et al. 1907 "The himberic green, Soll 147, pp. 203-6	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	01.5	RALIER 1905 "The Owners Sense The County	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	
	6110		
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
		prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
	+	Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996. "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
	·	artery occulsion in rats," Brain Research, Vol. 739:88-96	
	C20	BENIT et al., 1993, "The 'WS motif common to v-mpl and members of the cytokine receptor superfamily is	
	L	dispensable for myeloproliferative leukemia virus pathogenicity." Oncogene 8787-790	

EXAMINER NYI-4088719v2
NYI-4088719v2

DATE CONSIDERED

Sheet 8 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999 APPLICANT	10/573,905
Coleman et al.	T
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner			7
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983- 15993	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 9 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ARTUNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner			Т
Initials	_ -	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	ľ
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597.	
			\bot
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding	+
	C42	to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci.,	╁
	0.5	149:40-45.	İ
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-	t
		241	
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	T
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure:	╁
	""	angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through	t
	"	separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res.	T
		Vol. 81, pp. 29-42	
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil.,	T
		65:370-374.	ı
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a	T
		Reduced Pressure," Nature, 191:1065-1067.	1
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante,	Г
		35:751-760.	
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of	
		Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-	
		scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the	
	_	mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors:	Г
		insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by	
		expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest.	ĺ
	_	102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the	
		cell surface," Nature, Vol. 415, pp. 175-179	
	C58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and	
	<u> </u>	neuroprotective potential." Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.	\Box
	1	86(3):681-687	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 10 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		Т
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	T
-	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	\vdash
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	-
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	

EXA	MIN	ER
NYI-	10887	19v2

DATE CONSIDERED

Sheet 11 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CARITAL LETTERS) Title Date Participat Research	Т
minais	C81	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) EMIR, 2004, "Erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	<u> </u>
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> ," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	T
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS				
Examiner						
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T			
	C102					
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711				
	C103	GENBANK No. M59941, 1994				
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.				
		Chem Soc., Vol. 124(4):544-555				
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,				
	10.03	Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	ļ			
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	 			
	100	Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.				
	C107		\vdash			
	(107	323.				
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	†			
	10.00	neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455				
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental				
	10.07	spinal cord injury," PNAS, Vol. 102(45):16379-84				
	C110		一			
	10110	rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631				
	CHI	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	\vdash			
	(111	clinical efficacy," Pharm. Ther. Vol. 80(2):123-147				
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	\vdash			
	C112	therapy. J Sleep Res. 4(S1): 130-134				
	0112	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating	-			
	C113	bcl-x _L expression", Blood 94:87-96				
		GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	<u> </u>			
	C114					
·		Kidney Intl. 38:480-486	<u> </u>			
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal				
		degeneration," Nature Medicine, Vol. 8(7):718-724				
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.				
····		1592:215-223				
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and				
		antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584				
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar				
	<u> </u>	granule cells," Toxicological Sciences, Vol. 64:83-89				
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II.				
		Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.				
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF				
	``'-"	receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066				
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and				
	(121	Bioengineering, Vol. 16:1069-1079				
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP				
	1122	The state of the s				

EXAMINER
NY1-4088719v2

DATE CONSIDERED

Sheet 13 of 26 of List of References

	ATTY, DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		ļ
	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	Т
	C123		
	C124	1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128		
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	194:457-462.	
	C136	Nephron, Vol. 72, pp. 30-36	
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179	
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 14 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			_
Initials	<u> </u>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C141	JUUSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolonge transport and pr	╁∸
		derivery of adenovital vectors to mouse liver and line " Hum Gene Ther 7/12\.1555 (c	1
	C142	JOSSE et al., 1999, Tryptophan residue(s) as major components of the human carum paragraphs at the significant and the signifi	┼
	 -	Chem Diol Interact, vol. 119+1/01/9-84	
	C143	JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino acid residues by	+
	 	1 5 out selective iductifing and site-directed militagenesis "Them Riol Internet Vol. 110 120 71 70	1
	C144	JODINSKI Et al., 1990. The bela c component of the granulocyte-magraphaga actoms at the control of the granulocyte-magraph	
	ł	1 Col / interregally 5 (1L-5)/1L-5 receptor interacts with a nyhrid GM_CSE/em/th/concletin recents 1.4.	
	-	promotation and octa-globin mixing expression " Mol. Med. 2/6).766, 772	1
	C145		
	CIAC	1 or your operating receptor. In those your 17 table 18 table	ĺ
	C146	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury", Proc. Natl. Acad. Sci. USA 99(16):10659-10664	
	C147	1 "Jary 5 1 100, 14dii, Acau, 301, U3A 991 [0]: [0]0 39- [1]064	
	1 (147	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system", Pediatr. Res. 43(1):40-49	
	C148	JUII, et al. 1998 "Tissue distribution of anothrops is in and the income is in and the income is in and the income is in and the income is in and the income is in an and the income is in an analysis of the income is in an	
	C146	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus", Early Human Devel. 52(3):235-249	
	C149	JUUL et al., 2001, "Recombinate Abstracts 27(1) 000 (2) crosses the blood brain barrier (BBB) in preterm fetal	
	(14)	sheep", Soc. for Neuroscience Abstracts 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San	
	}		
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier tensor of a Childian Lands	
		and a monocional antibody to the transferrin recentor " Drug Motoh Diomog Val 20/11/00 106	
	C152	To the term of the	
		Glycoolology, vol. 11(12):1043-1049	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term efficacy mitral considerable and short-term e	
		more province it in the contract of the contra	
ŀ	C154	KEIGHLEY, 1968, "Further Experiences with Assays Units and Standards of Englishmen significant and Standards of Englishmen sig	
ř	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"	
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3	
1	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	
İ	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant crythropoietin and cepharanthin in a girl with refractory anemia." Innances I. Clin. Hammetology, Vol. 25(7), 604, 606	
	C139 I	KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1," Blood, Vol 73(2):375-80	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 15 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

NON PATENT LITERATURE DOCUMENTS			
Examiner			_
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C160		
	<u> </u>	Obstetrics and Gynecology, 96(5):826-828.	╀
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic	
		neurons in vitro and in vivo", Brain Res. 609:29-35	⊢
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic	İ
	+	mechanism.", Behav. Neural Biol. 62:237-243	╄
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in	1
·		patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	╀
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following	
		neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	╀
	C165		
		cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	\vdash
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional	1
	+	asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	⊢
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive	
		and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J.	į .
	+	Cardiovasc. Pharmacol. 31(4):601-608 LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A.	\vdash
	C168	95:11371-11376	
	-	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol.	╁
	C169	305, pp. 239-242	
	0.70	1 53410 + 1 1000 (9) 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	┼
	C170	93:75-80	1
	6171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid	\vdash
	C171	progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	C172	The book with the state of the	┢
	C172	fetuses", Pediatr. Res. 40(3):376-380	
	C173	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing	H
	C1/3	various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	C174	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund,	\vdash
	C1/4	http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked	T
	101/3	glycans," Anal. Biochem. 219:207-217	1
	C176	TIPINION TO THE TOTAL THE TANK	\vdash
	10176	Res. 692:143-153	Ì
	C177		╁╴
	C177	Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	(1176	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol.	t
	C178	166:159-169	l
	0170	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct	1
	C179	hematopoietic and neural expression". Proc. Assoc. Am. Physicians 108(6):449-454	l

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 16 of 26 of List of References

ATTY. DOCKET NO. | APPLICATION NO. | 10165-042-999 | 10/573,905 |

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

Coleman et al. | ART UNIT | May 30, 2006 | 1647

NON PATENT LITERATURE DOCUMENTS			
Examiner		(Inch de consecutive (in CADITAL LETTERS) (Ed. Dec. Berliners Berliners Berliners	Т
nitials	C180	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
·- · · · · · · · · · · · · · · · · · ·	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
-	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
. .	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll. Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 17 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
,	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
···	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
,	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

EXAMINER NYI-4088719v2	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 18 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS				
Examiner	1	(Include name of the outbox (in CADITAL LETTERS) Title Date Partitions Dagge Fts.)	T	
Initials	C221	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	'	
	C222			
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332		
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website http://cancerweb.ncl.ac.uk/omd . Published at the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB Project.		
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261		
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267		
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69		
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082		
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60		
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92.		
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731		
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704		
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti- carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635		
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16		
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773		
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980		
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34		
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260(5 Pt 2): H1406-1414		
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131		

EXA	MI	INI	ER
NYI-	108	871	9v2

DATE CONSIDERED

Sheet 19 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T	(1 1 C. CANTALLETTERO, T. D. D. C. A. D. C. D. C. A. D. C. D. C. A. D. C. D. C. A. D. C. D. D. C. D. D. C. D. D. D. D. D. D. D. D. D. D. D. D. D.	_
Initials	C240	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company, Montvale, NJ), pp.1765-1769	T
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone- related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720	
. - .	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
	C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8	
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
	C252	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAM	IN	ER
NYI-408	887	19v2

DATE CONSIDERED

Sheet 20 of 26 of List of References

APPLICATION NO.

1647

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C259	SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	
	C260	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262	SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift für Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only)	
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464	
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	Г
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin- dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29	
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	
	C274	STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C276	STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and	

EXAMINER
NYI-4088719v2

C278

DATE CONSIDERED

STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J.

Biological Properties," British J. Haematology, 100:79-89.

of Clinical Investigation, Vol. 35, pp. 711-717

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 21 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

l e					
ATTY. DOCKET NO.	APPLICATION NO.				
10165-042-999	10/573,905				
APPLICANT					
Coleman et al.					
FILING DATE	ARTUNIT				
May 30, 2006	1647				

		NON PATENT LITERATURE DOCUMENTS	
Examiner	<u> </u>		Т
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C279		
		blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and	Г
		Erythrocytosis," British J. Haematology, 113:49-51.	l
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol.	Т
		73:1525-1535	
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor	t
	0205	orientation," Nature 395:511-516	l
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by	\vdash
		inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in	Τ
		vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol.	
		81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood	
		flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on	
		chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys.	
		Res. Commun. 148(1):443-448	
	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis,"	Г
		Press Medicale, Vol. 31(11):505-514 (Abstract only)	
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats	
		with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced	
		anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- β Immunoreactivity and microglia are enhanced in the rat hippocampus	
	1	by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol	
	<u> </u>	19(12):5054-65	
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures	
		but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological	Ī
	1	assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein I (bone	
		morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins,"	
	~~	Blut, 44:173-175.	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	

EXAMINER
EXAMINER NYI-4088719v2

DATE CONSIDERED

Sheet 22 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10/573,905 APPLICANT Coleman et al.

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials	C299	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	Т
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	1
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42	
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83	
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 23 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Oncologist 1(5):337-339	Т
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	T
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	T
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	<u> </u>
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	
-	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	1
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	
-	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	1
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	T
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	T
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	\dagger
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	+-
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	+

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS). Title, Date, Pertinent Pages, Etc.)	Т		
	C346	Office Action, Application No. 09/716,963, date mailed: March 18, 2005			
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005			
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006			
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007			
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002			
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003			
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004			
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004			
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005			
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006			
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007			
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007			
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007			
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008			
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002			
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002			
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003			
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004			
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004			
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005			
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006			
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006			
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007			
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002			
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002			
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003			
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003			
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004			

EXAMIN	ER
NYI-40887	19v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 25 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO	A PRI LCATIONI NO
ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
Coleman et al.	
FILING DATE	ARTUNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
midais	C374	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	†	
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	\dagger	
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	T	
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	†	
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	1	
	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	+	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	\dagger	
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	T	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	1	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	1	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	†	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006		
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	+	
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	\dagger	
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	\vdash	
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	\vdash	
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	\dagger	
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	\vdash	
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	T	
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007		
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	╁	
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005		
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	T	
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007		
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	\vdash	
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL		
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975		

EXAMI	INER
NYI-408	8719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 26 of 26 of List of References

	filing date May 30, 2006	ART UNIT 1647	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Coleman et al.		
	ATTY. DOCKET NO. 10165-042-999	10/573,905	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912	
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008	

EXAMINER NYI-4088719v2

Express Mail No.: EV 654 895 272 US Express Mail No.: EV 654 895 286 US

Express Mail No.: EV 654 895 290 US Express Mail No.: EV 654 895 309 US

Sheet 1 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT May 30, 2006 1647

U.S. PATENT DOCUMENTS

*EXAMINER					PAGES, COLUMNS, LINES, WHERE
INITIAL		DOCUMENT NUMBER	DATE	NAME	RELEVANT PASSAGES OR RELEVAN
	A01	4,343,782	8/10/982	Shapiro	FIGURES APPEAR
	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	· · · · · · · · · · · · · · · · · · ·
	All	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
1	A18	5,621,080	04/15/97	Lin	
,	A19	5,625,035	04/29/97	Clemons	
/	120	5,661,125	08/26/97	Strickland	
/	121	5,696,080	12/09/97	O' Brien	
1	122	5,700,909	12/23/97	O'Brien	
/	123	5,714,459	02/03/98	O'Brien	
/	124	5,750,376	5/12/98	Weiss et al.	
	125	5,756,349	05/26/98	Lin	
		5,763,198	6/09/98	Hirth et al	
		5,767,078	06/16/98	Johnson et al.	

EXAMINER NYI-4088719v2

DATE CONSIDERED

Sheet 2 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

U.S. PATENT DOCUMENTS *EXAMINER PAGES, COLUMNS, LINES, WHERE INITIAL RELEVANT PASSAGES OR RELEVANT DOCUMENT NUMBER DATE NAME FIGURES APPEAR 5,773,569 A28 06/30/98 Wrighton et al. 5,824,672 A29 10/20/98 Simpkins et al. 5,830,851 A30 11/03/98 Wrighton et al. 5,835,382 A31 11/10/98 Wilson et al. 5,856,298 A32 01/05/99 Strickland 5,888,772 A33 03/30/99 Okasinski et al. 5,955,422 A34 09/21/99 Lin A35 5,997,865 12/7/99 Bennett et al. 6,048,971 Sytkowski et al. A36 4/11/00 6,071,970 6/06/00 A37 Mueller et al. A38 6,103,526 04/15/05 Smith et al. 6,153,407 11/28/00 A39 Sytkowski et al. 6,165,783 A40 12/26/00 Weiss et al. 6,242,570 6/05/01 A41 Sytkowski 6,291,661 09/18/01 Graddis et al. A42 6,340,742 A43 1/22/02 Burg et al. 6,399,336 A44 6/4/02 Paulson et al. 6,440,932 8/27/02 A45 Lehmann et al. 6,489,293 12/3/02 A46 Sytkowski et al. 6,521,245 A47 2/18/03 Zaharia Λ48 6,531,121 3/11/03 Brines et al. 6,583,272 Λ49 6/24/03 Bailon 6,645,522 11/11/03 Λ50 Naeff et al. 7,214,532 5/08/07 A51 Stern et al. 7,309,687 12/18/07 Λ52 Brines et al. 7,345,019 A53 3/18/08 Brines et al. 2002/0031806 3/14/02 Λ54 Lee

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

			U.S.	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A55	2002/0052309	5/02/02	Anagnostou et al.	FIGURES APPEAR
	A56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	Λ72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	A74	2004/0009902	1/15/04	Boime	
	Λ75	2004/0018978	1/29/04	Campana et al.	
	A76	2004/0091961	5/13/04	Evans et al.	
	Λ77	2004/0096447	5/20/04	Yasuda et al.	
	A78	2004/0122216	6/24/04	Nielsen et al.	
	Λ79	2004/0209812	10/21/04	Farrell et al.	
	180	2004/0214236	10/28/04	Brines et al.	
	181	2005/0176627	8/11/05	Cerami et al.	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A82	2006/0034799	2/16/06	Brines et al.	FIGURES APPEAR
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

	FOREIGN PATENT DOCUMENTS				
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME:	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
B01	C4 0 004 440	12/30/98	Roche Diagnostics Gmbh	RELEVANT FIGURES APPEAR	
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		-
B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
B04	EP 0640619	1/03/95	Amgen Inc.		
B05	EP 0668 351	8/23/95	Amgen, Inc.		
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

	FOREIGN PATENT			Т
	DOCUMENT COUNTRY CODE, NUMBER.			PAGES, COLUMNS, LINES, WHERE
	KIND CODE (IF KNOWN)	DATE	NAME	RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
B09	WO 00/032772	6/8/00	Eli Lilly & Co.	
B10		10/19/00	Kenneth S. Warren Laboratories	
BII	WO 00/24893	5/4/00	Amgen, Inc.	
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)	
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG	
B14	WO 01/81405	1/11/01	Amgen Inc.	
B15	WO 01/82952	11/08/01	Action Pharma APS	
B16	WO 01/82953	11/08/01	Action Pharma APS	
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG	
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.	
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.	
B20	WO 02/14356	2/21/02	Althoff, Claudia	
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG	
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG	
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.	
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.	
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.	
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.	
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.	
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.	
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B32	WO 06/002646	1/12/06	Lundbeck A/S	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 6 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

			FOREIG	SN PATENT DOCUMENTS		
		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	Т
	B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	ALEEL VIIIVI FIGURES ALT LAK	
	B35	WO 91/05867	5/02/91	Amgen Inc.		
	B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		
	B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		<u> </u>
	B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		
	B39	WO 95/05465	02/23/95	Amgen, Inc.		<u> </u>
	B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		
	B41	WO 97/08307	3/6/97	II Dong Pharmaceutical Co. Ltd.		<u> </u>
	B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		
	B43	WO 97/32895	9/12/97	Regents of the University of California		
	B44	WO 98/10650	3/19/98	East Carolina University		
	B45	WO 98/18926	05/07/98	G.D. Searle & Co.		
	B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
	B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		
	B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		
····	B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		
	B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		
	B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		
	B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		
	B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		
1	B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		
	B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		
,, ,,	B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		

EXAMINER
EXAMINER NYI-4088719v2

Sheet 7 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		T
Initials	- -	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of	Τ
		claims, and Ehrenreich clean copy of claims (10/02/06)	1
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	Т
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	Г
······		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	1.
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	
		alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	
-		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	Π
		Natl. Acad. Sci. USA 91:3974-3978	l
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	
		for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	Γ
	 	der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	l
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	Г
		Glycoproteins," Meth. Enzymol., 50:287-291.	
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	Г
		Cerebrovascular Disease, Vol. 9:131-135	
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	Г
	 	premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	
	 	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	C13	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	
	ļ	Cell. Biol. 14(10):6506-6514	
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	
	· · · · · ·	function relationships," J. Biol. Chem. 272(8):4985-4992	
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	
	↓	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	
		traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	
	<u> </u>	12.	
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
		projectin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain." Biochem, Biophys, Res	
	ļ	Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
		artery occulsion in rats," Brain Research, Vol. 739:88-96	
	C20	BENIT et al., 1993, "The 'WS motif common to v-mpl and members of the cytokine recentor superfamily is	_
		dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 8 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Т
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	*
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 9 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner	<u> </u>		
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597.	
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	\dagger
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	T
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42	
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	1
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179	
	C58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 10 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
· ·	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	

EXAMINER
NYI-4088719v2

^{*}ENAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 11 of 26 of List of References

	ATTY, DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Inchele come of the code of CADITAL LETTERS). Title Date Desired Date State	Т
Initials	C81	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages. Etc.) EMIR, 2004, "Erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	1
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T	,	Τ
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C102	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and	l
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	L
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	T
	"."	Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,	Г
		Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	T
	0.00	Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	ľ
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97(2):315-	
		323.	
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	Г
		neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental	Г
		spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in	Г
		rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	CHI	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	Г
		clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	
		therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating	
		bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	
		Kidney Intl. 38:480-486	
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal	
		degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.	
		1592:215-223	
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	
		antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	
		granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: 1. Chronic Anemias. II.	
		Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	_
	".2"	receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	
	"'''	Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	

EXAM	INER
NYI-408	88719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 13 of 26 of List of References

APPLICATION NO.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al.

FILING DATE ART UNIT
May 30, 2006 1647

ATTY. DOCKET NO.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	Т
	C123		
	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
<u> </u>	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462.	
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients, "Nephron, Vol. 72, pp. 30-36	
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179	
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER
EXAMINER NYI-4088719v2

DATE CONSIDERED

Sheet 14 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS			
xaminer			_
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following	+
		derivery of adenoviral vectors to mouse liver and lung." Hum, Gene Ther. 7(13):1555-66	1
	C142	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paragyonase active site."	4
		Chem Blot Interact, vol. 119-12():/9-84	1
	C143	JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino said residues by	+
		group-sciective labelling and site-directed mutagenesis." Chem Riol Interact. Vol. 110, 120,71,70	١
	C144	JUBINSK Y et al., 1996, "The beta c component of the granulocyte-macrophage colony stimulating forter (CA)	+
		Con // interieuxin 5 (1L-5 // IL-5 receptor interacts with a hybrid GM-CSF/erythronoletin recentor to influence	ı
		profiteration and beta-globin mKNA expression." Mol. Med. 2(6):766-773	I
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 recentor functionally associates with the	+
	<u> </u>	1 cryunopolettii receptor. Biood 90(5): 1867-1873	I
	C146	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia reportision	ł
	1	injury, 1100. Nati. Acad. Sci. USA 99(16):10639-10664	l
	C147	JUUL et al., 1998, "Erythropoietin and erythropojetin recentor in the developing human central persons	ł
		System , Pediatr, Res. 43(1):4()-49	١
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetue". Farly Human David, 52(2):225-240.	ł
		10tus, Early Human Devel. 32(3):233-249	l
	C149	JUUL et al., 2001, "Recombinant erythronoietin (FPO) crosses the blood brain boaring (DDD) in a contract of the contract of th	ŀ
		sheep, soc. for Neuroscience Abstracts 2/(1):929 (31st Annual Meeting of the Society for Neuroscience, Soc.	ı
		Dicgo, CA 1104, 10-13, 20011	ı
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	ŀ
		damage, Acia raculati. Supp. vol. 438. pp. 36-42	l
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of histin bound to a conjugate	L
		of a vidin and a monocional antibody to the transferrin recentor." Drug Metah Dispos. Vol. 22(1):00, 105	
	C152	KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin,"	L
		Olycoolology, voj. 11(12):1043-1049	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for all	_
		therapy of heart failure-induced milital regulation (fireflation 108.1705_1707	
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New	_
		1 Olk Acau. 301., 149.10-24.	
	C155	KESWANI et al., 2004, "A novel endogenous erythronoietin mediated nathway provents avantal decreases."	_
	1 1	Aim. Neutot. Vol. 30(0).013-820	
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3	
	0150	activation," Blood 99(1):102-110	
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	_
	", "	Am J Anat. Vol. 178:241-9.	
	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant crythropoietin and cepharanthin in a girl	
	C136	with refractory anemia," Japanese J. Clin. Hematology. Vol. 35(7):694-6988 (w/English abstract)	
	C159	KITAMURA et al. 1989 "Identification and analysis of human with	_
	(134	KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1," Blood, Vol 73(2):375-80	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 15 of 26 of List of References

	ATTY, DOCKET NO.	APPLICATION NO.
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	7
	C160		1
		Obstetrics and Gynecology, 96(5):826-828.	┡
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic	ı
·-·		neurons in vitro and in vivo", Brain Res. 609:29-35	\perp
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic	1
		mechanism.", Behav. Neural Biol. 62:237-243	L
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in	ľ
		patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following	Г
		neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle	Γ
		cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional	
	0.00	asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	١.
· · · · · · · · · · · · · · · · · · ·	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive	Γ
	0.07	and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J.	ı
		Cardiovasc. Pharmacol. 31(4):601-608	Г
· · · · · · · · · · · · · · · · · · ·	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A.	T
	100	95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol.	T
	(10)	305, pp. 239-242	l
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol.	T
	10170	93:75-80	
-	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid	T
	C1/1	progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	C172	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human	t
	C1/2	fetuses", Pediatr. Res. 40(3):376-380	l
	C172	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing	t
	C173	various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	0.74	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund,	H
	C174	http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	ĺ
	+	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked	H
	C175	glycans," Anal. Biochem. 219:207-217	
		LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain	╀
	C176		
		Res. 692:143-153	⊢
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the	
		Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	╀
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol.	
		166:159-169	┖
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct	1
		hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 16 of 26 of List of References

	ATTY, DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		1
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Land de control de CADITAL LETTERS) Title Date Periode Person Face	T
nitials	+	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem.	+-
	C180	272(51):32395-32400	
	CIRL	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site,"	+
	C181	Blood, Vol. 110(7):2408-2413	1
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand	1
	10102	activation," Science 283:987-990	1
	C183	CORDO A LAGOR WALL ALL CALL ALL CALL ALL CALL ALL CALL ALL	1
		Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions,"	Τ
		Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain	
		injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	┸
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood,	
		Vol. 98(9):2872-2874	╀
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1",	
	- 	Kidney Intl. 53:1259-1268	╀
	C188		
	-	Kidney Intl. 39:155-163 MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci.	╁
	C189	8:666-676	
	GIOO	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the	╁╌
	C190	brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	t
			╁
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison	
		with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216 MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat	╀
	C193	astrocytes", J. Biol. Chem. 269(30):19488-19493	
		MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary	╁
	C194	cultured astrocytes", Brain Res. 746:63-70	
	G105	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular	+-
	C195	Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS.	$^{+}$
	C190	USA 93:9471-9476	1
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit,"	†
	(177	Cytokine 13(4):240-243	ı
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta:	T
	176	differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll.	T
	3177	Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	t

EXAMINER	
NYI-4088719v2	2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 17 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS). Title, Date, Pertinent Pages, Etc.) Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 18 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ARTUNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
initials	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	Ť
	C222		
	C223	CIVADA A LOGGIO AL LA LIGATION CALLE LA LIGATION	
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website http://cancerweb.ncl.ac.uk/omd . Published at the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB Project.	
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69	
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92.	
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti- carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16	
	C235	oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773	
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980	
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	
	C238	260(5 Pt 2): H1406-1414	
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131	

EXAMINER
NY1-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 19 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	т
imiais	C240	PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company, Montvale, NJ), pp.1765-1769	†
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone- related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246		
	C247	D D 11 C 1	
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
	C252	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER NYI-4088719v2	
NYI-4088719v2	,

DATE CONSIDERED

Sheet 20 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C259		
		ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	
	C260	74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262		
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464	
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin- dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29	
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	
	C274	STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C276	STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J. of Clinical Investigation, Vol. 35, pp. 711-717	

EXAM	INER
NYI-408	88719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 21 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

i e	•
ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
	A DITE LOUIT
FILING DATE	ARTUNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
ilitiais	C279	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C281	73:1525-1535	
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448	
	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale, Vol. 31(11):505-514 (Abstract only)	
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- β Immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol 19(12):5054-65	
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," Blut, 44:173-175.	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 22 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10/573,905 ART UNIT May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C299	WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42	
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83	
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 23 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		Oncologist 1(5):337-339	Ì
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	1
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	

EXAMINER
NYI-4088719v2

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.	
10165-042-999	10/573,905	
APPLICANT		
Coleman et al.		
FILING DATE	ART UNIT	
May 30, 2006	1647	

	NON PATENT LITERATURE DOCUMENTS					
Examiner		(Include name of the outbook in CARITAL LETTERS) Title Date Region Record				
Initials	C346	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Office Action, Application No. 09/716,963, date mailed: March 18, 2005	<u>T</u>			
<u> </u>	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005				
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006				
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007				
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002				
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003				
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004				
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004				
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005				
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006				
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007				
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007				
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007				
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008				
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002				
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002				
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003				
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004				
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004				
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005				
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006				
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006				
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007				
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002				
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002				
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003				
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003				
	C373	Office Action, Application No. 09/717.053, date mailed: April 20, 2004				

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 25 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		T_
Initials	C374	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Office Action, Application No. 09/717,053, date mailed: May 3, 2005	T
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	+
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	╀
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	╁╌
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	+
-	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	╁
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	╁
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	+
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	T
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	\dagger
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	†
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	<u> </u>
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	╁
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	+
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	╁╴
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	\top
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	T
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	╁┈
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	\dagger
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	Ì
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	T
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	T
,	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	T
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	1
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

EXAMINER
NVI-1088719v2

DATE CONSIDERED

Sheet 26 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905
APPLICANT Coleman et al.	
FILING DATE May 30, 2006	ART UNIT 1647

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т				
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912					
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008					

EXAMINER NYI-4088719v2



Express Mail No.: EV 654 895 272 US

Express Mail No.: EV 654 895 286 US Express Mail No.: EV 654 895 290 US Express Mail No.: EV 654 895 309 US

Sheet 1 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE ART UNIT May 30, 2006

1647

*EXAMINER					PAGES, COLUMNS, LINES, WHERE
INITIAL	1	DOCUMENT NUMBER 4,343,782	DATE	NAME	RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01		8/10/982	Shapiro	
	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	All	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	A21	5,696,080	12/09/97	O' Brien	
	Λ22	5,700,909	12/23/97	O'Brien	
	A23	5,714,459	02/03/98	O'Brien	
	Λ24	5,750,376	5/12/98	Weiss et al.	
	A25	5,756,349	05/26/98	Lin	
		5.763,198	6/09/98	Hirth et al	
		5,767,078	06/16/98	Johnson et al.	

EXAMINER NYI-4088719v2

DATE CONSIDERED

Sheet 2 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

	T				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		PAGES. COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A28	5,773,569	06/30/98	Wrighton et al.	FIGURES APPEAR
	A29	5,824,672	10/20/98	Simpkins et al.	
·	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	A46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	Λ48	6,531,121	3/11/03	Brines et al.	
	Λ49	6,583,272	6/24/03	Bailon	
		6,645,522	11/11/03	Naeff et al.	
	Λ51	7,214,532	5/08/07	Stern et al.	
		7.309,687	12/18/07	Brines et al.	
		7,345,019	3/18/08	Brines et al.	
		2002/0031806	3/14/02	Lee	

EXAMINER
NYI-4088719v2

Sheet 3 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

				1 Way 30, 2000	1647
			U.S.	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
	A55	2002/0052309	5/02/02	Anagnostou et al.	FIGURES APPEAR
-	A56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	Λ72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	A74	2004/0009902	1/15/04	Boime	
	Λ75	2004/0018978	1/29/04	Campana et al.	
	Λ76	2004/0091961	5/13/04	Evans et al.	
	Δ77	2004/0096447	5/20/04	Yasuda et al.	
	A78	2004/0122216	6/24/04	Nielsen et al.	
	Λ79	2004/0209812	10/21/04	Farrell et al.	
	A80	2004/0214236	10/28/04	Brines et al.	
+		2005/0176627	8/11/05	Cerami et al.	
				Column et al.	

EXAMINER
NYI-4088719v2

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	FIGURES AFFEAR
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

	FOREIGN PATENT DOCUMENTS					
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR		
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh	RELEVANT FIGURES APPEAR	H	
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		F	
B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.			
B04	EP 0640619	1/03/95	Amgen Inc.		\vdash	
B05	EP 0668 351	8/23/95	Amgen, Inc.		μ-	
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG			
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)			
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)			

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		FOREIG	SN PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
B09		6/8/00	Eli Lilly & Co.	RELEVANT FIGURES APPEAR	Т
B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		
B11	WO 00/24893	5/4/00	Amgen, Inc.		
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)		-
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		
B14	WO 01/81405	1/11/01	Amgen Inc.		
B15	WO 01/82952	11/08/01	Action Pharma APS		ļ —
B16	WO 01/82953	11/08/01	Action Pharma APS		
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		
B20	WO 02/14356	2/21/02	Althoff, Claudia		
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
 B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
 B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		_
 B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	·	
B32	WO 06/002646	1/12/06	Lundbeck A/S		
B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 6 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B34		2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	RECEVAINT FIGURES AFFEAR	†
B35	WO 91/05867	5/02/91	Amgen Inc.		t
B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		t
B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		+
B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		t
B39	WO 95/05465	02/23/95	Amgen, Inc.		ł
B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		ŀ
B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.		ŀ
B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		
B43	WO 97/32895	9/12/97	Regents of the University of California		ŀ
B44	WO 98/10650	3/19/98	East Carolina University		r
B45	WO 98/18926	05/07/98	G.D. Searle & Co.		
B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		-
B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		-
B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		-
B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		-
B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		-
B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		_
B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		-
B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		_
B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		-
B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		_
B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		_

EXAMINER
NYI-4088719v2

Sheet 7 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			1
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Ιт.
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper I. Declaration, Brines clean copy of	1
		claims, and Ehrenreich clean copy of claims (10/02/06)	
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	十一
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	T
		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	İ
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	十
		alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	\vdash
		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	-
		Natl. Acad. Sci. USA 91:3974-3978	i
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	\vdash
		for Bioassay," Bull. Org. mond. Sante, 47:99-112.	Ì
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	-
		der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	\vdash
		Glycoproteins," Meth. Enzymol., 50:287-291.	
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	\vdash
		Cerebrovascular Disease, Vol. 9:131-135	
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	-
		premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	
	0.2	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	C13	BARBER et al.,1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	
	0.5	Cell. Biol. 14(10):6506-6514	
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	
	``'	function relationships," J. Biol. Chem. 272(8):4985-4992	
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	
	613	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	
	1010	traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	_
	[017	12.	
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
	1018	prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
		Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996. "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
	[[[artery occulsion in rats," Brain Research, Vol. 739:88-96	
·····	1000	RENIT et al. 1003 "The WS motif common to ward a land to the state of	
	C20	BENIT et al., 1993, "The 'WS motif common to v-mpl and members of the cytokine receptor superfamily is	
 -	نـــــــــــــــــــــــــــــــــــــ	dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	

EXAMINER NYI-4088719v2
NYI-4088719v2

DATE CONSIDERED

Sheet 8 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

1	
ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	T
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	T
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	T
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	T
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	T
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	ľ
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-15993	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER NYI-4088719v2
NYI-4088719v2

DATE CONSIDERED

Sheet 9 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials	-	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597.	
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	
· · · · · · · · · · · · · · · · · · ·	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42	Ī
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179	
	C'58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 10 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation	
	1	to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem.	-
		Vol. 10(1):32-7	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist,	Т
·		Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival - Modifications to the	
		tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	1
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's	+
	1 003	disease," Pharm. Res. 15(3):386-98	ŀ
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley &	+
	C04	Sons, p. 122, p. 508	
	015	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple	╁
	C65	sclerosis," Brain, Vol. 128, pp. 375-385	
	+	Sciences, Blatti, vol. 126, pp. 575-363	╄
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and	
		platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	丄
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the	
		mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant	П
		erythropoietin treatment", ASAIO J. 38:M477-M480	
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation:	Τ
		prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	ı
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global	1
	1	ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, np. 71-78	1
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	+-
	+		L
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New	+
	10/3	York, 1993	1
	074	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion,	-
	C74	and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	+	and Biological Function, J. Biol. Clem., 203(33),1/310-1/321.	<u> </u>
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance,"	1
	 	Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	┖
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP),"	
	<u> </u>	Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med.	
		8(8):495-505	
	C:78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular	†
		Psychiatry, 9:42-54	1
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	\vdash
	10/3		L
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 11 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	<u> </u>		Τ-
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	T
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
· · · · ·	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	\vdash

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C102		
	ļ	Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	<u> </u>
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	
	0.0.	Chem Soc., Vol. 124(4):544-555	
	C105		
	10103	Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	l
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	
	100	Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97(2):315-	\vdash
	10107	323.	
· · · · ·	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	
	0.00	neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental	\vdash
	10.07	spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in	H
	10110	rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	C111	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	┢
	10111	clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	l
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	┢
	CITZ	therapy. J Sleep Res. 4(S1): 130-134	
	0112	GREGORY et al., 1999, "GATA-I and erythropoietin cooperate to promote erythroid cell survival by regulating	┼
	C113	bcl-x _L expression", Blood 94:87-96	
		GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	⊢
	C114	Kidney Intl. 38:480-486	
	+		_
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal	
	_	degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.	
		1592:215-223	<u> </u>
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	
		antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	
		granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II.	
		Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	
	"-"	receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	
	"	Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	

EXAM	IN	ER
NYI-408	87	19v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 13 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	_
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		_
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
iiitiais	 	in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	Ť
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209	
	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462.	
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients, "Nephron, Vol. 72, pp. 30-36	
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327	
-	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179	
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER
NYI-4088719v2

Sheet 14 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

NON PATENT LITERATURE DOCUMENTS				
Examiner	1		_	
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1	
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgens auraceia. C. II.	+	
	_	derivery of adenoviral vectors to mouse liver and lung." Hum. Gene Ther. 7(13):1555-66	1	
	C142	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paracychasa active site."	$^{+}$	
		Chem Dioi interact. vol. 119-120:79-84		
	C143		╁	
		I Stoup-scientive labelling and site-directed militagenesis "("hem Riol Interact Vol. 110, 120.71, 70	l	
	C144	JUDINSK Y et al., 1996, "The beta c component of the granulocyte-macrophaga colony stimulating for the Colony	╁	
	1	1 Col // Interlegating (1L-3)/1L-3 receptor interacts with a hybrid GM-CSF/erythropoietin recentor to influence	L	
		promeration and beta-global mixing expression." Mol. Med. 7(6)-766-773	l	
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 recentor functionally associates with the	╀	
		1 cryantopoletin receptor, B100d 90(5):1867-1873	l	
	C146	JUNK et al., 2002, "Erythropojetin administration protects retinal neurons from couts inchession and fine and f	┝	
	<u> </u>	mjury , 1100. Nati. Acad. Sci. USA 99(16):10639-10664	ĺ	
	C147	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central persons	┝	
		system, Pediatr. Res. 43(1):40-49	l	
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	H	
	<u> </u>	1 retus , Larry Fluritan Devel, 32(3):233-249		
	C149	JUUL et al., 2001, "Recombinant erythropojetin (EPO) crosses the blood brain barrier (BBD) in greature food	┞	
		siecep, soc. for Neuroscience Abstracts 2/(1):929 (31st Annual Meeting of the Society for Neuroscience, San 1		
		Diggo, CA (Nov. 10-13, 2001)		
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	_	
		Talliago, ricia i acujali, Supp. vol. 438. hb 36-47		
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotic bounds."	_	
	<u></u>	or avidin and a monocional antibody to the transferrin recentor "Drug Metah Dienos, Vol. 22(1):00, 105		
	C152	KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin,"	_	
		GlyCobiology, vol. 11(12):1043-1049		
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral considerable and extra considerable and short-term efficacy of percutaneous mitral considerable and extra considerable and ex		
		therapy of heart familie-induced filling regulation (fremation 100.1705 1707		
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New		
	1 1	1 olk Acad. Sci., 149,10-24.		
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"		
		7 tim. 14cutot. Vot. 30(0),013-020		
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3		
		activation, D1004 99(1):102-110		
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"		
	5.57	Am J Anat. Vol. 178:241-9.		
	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant erythropoietin and cepharanthin in a girl	_	
	C136	with refractory anemia, Japanese J. Clin. Hematology. Vol. 35(7):694-6988 (w/English abstract)		
	C159	KITAMURA et al. 1989 "Identification and analysis of hymnology (W/English abstract)		
	C139	KITAMURA et al., 1989, "Identification and analysis of human crythropoietin receptors on a factor-dependent cell line, TF-1," Blood, Vol 73(2):375-80		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 15 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10165-042-999 10/573,905

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(I I I C CADITAL I STTERS) Till Day Periocat Process	T
Initials	C160	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96(5):826-828.	
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo", Brain Res. 609:29-35	
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	C166	LA1 et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31(4):601-608	
	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A. 95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol. 305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol. 93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	C172	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40(3):376-380	
	C173	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	C174	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund, http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," Anal. Biochem. 219:207-217	
	C176	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	

EXAMIN	ER
NYI-40887	19v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 16 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

NON PATENT LITERATURE DOCUMENTS			
Examiner			Ι_
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C180	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	Γ
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll. Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	T

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 17 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ARTUNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	Γ
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 18 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
10103-042-777	10/3/3,703
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Leal, de como of the outhor (in CADITAL LETTERS) Title Date Partinent Pages Etc.)	Т
Initials	C221	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages. Etc.) OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	†
	C222		
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332	
	C224	the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB Project.	
	C225	rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	
	C226	rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	
	C227	factor or thrombopoietin," Cytokine 8(1):66-69	
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	
	C230	Vol. 70:1781-92.	
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	
	C233	carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	C234	histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773	
	C236	11(4):974-980	
	C237	infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260(5 Pt 2): H1406-1414	
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 19 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

(Include name of the author (in CAPITAL LETTERS). Title, Date, Pertinent Pages, Etc.) PHYSICIANS' DESK REFERENCE, 1995, 49th Edition (Medical Economics Data Production Company, Montvale, N.), pp.1765-1769 PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone related peptide (hPTHP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717-720 C242 PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45 C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-3525 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design. Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Frythropoietin receptor activation by a ligand-induced conformation change," Science 283-990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1993, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1999, "First indial second phases of biphasic fever: two sequential stages of the			NON PATENT LITERATURE DOCUMENTS	
PHYSICIANS' DESK REFERENCE, 1995, 49th Edition (Medical Economics Data Production Company, Montvale, NJ), pp.1765-1769 C241 PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717-720 C242 PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45 C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Witric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283-990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 ROSHA (1990, "Role of neuroexcitation i	Examiner	-		T
Montvale, NJ), pp. 1765-1769 C24 PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717-720 C242 PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45 C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):1173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al. 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283-990-993 C249 ROBINSON et al., 1995, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase d	nitials	<u> </u>	1	1
C241 PLBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone- related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720 C242 PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45 C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-3522 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design. Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283-990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndromer?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", 67(8):1442-1452 SADAMOTO et al., 1998, "Erythropoietin preve		C240		
related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717-720 C242 PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45 C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 67(14):1834-1842 C254 RUSH et al., 19				L
C242 PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45 C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design. Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C255 SALTO et al., 1990, "Role of neuroexcitation in development of blood-br		C241		
C242 PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45. C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1999, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin provents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C354 SATANEAKA et al., 1998, "In vivo evidence that erythropoietin protects				
Chem. 246(4):930-45 C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design. Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1998, "Brythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C354 SATAKE et al., 1990, "Role of neuroexcitation in developme				
C243 PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Freparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257;347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery",		C242		-
Natl. Acad. Sci. USA 91:5705-5709 C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 SATANKA et al., 1998, "In vivo evidence that erythropoietin ran increas	· 			L
C244 PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design. Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1999, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery". Biochem. Biophys. Res. Comm. 253:26-32 SADAMOTO et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin: an increase in in vitro act		C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc.	Π
procedure," Diabetes, Vol. 32:1087-1091 C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery". Biochem. Biophys. Res. Comm. 253:26-32 C256 SATO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51,				
C245 PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SATANE et al. 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C258 SATANE et al. 1990, "C		C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation	Γ
conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 C240 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design. Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SATO et al., 1999, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-				l
C246 QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 SAKANAKA et al., 1999, "In vivo evidence that erythropoietin: an increase in in vitro activity by SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces	Τ
Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C258 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin: an increase in in vitro activity by		1	conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
Chem. 273(18):11173-11176 C247 REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin ran increase in in vitro activity by SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol.	Γ
Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C258 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		02.0		
Pharmaceutical Design, Vol. 9, pp. 1-8 C248 REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C258 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current	Τ
283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		02.7		l
283:990-993 C249 ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid." Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science	Τ
conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		02.10		
conformation," J. Biol. Chem. 250(18):7435-42 C250 ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and	Τ
syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		02.17	conformation," J. Biol. Chem. 250(18):7435-42	
syndrome?" The American Physiological Society, pp. R244-253 C251 ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness	Γ
Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		0230		
Peptides 19(6):1023-1030 C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells".	T
C252 ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by				
acid," Vis. Res., 37(24):3445-51 C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C252		
C253 RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C232		
endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C253	D1011 - 1 1002 4D - 11 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	T
65(14):1834-1842 C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		1 6233		
C254 RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by				
67(8):1442-1452 C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C254		t
C255 SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C234		ļ
with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		(:255		t
C256 SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		1 (2)		İ
following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C256	CAUTO A LAGOR PLACE TO THE CAUTO A CAU	\vdash
C257 SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C230		
Natl. Acad. Sci. USA 95:4635-4640 C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by		0355	SAKANAKA et al. 1998 "In vivo evidence that erythronoietin protects neurons from ischemic democe". Proc	+
C258 SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by		C257		1
			CATAKE A LICON WOLL IN THE STATE OF THE STAT	\vdash
		C258	guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINE	₹
NY1-4088719	v 2

DATE CONSIDERED

Sheet 20 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C259		
		ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	_
	C260	74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262		
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain	T
	C203	and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	6244	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent	╁─
	C264	growth in hematopoietic cell lines," Blood 88(2):455-464	
 	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in	
	C263	Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J	
····	_	Ultrastruct Res. Vol. 88(1):18-29	_
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J.	
		Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	
	C274	STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and	
	[Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc.	_
	(2/3	Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C276	STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
	[2/0]	Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human	
		Urinary Erythropoietins," J. Endocrinol., 134:459-484.	l
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and	-
	(2//	Biological Properties," British J. Haematology, 100:79-89.	
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J.	
	[(2/8	of Clinical Investigation, Vol. 35, pp. 711-717	

EXAMIN	ER
NYI-40887	19v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 21 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C279	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral	
	-	blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	-
	C280	Erythrocytosis," British J. Haematology, 113:49-51.	
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535	
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283	orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
<u>-</u>	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448	
	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale, Vol. 31(11):505-514 (Abstract only)	
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- β Immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol 19(12):5054-65	
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," Blut, 44:173-175.	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 22 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Include name of the early of CARITAL LETTERS) Title Date Buringer Bases (in CARITAL LETTERS)	T
nitials	G200	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	+'
	C299		4
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	T
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	Τ
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42	
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83	
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	T
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	T

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 23 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
		Oncologist 1(5):337-339	
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	T
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	T
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	T
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	T
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	T
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	
<u>-</u>	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	1
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	T
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	T
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	T
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	T
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	1
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	†
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	T

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C346	Office Action, Application No. 09/716,963, date mailed: March 18, 2005	
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	-
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
· ··· · · · · · · · · · · · · · · · ·	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	

EXA	MIN	NER
NYI-	40887	719v2

Sheet 25 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials	G274	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Office Action, Application No. 09/717,053, date mailed: May 3, 2005	T
	C374	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	-
	C375	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	\bot
 	C376	•	-
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	\bot
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	ļ
	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	<u> </u>
·	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	1
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	1
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	1
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	\top
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	T
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	1
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	\dagger
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	╁┈
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	T
· · ·	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	T
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	T
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	T

EXAMINER	ł
NYI-4088719v	0

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 26 of 26 of List of References

APPLICATION NO.

1647

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912	
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008	

EXAMINER NYI-4088719v2

Sheet 1 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE ART UNIT May 30, 2006 1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	4,343,782	8/10/982	Shapiro	FIGURES APPEAR
	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	All	5,350,836	9/27/94	Kopchick et al.	
-	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	418	5,621,080	04/15/97	Lin	
/	119	5,625,035	04/29/97	Clemons	
	120	5,661,125	08/26/97	Strickland	
/	121	5,696,080	12/09/97	O' Brien	
	122	5,700,909	12/23/97	O'Brien	
	23	5,714,459	02/03/98	O'Brien	
	24	5,750,376	5/12/98	Weiss et al.	
		5,756,349	05/26/98	Lin	
		5,763,198	6/09/98	Hirth et al	
—— <u>—</u>		5,767,078	06/16/98	Johnson et al.	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 2 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

			U.S. 1	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A28	5,773,569	06/30/98	Wrighton et al.	FIGURES APPEAR
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	Λ46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	Λ48	6,531,121	3/11/03	Brines et al.	
	Λ49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
	A51	7,214,532	5/08/07	Stern et al.	
	Λ52	7,309,687	12/18/07	Brines et al.	
	A53	7,345,019	3/18/08	Brines et al.	
	Λ54	2002/0031806	3/14/02	Lee	

EXAMI	NE	R
NYI-4088	8719	v2

DATE CONSIDERED

Sheet 3 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A55	2002/0052309	5/02/02	Anagnostou et al.	FIGURES APPEAR
	A56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	A72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	A74	2004/0009902	1/15/04	Boime	
	A75	2004/0018978	1/29/04	Campana et al.	
	۸76	2004/0091961	5/13/04	Evans et al.	
,	A77	2004/0096447	5/20/04	Yasuda et al.	
,	178	2004/0122216	6/24/04	Nielsen et al.	
/	179	2004/0209812	10/21/04	Farrell et al.	
1	180	2004/0214236	10/28/04	Brines et al.	
	\81	2005/0176627	8/11/05	Cerami et al.	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

	U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN' FIGURES APPEAR	
	A82	2006/0034799	2/16/06	Brines et al.	PIGURES APPEAR	
	A83	2006/0216757	9/28/06	Brines et al.		
	A84	2007/0298031	12/27/07	Brines et al.		
	A85	2008/0045412	02/21/08	Brines et al.		
	A86	09/290,938	4/13/99	Brines et al		
	A87	09/547,220	4/11/00	Brines et al.		
	A88	09/718,829	11/21/00	Brines et al.		
	A89	09/716,963	11/21/00	Brines et al.		
	A90	09/716,960	11/21/00	Brines et al.		
	A91	10/554,517	10/25/05	Brines et al.		
	A92	11/283,024	11/18/05	Cerami et al.		
	A93	11/631,458	7/01/05	Brines et al.		
	A94	11/880,275	7/19/07	Brines et al.		

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh	RELEVANT FIGURES APPEAR	\vdash
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		-
B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
B04	EP 0640619	1/03/95	Amgen Inc.		\vdash
B05	EP 0668 351	8/23/95	Amgen, Inc.		-
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		-
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		_

EXAMIN	ER
NYI-40887	1992

DATE CONSIDERED

Sheet 5 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		FOREIG	EN PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE)	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
B09		6/8/00	Eli Lilly & Co.	RELEVANT FIGURES APPEAR	T
B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		
BII	WO 00/24893	5/4/00	Amgen, Inc.		
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)		
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		<u> </u>
B14	WO 01/81405	1/11/01	Amgen Inc.		<u> </u>
B15	WO 01/82952	11/08/01	Action Pharma APS		
B16	WO 01/82953	11/08/01	Action Pharma APS		
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		
B20	WO 02/14356	2/21/02	Althoff, Claudia		
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		-
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		-
B32	WO 06/002646	1/12/06	Lundbeck A/S		\dashv
B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 6 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		FOREIG	EN PATENT DOCUMENTS	
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER KIND CODE (IF KNOWN)	, DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
E	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	RELEVANT FIGURES APPEAR
E	35 WO 91/05867	5/02/91	Amgen Inc.	
E	36 WO 92/08493	5/29/92	Brigham & Women's Hospital	
E	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)	
E	38 WO 94/24160	10/27/94	Brigham and Women's Hospital	
E	39 WO 95/05465	02/23/95	Amgen, Inc.	
В	40 WO 96/14081	5/17/96	Boehringer Mannheim GMBH	
В	41 WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.	
В	42 WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)	
В	43 WO 97/32895	9/12/97	Regents of the University of California	
В	44 WO 98/10650	3/19/98	East Carolina University	
В	45 WO 98/18926	05/07/98	G.D. Searle & Co.	
В	46 WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)	
В	47 WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.	
В	18 WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.	
В	19 WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.	
В	₅₀ WO 93/25221	12/23/93	Alkerms Controlled Therapeutics	
В	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV	
B:	92 WO 91/06667	5/16/91	Cell Genesys, Inc.	
B:	3 WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)	
B	4 WO 86/03520	6/19/86	Genetics Insitute, Inc.	
B	5 WO 85/02610	6/20/85	Kirin-Amgen, Inc.	
B5	6 WO 99/21966	5/06/99	Neurospheres Holdings Ltd.	

EXAMINER NYI-4088719v2
NYI-4088719v2

Sheet 7 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	•
Examiner	T		T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper I. Declaration, Brines clean copy of	1
		claims, and Ehrenreich clean copy of claims (10/02/06)	1
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	1
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	1
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	T
. 		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	1
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	1
	-	alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	
		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells" Proc	
		Natl. Acad. Sci. USA 91:3974-3978	
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	
		for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	
·		der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	
	 	Glycoproteins," Meth. Enzymol., 50:287-291.	
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	
····		Cerebrovascular Disease, Vol. 9:131-135	ĺ
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	
		premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	
	-	activity, Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	C13	BARBER et al.,1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	
· · · · · · · · · · · · · · · · · · ·	ļ	Cell. Biol. 14(10):6506-6514	
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	
	ļ	tunction relationships," J. Biol. Chem. 272(8):4985-4992	
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	
	-	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	
	<u> </u>	traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	
	<u> </u>	12.	
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
		profactin, erythropoletin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
		Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
		artery occulsion in rats," Brain Research, Vol. 739:88-96	
	C20	BENIT et al., 1993, "The 'WS motif common to v-mpl and members of the cytokine recentor superfamily is	
		dispensable for myeloproliferative leukemia virus pathogenicity." Oncogene 8787-790	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 8 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	····
FILING DATE	ARTUNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		Ţ-
Initials	+	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	7
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	T
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
-	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	T
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-15993	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	-
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
-	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 9 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

(Include name of the author (in CAPITAL LETTERS). Title. Date. Pertinent Pages. Etc.) Guide BRUNEVAL et al., 1993, "Erythropoletin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597. Guide et al., 2002, "Recombinant human erythropoletin influences revascularization and healing in a rat model of random ischaemic flags," Acta Derm Venereol., Vol. 82:411-417 Guide frandom ischaemic flags," Acta Derm Venereol., Vol. 82:411-417 Guide frandom ischaemic flags," Acta Derm Venereol., Vol. 82:411-417 Guide frandom ischaemic flags," Acta Derm Venereol., Vol. 82:411-417 Guide frandom ischaemic flags," Acta Derm Venereol., Vol. 82:411-417 Guide frandom ischaemic flags," Acta Derm Venereol., Vol. 82:411-417 Guide frandom ischaemic flags, "Comparative Assay of Erythropoletin Standards," Annals New York Acad. Sci., 149:40-45. Guide frandom ischaemic flags, "Comparative Assay of Erythropoletin Standards," Annals New York Acad. Sci., 149:40-45. Guide frandom ischaemic flags, "Guidentification of a neurotrophic sequence in erythropoletin", Int. J. Mol. Med. 1:235-241 Cuide frandom ischaemic flags, "Forting and basolater of Erythropoletin receptor complex," Proteins 24:394-401 Cuide frandom ischaemic flags, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 Cuide frandom ischaemic flags and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6): 1149-55. Cuide frandom ischaemic flags and basolateral transferrin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 Cuide francom ischaemic flags and processing of erythropoletin, receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 Cuide frandom ischaemic flags and processing of erythropoletin," Arch. Phys. Med. Rehabil., 65:370-374. Cottes et al., 1961, "Bio-Assay of Erythropoletin in Mice Made Polycythaemi	NON PATENT LITERATURE DOCUMENTS				
BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597. C41 BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol, Vol. 82:411-417 C42 BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331 C43 CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45. C44 CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 C45 CAROIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6): 1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES et al., 1969, "Quartitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZCOCREA et al., 2000, "Erythropoietin reduces the degree of arthriti	Examiner			Т	
Erythrocytosis," Blood, 81(6):1593-1597. C41 BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417 C42 BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/egi.contents/abstract/29/3/331 C43 CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45. C44 CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 C45 CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C54 CVERS, 1968, "Quantitative Estimation of the omnous	Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1	
C41 BUEMI et al., 2002, "Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417 C42 BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/egi.contents/abstract/29/3/331 C43 CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45. C44 CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 C45 CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 2009, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C54 CUZCOREA et al., 2000, "Borney Control of the Memato, 28(3):231-243 C55 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a pro		C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythropytosis" Blood, 81(6):1593-1597		
model of random ischaemic flaps," Acta Derm Venereol., Vol. 82-411-417 C42 BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331 C43 C44 CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45. C45 C46 CAMPANA et al., 1998, "identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 C45 CAROVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 C49 C49 C49 C40 C40 C41 C49 C41 C49 C42 C49 C42 C49 C44 C44 C50 C67 C67 C67 C75 C75 C75 C76 C76		C41		+	
C42 BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331 C43 CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45. C44 CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 C45 CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZCOCEA et al., 2000, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 D*ANDREA et al., 2000, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature,		C41	model of random ischaemic flans "Acta Derm Venered Vol. 82:411-417		
to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331 C43 CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45. C44 CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 C45 CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2000, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 DALE et al., 2001, "The		C42	BUNDGAARD and MOLLER 1981 "Horseradish perovidese and microperovidese. Their purity and hinding	╁	
C43 CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45. C44 CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 C45 CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZCOCREA et al., 2000, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C55 D'ANDREA et al., 1998, "Dysregulated hematopoiceis and a progressive neurological disorder induced by expression of an activated form of the human commo		[C42	to serum proteins." The Journal of Histochemistry (Abstract) www.ihc.org/ggi.contents/abstract/79/3/131		
149:40-45. C44 CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 C45 CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 33:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alaninescanning mutagenesis," Science, Vol. 24:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2002, "Model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 DAME et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagu		C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythronoietin Standards," A pnals New York Acad Sci	+	
C44 CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 C45 CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "Enythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice." J. Clin. Invest. 102(11):1951-1960 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retentio		1043	149:40-45.	ı	
C45 CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2007, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential." Biology of the Neonate,		C44		t	
C46 CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C59 D'ANDREA and ZON, 1990, "Erythropoietin in the central nervous system and its neurotrophic and neuroprote			241		
angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	T	
angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure:	+	
C47 CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1140-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitops mapping of hGH-receptor interactions by alaninescanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.			angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325]	
separate endosomes," J Cell Biol. Vol. 114(6):1149-58. C48 CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure." Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.	_	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through	t	
Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.			separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	l	
Vol. 81, pp. 29-42 C49 CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res,	T	
 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential." Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 			Vol. 81, pp. 29-42		
 65:370-374. C50 COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential." Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 		C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil.,	T	
Reduced Pressure," Nature, 191:1065-1067. C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.			65:370-374.		
C51 COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a	Ī	
C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		↓	Reduced Pressure," Nature, 191:1065-1067.		
C52 COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. C53 CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante,	Γ	
Erythropoietin, Annals New York Acad. Sci., 149:12-17. CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.					
CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of	Γ	
scanning mutagenesis," Science, Vol. 244:1081-1085 C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.					
C54 CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest,		C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-		
mouse," Arthritis & Rheumatism, Vol. 52(3):940-950 C55 D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.			scanning mutagenesis," Science, Vol. 244:1081-1085	L	
D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest,		C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the	ĺ	
insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		ļ	mouse, Arthritis & Rheumatism, Vol. 52(3):940-950	L	
C56 D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		C55	D ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors:		
expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		 	Insignts from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	L	
102(11):1951-1960		C56	D'ANDREA et al., 1998, "Dysregulated hematopolesis and a progressive neurological disorder induced by		
C57 DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179 C58 DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.			expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest.		
C58 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.	· · · · · · · · · · · · · · · · · · ·	 		<u> </u> _	
DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		C57	cell surface." Nature, Vol. 415, pp. 175-170		
neuroprotective potential," Biology of the Neonate, 79(304):228-35 C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		-	DAME et al. 2001. "The hieles of anthonorisis is the control of the little of the control of the little of the control of the little of the control of the little of the control of the little of the	L	
C59 D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.		C58	neuroprotective notential." Biology of erythropoletin in the central nervous system and its neurotrophic and		
C59 DANDREA and ZOIN, 1990, "Erythropoletin receptor. Subunit structure and activation," J. Clin. Invest.			D'ANDREA and ZON 1000 WE make as in increase Calculated the increase of the in		
		C59	86(3):681-687		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 10 of 26 of List of References

1647

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905 APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Include name of the author (in CADITAL LETTERS) Title D. (D. () D. ()	
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation	
		to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	İ
	C(1	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist,	╁
	C61	Vol. 3:314-318	İ
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the	+-
	C02	tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	i
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's	+-
	1003	disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley &	1
	00.	Sons, p. 122, p. 508	ı
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple	T
		sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and	
		platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the	Г
		mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant	Γ
		erythropoietin treatment", ASAIO J. 38:M477-M480	L
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation:	
		prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	<u> </u>
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global	
	+	ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	ļ
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	l
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	Ī
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New	\vdash
	6/3	York, 1993	1
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion,	
	0	and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance,"	
		Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP),"	
		Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med.	Г
		8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular	
		Psychiatry, 9:42-54	
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	
	1 (80	Blood 67(2).493-302	

EXAMINER NYI-4088719v2
NYI-4088719v2

DATE CONSIDERED

Sheet 11 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ARTUNIT	,
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T_
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	T
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	Γ
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

EXAMIN	ER
NYI-40887	19v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C102	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and	
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	<u> </u>
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	†
	0.01	Chem Soc., Vol. 124(4):544-555	1
	C105		<u> </u>
	10.00	Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106		
	0.00	Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	
	C107	COLDINACODD . 1 1000 // A C D d Ld Ld Ld Ld Ld Ld Ld Ld Ld Ld Ld Ld L	
	0.07	323.	
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	
	0.00	neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	00010 - 1 0000 (014 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	0.07	spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in	
	""	rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	CIII	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	
	"	clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	
	"	therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating	
		bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin".	
	"	Kidney Intl. 38:480-486	
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal	
		degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.	
	""	1592:215-223	
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	
		antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	
	0.110	granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II.	
		Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	
	120	receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	
	1 (121	Bioengineering, Vol. 16:1069-1079	
	(122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	
	C122	The second standard of the process of the second controlled, prince in, dozenthaling study of ARANESF	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 13 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain	
	0.23	expressed in Escherichia coli," J. Biol. Chem. 267(21):15205-15209	
	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an	
	0.12.	erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a	
		specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	L
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database,	
		FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human	
		megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	<u> </u>
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
· · · · · · · · · · · · · · · · · · ·	C120	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit	t
	C129	and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction	T
	C130	with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin	T
	CISI	in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal	T
	C132	fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes:	T
	(133	pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in	1
	C134	ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun.	
		188(1):352-357	İ
	C135	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem.,	Π
	10133	194:457-462.	1
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients, "	Γ
	10130	Nephron, Vol. 72, pp. 30-36	L
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family,"	
	0.5,	Science 247:324-327	L
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human	Γ
	0.55	granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires	
		the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces	
	","	infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol.	
		139:173-179	<u>L</u> .
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood	
	````	76(1):31-35	1

EXAMIN NYI-40887	ER
NYI-40887	19v2

**DATE CONSIDERED** 

Sheet 14 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	<u> </u>		<del></del>
Initials	<del> </del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgers assertion C. U.	+•
_	_	derivery of adenoviral vectors to mouse liver and lung." Hum Gene Ther 7(13):1555-66	
	C142	JUSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paragyonase active site."	†
	<del></del>	1 Chem Biol Interact, Vol. 119-120:79-84	
	C143		†-
	<del></del>	group-selective labelling and site-directed mutagenesis." Chem Riol Interact Vol. 110-120-71-79	
	C144	JUDINSKY et al., 1996, "The beta c component of the granulocyte-macrophage colony stimulating for the CO. A.	1
		Col / interretaking (IL-3)/IL-3 receptor interacts with a hybrid GM-CSF/erythronologie recenter to the first	
	<del></del>	promeration and deta-globin mking expression." Mol. Med. 2(6):766-773	
	C145		<b>†</b> –
	<b>-</b>	Crythropoletin receptor,   B100d 90(2):1867-1873	l
	C146	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion	
	-	mjury , Proc. Nati. Acad. Sci. USA 99(16):10659-10664	
	C147	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous	-
	<del> </del>	system, rediatr. Res. 43(1):40-49	
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	$\vdash$
<del></del>	<u> </u>	1 icius ; Larry Turnan Devel, 32(3):233-249	
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	
		sheep, soc. for Neuroscience Abstracts 2/(1):929 (31st Annual Meeting of the Society for Neuroscience, Soc.	
	-	Diego, CA (104, 10-13, 2001)	
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	_
	1	damage, Acia i aculati. Supp. Vol. 438. DD. 30-47	
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate	
	<del> </del>	or avidin and a monocional antibody to the transferrin recentor." Drug Metab Dispos. Vol. 22(1):00, 105	
	C152	KAWASAKI et al., 2001, Structural analysis of sulfated N-linked oligosaccharides in engineering.	_
	<b>├</b> ──┤	Glycoolology, Vol. 11(12):1(143-1(149)	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	
		wivings of figure induced filling replication a regulation inverse.	
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Englishers "Appele News	
		1 Otk Acad. 301., 147.10-24.	
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"	
	, ,	7 min. ( early, vol. 50(0),015-020	
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3	_
		400 44000, D1004 77(1), 102-110	
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	
		7111 3 7111di. 4 01, 170,441-9.	
ı	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant crythropoietin and cepharanthin in a girl	
		with terractory anomal, Japanese J. Clin. Flematology, Vol. 35(7):694-6988 (w/English observed)	
	C159 L	KITAMORA et al., 1989, "Identification and analysis of human erythropoietin receptors on a force of the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second sec	
		line, TF-1," Blood, Vol 73(2):375-80	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 15 of 26 of List of References

	ATTY, DOCKET NO.	APPLICATION NO.	1
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT  Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(I. I. I	Т
nitials	<del></del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	╀
	C160		
		Obstetrics and Gynecology, 96(5):826-828.  KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic	-
	C161	neurons in vitro and in vivo", Brain Res. 609:29-35	
	<del> </del>	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic	┝
	C162	mechanism.", Behav. Neural Biol. 62:237-243	ĺ
	+	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in	╁
	C163	patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
		KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following	┝
	C164		l
	+	neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	┝
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle	
	-	cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129  LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional	┝
	C166	asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
		LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive	⊢
	C167	and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J.	
		Cardiovasc. Pharmacol. 31(4):601-608	
	+	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A.	┢
	C168	95:11371-11376	
		LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol.	H
	C169	305, pp. 239-242	
	10.50	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol.	╁
	C170	93:75-80	
		LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid	╁
	C171	progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
		LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human	$\vdash$
	C172	fetuses", Pediatr. Res. 40(3):376-380	1
	+	L1 et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing	H
	C173	various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	10.51	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund,	H
	C174	http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	+	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked	┢
	C175	glycans," Anal. Biochem. 219:207-217	l
	<del></del>	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain	╁
	C176	Res. 692:143-153	
	<del>                                     </del>	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the	┝
	C177	Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
		LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol.	-
	C178		l
	<b>_</b>	166:159-169	⊢
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct	ĺ
		hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	

EXAM	IN	ER
NYI-408	87	19v2

DATE CONSIDERED

Sheet 16 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
antidis .	C180		
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll. Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 17 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

1	i
ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ARTUNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
-	C207	A CONTRACTOR AND A STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	A WIDA WAA WILL 1 1001 WG it is best and a wise of the interleuting 6 signal transducer on 120 is consorred	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

EXAMINER NYI-4088719v2	
NYI-4088719v2	2

DATE CONSIDERED

Sheet 18 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner			T,
nitials	-	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	17
	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol.	
·-····································		9(1):suppl. 2:12-15 OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid	╁
	C222	chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	1
	6222	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion	╁╴
	C223	57:328-332	ļ
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website <a href="http://cancerweb.ncl.ac.uk/omd">http://cancerweb.ncl.ac.uk/omd</a> . Published at	T
	C224	the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB	
		Project.	
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the	Γ
		rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	L
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the	
		rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	L
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development	
		factor or thrombopoietin," Cytokine 8(1):66-69	↓_
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the	
		introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	╀
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain	
		barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60  Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem.	╀
	C230	Vol. 70:1781-92.	
	C221	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	╁
	C231		╀
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a	
		recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	╀
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti- carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	<del> </del>	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major	╁
	C234	histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta	ŀ
		2m," Eur. J. Immunol. 25:1609-16	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked	t
	(.233	oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-	ĺ
		773	
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics	Γ
	0230	11(4):974-980	
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral	
		infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	L
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol.	ĺ
		260(5 Pt 2): H1406-1414	L
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525	
		and 2125-2131	L

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 19 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS			
Examiner		(Include come of the earlier (in CADITAL LETTERS). Title Date Bestings Bases Fac.)	Ţ.,
Initials	C240	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company, Montvale, NJ), pp.1765-1769	7
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone- related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246	0.00 4 4000 (0.00 10 10 10 10 10 10 10 10 10 10 10 10 1	
	C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8	
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
*. *	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
	C252	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	<u> </u>
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 20 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS			
Examiner			
Initials	<del></del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C259		
		ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	┺
	C260	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262		✝
	C202	Neonatologie (202)(2), pp 64-68 (Abstract Only)	
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain	$\vdash$
	C203	and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for	
		erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent	╁╴
	C204	growth in hematopoietic cell lines," Blood 88(2):455-464	
· · · · · · · · · · · · · · · · · · ·	C2(5	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in	╁╌
	C265	Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266		$\vdash$
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	$\vdash$
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-	t
	C208	dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269		+-
	C209	Proc. Natl. Acad. Sci. USA 98(7):4044-4049	ľ
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J	+-
	C270	Ultrastruct Res. Vol. 88(1):18-29	1
	0051	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood,	┢
	C271	73:90-99.	
		STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J.	╁
	C272	Biol. Chem. 235(11): 3177-3181	l
	-	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	⊢
	C273	·	Į
	C274	STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and	
		Inflammation, pp. 897-898, 1865-1866	l
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc.	
	02/3	Natl. Acad. Sci. U. S. A. 99(22):13972-4	
· · · · · · · · · · · · · · · · · · ·	C276	STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
	""	Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human	
		Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and	-
	[ 0.277 ]	Biological Properties," British J. Haematology, 100:79-89.	
	C220	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J.	$\vdash$
	C278	of Clinical Investigation, Vol. 35, pp. 711-717	

<b>EXAMINER</b>	
NYI-4088719v2	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 21 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C279		
		blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	ļ
	C280		1
		Erythrocytosis," British J. Haematology, 113:49-51.	
	C281		
		73:1525-1535	_
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor	╁╴
	C263	orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by	+
	C204	inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
-	C285	TARIBA . 1 1007 (N)	$\vdash$
	C283	vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol.	╁
	C286	81:395-402	
		TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood	
	C287	flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	l
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on	╁╌
	C288	chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C200	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys.	╁╴
		Res. Commun. 148(1):443-448	l
	6200	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis,"	┢
	C290	Press Medicale, Vol. 31(11):505-514 (Abstract only)	
	-	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats	├
	C291	with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
		VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced	├
	C292	anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	61202		<b>-</b>
	C293	VEZANNI et al., 1999, "Interleukin-1- $\beta$ Immunoreactivity and microglia are enhanced in the rat hippocampus	
		by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol	l
		19(12):5054-65	L_
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures	
		but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological	
		assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	L.
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone	
		morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	_
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins,"	-
	(29/	Blut, 44:173-175.	
	(200	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	$\vdash$
	C298	2225, 776, 7426779, of matational effects in proteins, Dioenemistry, 761, 27(37),0309-0317	l

EXAMINER	
NYI-4088719v2	

**DATE CONSIDERED** 

Sheet 22 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
initiais	C299	WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	1
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	-
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	†
	C302		Γ
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	1
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:1-32-1-42	
	C306	utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	
	C308	Thromb. Haemost. 78:1505-1509	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83	
	C310		
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
-	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	
	C316	erythropoietin," Blood 82(6):1713-1719	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 23 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Oncologist 1(5):337-339	Т
	C320	Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Contro	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
-	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	1
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	$\top$
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	$\dagger$
· · · · · · · · · · · · · · · · · · ·	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	1
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	$\top$
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	1
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	$\top$
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	+
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	†
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	$\top$
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	$\dagger$
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	+
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	$\dagger$
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	T
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	+
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	+

<b>EXAMINER</b>	
NYI-4088719v2	

**DATE CONSIDERED** 

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials	C346	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Office Action, Application No. 09/716,963, date mailed: March 18, 2005	T
	C346	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
<del> </del>	C347	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C348	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
	1	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C350	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C351	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C352	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
	C353		
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	

<b>EXAMINER</b>
NVI-J088719v2

DATE CONSIDERED

Sheet 25 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C374	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	T
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	
-	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	1
······································	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	1
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	1
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	1
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 26 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		
	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912	
	C402	0.00	

EXAMINER NYI-4088719v2



Express Mail No.: EV 654 895 272 US Express Mail No.: EV 654 895 286 US

Express Mail No.: EV 654 895 290 US Express Mail No.: EV 654 895 309 US

Sheet 1 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905 APPLICANT Coleman et al.

FILING DATE ART UNIT May 30, 2006 1647

### **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	<u> </u>	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	4,343,782	8/10/982	Shapiro	FIGURES APPEAR
	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	All	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	A21	5,696,080	12/09/97	O' Brien	
	A22	5,700,909	12/23/97	O'Brien	
	123	5,714,459	02/03/98	O'Brien	
1	124	5,750,376	5/12/98	Weiss et al.	
/	125	5,756,349	05/26/98	Lin	
/	126	5,763,198	6/09/98	Hirth et al	
/	127	5,767,078	06/16/98	Johnson et al.	

EXAMINER
NYI-4088719v2

Sheet 2 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

			U.S. 1	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A28		06/30/98	Wrighton et al.	FIGURES APPEAR
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
<u> </u>	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	Λ46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	Λ48	6,531,121	3/11/03	Brines et al.	
	Λ49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
	A51	7,214,532	5/08/07	Stern et al.	
	A52	7,309,687	12/18/07	Brines et al.	
	Λ53	7,345,019	3/18/08	Brines et al.	
	Λ54	2002/0031806	3/14/02	Lee	

<b>EXAMINER</b>
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 3 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

#### U.S. PATENT DOCUMENTS *EXAMINER PAGES, COLUMNS, LINES, WHERE INITIAL RELEVANT PASSAGES OR RELEVANT DOCUMENT NUMBER DATE NAME FIGURES APPEAR 2002/0052309 A55 5/02/02 Anagnostou et al. 2002/0061849 A56 5/23/02 Nielsen et al. 2002/0077294 A57 6/20/02 Kay et al. 2002/0081734 A58 6/27/02 Choi et al. 2002/0086816 A59 7/04/02 Brines et al. 2002/0142370 10/3/02 A60 Paulson et al. 2002/0160460 A61 10/31/02 Paulson et al. A62 2003/0003529 1/2/03 Bayer 2003/0040037 A63 2/27/03 Bayer 2003/0072737 4/17/03 A64 Brines 2003/0077753 4/24/03 A65 Tischer 2003/0083251 5/01/03 A66 Westfenfelder 2003/0104988 A67 6/5/03 **Brines** 2003/0113871 6/19/03 A68 Lee et al. 2003/0118547 6/26/03 Vandenberg A69 2003/0120045 6/26/03 A70 Bailon 2003/0124115 A71 7/3/03 Lee et al. 2003/0134798 Λ72 7/17/03 Brines et al. 2003/0166566 A73 9/04/03 Kinstler et al. 2004/0009902 A74 1/15/04 Boime 2004/0018978 A75 1/29/04 Campana et al. 2004/0091961 5/13/04 Λ76 Evans et al. 2004/0096447 Λ77 5/20/04 Yasuda et al. 2004/0122216 6/24/04 A78 Nielsen et al. 2004/0209812 10/21/04 Λ79 Farrell et al. 2004/0214236 10/28/04 A80 Brines et al. 2005/0176627 Α81 8/11/05 Cerami et al.

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 4 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	PIGURES APPEAR
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

·		POREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh	RELEVANT FIGURES APPEAR	$\vdash$
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		_
B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
B04	EP 0640619	1/03/95	Amgen Inc.		
B05	EP 0668 351	8/23/95	Amgen, Inc.		
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		

<b>EXAMINER</b>
NYI-4088719v2

DATE CONSIDERED

Sheet 5 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

<del></del>			N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE		PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	T
B09	1110 00100	6/8/00	Eli Lilly & Co.	RELEVANT FIGURES APPEAR	$\downarrow$
BIO	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		+
B11	WO 00/24893	5/4/00	Amgen, Inc.		+
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)		+
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		+
B14	WO 01/81405	1/11/01	Amgen Inc.		+
B15	WO 01/82952	11/08/01	Action Pharma APS		ł
B16	WO 01/82953	11/08/01	Action Pharma APS		+
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		H
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		H
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		H
B20	WO 02/14356	2/21/02	Althoff, Claudia		H
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		-
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		H
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		_
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		_
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		_
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		_
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		_
B32	WO 06/002646	1/12/06	Lundbeck A/S		_
B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		_

<b>EXAMINER</b>
NYI-4088719v2

DATE CONSIDERED

Sheet 6 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		FOREIG	IN PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER KIND CODE (IF KNOWN)	, DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
В	34 WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	RELEVANT FIGURES APPEAR	$\dagger$
В	35 WO 91/05867	5/02/91	Amgen Inc.		t
В	36 WO 92/08493	5/29/92	Brigham & Women's Hospital		H
В	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		-
В	38 WO 94/24160	10/27/94	Brigham and Women's Hospital		$\vdash$
B.	9 WO 95/05465	02/23/95	Amgen, Inc.		$\vdash$
B	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		┝
B	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.		$\vdash$
B	2 WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		-
B4	3 WO 97/32895	9/12/97	Regents of the University of California		H
B	4 WO 98/10650	3/19/98	East Carolina University		Γ
B4	5 WO 98/18926	05/07/98	G.D. Searle & Co.		_
B4	6 WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		_
B4	7 WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		_
B4	8 WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		_
B4	9 WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		
B5	0 WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		_
В5	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		
B5	WO 91/06667	5/16/91	Cell Genesys, Inc.		
B5	3 WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		_
B5	WO 86/03520	6/19/86	Genetics Insitute, Inc.		_
B5	5 WO 85/02610	6/20/85	Kirin-Amgen, Inc.		
B5	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 7 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials	ļ	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	17
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of	T
		claims, and Ehrenreich clean copy of claims (10/02/06)	ı
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	Ť
	<del></del> -	myocardial ischemia," Shock, Vol. 22(1), pp 63-69	i
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	T
		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	Τ
		alpha-crystallins," Current Eve Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	Г
-		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	ı
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	Г
	<del></del>	Natl. Acad. Sci. USA 91:3974-3978	L
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	
<del></del>		for Bioassay," Bull. Org. mond. Sante, 47:99-112.	L
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	
	<del></del>	der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	
	+	Glycoproteins," Meth. Enzymol., 50:287-291.	L
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	
	-	Cerebrovascular Disease, Vol. 9:131-135	L
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	
	1010	premature rabbits," Pediatric Res., Vol. 40(3):381-387	L
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	
	012	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	L
	C13	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol. Cell. Biol. 14(10):6506-6514	
	1014	RAPRONE et al. 1007 "Mutaganacia studio a Calla la constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constanti del constan	_
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships," J. Biol. Chem. 272(8):4985-4992	
	6316	BARRON et al. 1004 "Alternatively enjoyd mDNA and discount in the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the	
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	CIC	BASKAVA et al. 1907 "The highesis opening of the lead, bein being the	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	_
	(17	12.	
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
	1618	prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
		Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
	[ [19	artery occulsion in rats," Brain Research, Vol. 739:88-96	
	C20	BENIT et al., 1993, "The 'WS motif common to <i>v-mpl</i> and members of the cytokine receptor superfamily is	
	1020	dispensable for myeloproliferative leukemia virus pathogenicity." Oncogene 8787-790	

<b>EXAMINER</b>
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 8 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-	
		1598	
· <del></del>	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	Ť
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	T
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	$\dagger$
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac	╁
	520	disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	$\dagger$
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	t
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	-
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-15993	$\mid$
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	H
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	$\vdash$
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
		BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER
EXAMINER NYI-4088719v2

**DATE CONSIDERED** 

Sheet 9 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ARTUNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Т
Initials	<u> </u>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With	
		Erythrocytosis," Blood, 81(6):1593-1597.	
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat	
		model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	$oldsymbol{\perp}$
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding	
		to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	上
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci.,	
		149:40-45.	1
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-	İ
		241	L
,	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	ĺ
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure:	1
	0.0	angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	İ
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through	†
	"	separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res,	T
		Vol. 81, pp. 29-42	
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil.,	
	"	65:370-374.	
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a	T
		Reduced Pressure," Nature, 191:1065-1067.	1
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante,	$\top$
		35:751-760.	
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of	Г
		Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-	
		scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the	
		mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	
_	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors:	
		insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	l
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by	
	1	expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest.	
		102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the	
		cell surface," Nature, Vol. 415, pp. 175-179	
	C58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and	
		neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.	
		86(3):681-687	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 10 of 26 of List of References

### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
Initials	<del></del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	<u>  T</u>
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	Ī
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
-	C'78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	

EXAMINER	
NYI-4088719v2	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 11 of 26 of List of References

### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

Examiner Initials  (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  EMIR, 2004, "Erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury," transplantation Proceedings, Vol. 36, pp. 2935-2938  ERBAYRAKTAR et at al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo." Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6  ERBAYRAKTAR et al., 2003, "Sainte-Ruffine, France, Maisonneuve p. 5.  C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia." PNAS, Vol. 103(46):17531-17536  C87 FARELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upme.cdu/consultria/july 1995.html  C89 FDA Alert, 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.pFDA.gov.CDER/DRUG/InfoSheets/HOP/RHE2007-HCP, htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 893-600  C92 FORESTA et al., 1994, "Erythropoietin simulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action—it tak	Initials	
C81 EMIR. 2004. "Erythropoietin on bol-2 gene expression in rat cardiac myocytes after traumatic brain injury." Transplantation Proceedings, Vol. 36, pp. 2935-2938  C82 ERBAYRAKTAR et al., 2003, "Asialocrythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6  C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury." www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia," "PNAS, Vol. 103(46):17531-17536  C87 FARELL et al., 2001, "Erythropoietin cross set be blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consul/tria/july 1995.html  C89 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consul/tria/july 1995.html  C89 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin intimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action—it takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R. I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc	EMIR, 2004, "Erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938  C82 ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotes activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6  C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
Transplantation Proceedings, Vol. 36, pp. 2935-2938  C82  ERBA YRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6  C83  ERBA YRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006  C84  EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85  EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86  FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87  FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88  FAUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C89  FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90  FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91  FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93  FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94  FRESHNEY, R.I., 1993, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A. R. Liss, Inc. NY 1983  C95  FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of	Transplantation Proceedings, Vol. 36, pp. 2935-2938  C82 ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprote activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6  C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6  C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001. pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001. "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARKELL et al., 2001. "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995. html  C89 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995. html  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J.	C82 ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprote activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6  C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
activity in vivo." Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6  C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C89 FAURI And KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C99 FEIGIN et al., 2002, "Accent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier." J. Controlled Release, Vol. 46:117-28  C96 FUEDAN et al., 1997, "Role of alternative splicing of the rat erythrop	activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6  C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006 C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5. C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782. C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536 C87 FARELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001) C88 FARUKI and k1SS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.pDA.gov.CDER/DBUG/InfoSheets/HCP/RHE2007.HCP/htp C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9 C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600 C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756 C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action—it takes two to tango, but how?" Endocrinology 143(1):2-10 C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983 C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28 C96 FRIEDMAN et al., 1997, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8 FUJITA et al., 19	C83 ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	ctive
www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/aijuly 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and	www.molmed.org. July 2006  C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated crythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.jPDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007-HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cell	C84 EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.  C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	·
C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Frythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action—it takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P, M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier." J. Controlled Release, Vol. 46:117-28  C96 FRIDEMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  FUKUDA et al., 1999, "Survival of Recombinant Erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C99 FUKUDA et al., 1990, "The human interleukin-2 receptor: insi	C85 EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.  C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consul/fria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1999, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-	C86 FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001. "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUK1 and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action—it takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier." J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  FUITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1999, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol.	severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001. "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUK1 and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action—it takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier." J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  FUITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1999, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol.	severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536  C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK. 2002, "Minireview: Receptor dimerization in GH and erythropoietin action—it takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUNG et al., 1990, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERT	C87 FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al. 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUNG et al., 1999, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1999, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):72	Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)  C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1998, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	C88 FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medici path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action—it takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier." J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells." Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	path.upmc.edu/consult/ria/july 1995.html  C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	ne
C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	C89 FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	,
http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1999, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp  C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates, Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	C90 FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
Curr. Opin. Neurol. 15(4):483-9  C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier." J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		
C91 FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	Curr. Opin. Neurol. 15(4):483-9	
tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600  C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	FIGURES A 1 1001 WE I I I I I I I I I I I I I I I I I I	
C92 FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		
and Metabolism, Vol. 78(3):753-756  C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	DODDOTH I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE I LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LOOK WE IN LO	logy
C93 FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		
how?" Endocrinology 143(1):2-10  C94 FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango.	out
FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		
1983  C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		Y
across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		-
across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28  C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	C95 FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutic	s
C96 FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	1
of Kidney Disease, Vol. 26(1), pp. 202-8  C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		rnal
C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	of Kidney Disease, Vol. 26(1), pp. 202-8	
erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5  C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	C97 FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and	
C98 FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		İ
Carbohydrates," Blood, 73(1):84-89.  C99 FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		
FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		ŀ
transduction," Semin. Immunol. 2:119-128  C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		
C100 GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230		
269(10):7224-7230	CARPTUED - 1 1004 - CI	/ol.
0.000		· • · ·
LCIALLUAKUIA ELAL. 1990. "ISCHEMIC STOKE AND INCOMPLETE INTARCTION" NITOKE VAL 7/14\1/16\1.765	C101 GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

EXA	MI	INI	ER
NYI-4	108	871	9v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		,	Ī
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C102		
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	
		Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,	
	0.05	Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	1
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	
	100	Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	ŀ
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97(2):315-	t —
	10107	323.	l
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	
		neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental	
		spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in	
		rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	C111	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	
		clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	
	0112	therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating	
	10113	bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	
	10114	Kidney Intl. 38:480-486	ļ
-	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal	$\vdash$
	(113	degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.	$\vdash$
	C110	1592:215-223	
	CUIT	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	<del></del>
	C117	antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
<u> </u>	CITE	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	_
	C118	granule cells," Toxicological Sciences, Vol. 64:83-89	
	<del> </del>	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: 1. Chronic Anemias. II.	_
	C119	Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	+		
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	
_	<del></del>	receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	
	ļ	Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	

EX	$\mathbf{AM}$	IIN	ER
NY	[-40]	887	19v2

**DATE CONSIDERED** 

Sheet 13 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
Initials	<del> </del> -	in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	+
	C123		$\dagger$
	C124	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C125	The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	
	C126	The production of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of	
	C127	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C128	1	
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	1117 A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C131	HODEON A LICENSE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE S	
	C132	THE TRANSPORT OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF T	
	C133	THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY O	T
	C134	11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C135	that a 1 1000 4DL is a Line of District Classical Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic Characteristic C	
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients, "Nephron, Vol. 72, pp. 30-36	
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	14.21G + 1 1000 "D 1 11"	
	C140	LONGS at al. 1000 Williams and his production and his logic characteristics." Bland	

EXAMINER
EXAMINER NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 14 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			т
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following	+
<del></del>		derivery of adenovital vectors to mouse liver and lung." Hum. Gene Ther. 7(13)-1555-66	
	C142	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paragyonase active site."	$^{+}$
	<u> </u>	Chem Biol Interact, vol.   19-120:79-84	1
	C143		+
		gloup-sciective labelling and site-directed militagenesis." Chem Riol Internet   Vol. 110 120-71 70	1
	C144	JUBINSK Y et al., 1996, "The beta c component of the granulocyte-macrophage colony stimulating forter (C)	+
		1 Col / Interreducti 5 (1L-5)/1L-5 receptor interacts with a hybrid CiM-CSF/erythronoietin recentor to influence	1
		promeration and deta-globin miking expression " Mol. Med. 216)-766-773	l
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 recentor functionally associated with the	t
	J	Crythropotethi receptor,   B100d 90(5):1867-1873	l
	C146	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia reposition	╁
	ļ	injury, 110c. Nati. Acad. Sci. USA 99(16):10659-10664	l
	C147	JUUL et al., 1998, "Erythropoietin and erythropojetin recentor in the developing human central persons	۲
	<del> </del>	system, Pediatr. Res. 43(1):40-49	١
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	┝
		letus, Early Human Devel. 52(3):235-249	l
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	┝
		sheep, soc. for Neuroscience Abstracts 2/(1):929 (31st Annual Meeting of the Society for Neuroscience, Soc.	
	<u> </u>	Diego, CA 1104, 10-13, 2001)	
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	┝
		damage, Acia raculati, Supp. voj. 438. pp. 36-47	
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound to a carrier transport of histin bound	_
	L	or aviant and a monocional antibody to the transferrin recentor." Drug Metab Dispos, Vol. 22(1):00, 105	
	C152	NA WASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in engthronoistin."	_
		Glycobiology, Vol. 11(12):1043-1049	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	_
·	1	therapy of ficall failure-induced mitral regulation. Circulation, 100-1705, 1707	
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin." Appels News	
	1 1	1 Oik Acad. Sci., 147, 10°24.	
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"	
		71111. 14CUIOI. 401. J0103.01J-020	
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3	
		activation, Dioog 99(1), 102-110	
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	_
		Am 3 Anal, 401, 176,241-9.	
	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant crythropoietin and cepharanthin in a girl	
		with refractory anemia," Japanese J. Clin. Hematology, Vol. 35(7):694-6988 (w/English abstract)	
	C159	KITAMURA et al., 1989. "Identification and analysis of human erythropoietin receptors on a factor-dependent cell	
	~,,,,	line, TF-1." Blood, Vol 73(2):375-80	

<b>EXAMINER</b>	
NYI-1088719v7	,

Sheet 15 of 26 of List of References

	ATTY, DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Coleman et al.		
	FILING DATE May 30, 2006	ART UNIT	

		NON PATENT LITERATURE DOCUMENTS	
Examiner			1,
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C160	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis,"	
		Obstetrics and Gynecology, 96(5):826-828.	╄
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic	
	<del> </del>	neurons in vitro and in vivo", Brain Res. 609:29-35	╀
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic	
		mechanism.", Behav. Neural Biol. 62:237-243  GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in	╁
	C163		
		patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367  KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following	╁
	C164	KUMRAL et al., 2004, "Erythropoietin improves iong-term spatial memory deficits and brain injury ionowing	1
	<del> </del>	neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86  KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle	+
	C165	cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	_	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional	+
	C166	asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
		LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive	╁
	C167	and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J.	1
		Cardiovasc. Pharmacol. 31(4):601-608	
		LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A.	t
	C168	95:11371-11376	
	1010	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol.	t
	C169	305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol.	T
	10170	93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of P13 kinase pathway activation on human myeloid and erythroid	T
	101/1	progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	C172	Ll et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human	1
	C172	fetuses", Pediatr. Res. 40(3):376-380	
	C173	Ll et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing	T
	10173	various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	C174	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund,	Τ
	0174	http:/www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked	
	10175	glycans," Anal. Biochem. 219:207-217	
	C176	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain	
	10170	Res. 692:143-153	l
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the	Γ
		Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol.	
	101/8	166:159-169	
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct	T
	1017	hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	

<b>EXAMINER</b>
NIVI-1088719v2

DATE CONSIDERED

Sheet 16 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Coleman et al.		
	Coleman et al.		
	FILING DATE	ART UNIT	-
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner	<u></u>		_
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C180	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182		
	C183	1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186		
-	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C188		
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll. Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 17 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Vol. 51:220-222	Т
•	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
<u></u>	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	Γ

EXAMINER NYI-4088719v2
NYI-4088719v2

DATE CONSIDERED

Sheet 18 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Coleman et al.	
	FILING DATE May 30, 2006	ART UNIT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	1	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
muais	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	Ť
	C222		
-	C223	OTTO TO THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PR	
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website <a href="http://cancerweb.ncl.ac.uk/omd">http://cancerweb.ncl.ac.uk/omd</a> . Published at the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB Project.	
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69	
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92.	
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti- carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773	
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980	
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260(5 Pt 2): H1406-1414	
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131	

<b>EXAMINER</b>
NYI-4088719v2

DATE CONSIDERED

Sheet 19 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	i
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Include some of the surface (in CADITAL LETTERS) Title Day Day in AD	_
nitials	<del> </del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company,	T
	C240	Montvale, NJ), pp.1765-1769	ŀ
		PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-	+
	C241	related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717-	
		1 720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol.	+
	C242	Chem. 246(4):939-45	İ
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc.	+
	C243	Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation	T
	02	procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces	
		conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	l
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol.	П
		Chem. 273(18):11173-11176	
	C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current	
		Pharmaceutical Design, Vol. 9, pp. 1-8	
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science	
		283:990-993	_
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and	
	-	conformation," J. Biol. Chem. 250(18):7435-42	<u> </u>
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness	
·· · ··	<del></del>	syndrome?" The American Physiological Society, pp. R244-253  ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells",	-
	C251	Peptides 19(6):1023-1030	
	60.50	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic	╁
	C252	acid," Vis. Res., 37(24):3445-51	]
	G252	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from	┢
	C253	endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem.	
		65(14):1834-1842	l
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry,	╁╴
	C234	67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats	1
	(23)	with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes	
		following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc.	
		Natl. Acad. Sci. USA 95:4635-4640	
-	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by	
		guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER NYI-4088719v2  DATE CONSIDERED	
-----------------------------------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 20 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	17
	C259		1
		ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	L
	C260	74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262		Ī
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	C264		
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266		
	C267		
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270		
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
<u> </u>	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	
	C274	STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C276	STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J. of Clinical Investigation, Vol. 35, pp. 711-717	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 21 of 26 of List of References

APPLICATION NO.

ART UNIT

1647

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) 10165-042-999 10/573,905 APPLICANT Coleman et al.

ATTY. DOCKET NO.

FILING DATE

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T	(I. I. I. S. C. CADITAL I STEEDS) THE D. C. D. C. C.	T
Initials	C279	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	T
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535	
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448	
	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale, Vol. 31(11):505-514 (Abstract only)	
,	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- $\beta$ Immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol 19(12):5054-65	
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," Blut, 44:173-175.	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins." Biochemistry, Vol. 29(37):8509-8517	

EXAMINER NYI-4088719v2
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 22 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the outbox (in CARITAL LETTERS) Title Date Participat Bases Fee)	T ₁
muais		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	+-
	C299		$\perp$
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	T
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42	Ī
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	T
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509	
	C309	10.000000000000000000000000000000000000	
	C310	7771 - 1 1000 (2)	T
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	1
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	T
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	T
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	Γ
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	H

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 23 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	T -	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	<del>                                     </del>	Oncologist 1(5):337-339	Ť
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	1
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	1
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	T
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	T
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	T
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	T
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	T
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	Ť
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	1
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	<b>†</b>
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	$\dagger$
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	$\dagger$
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	T
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	<del>                                     </del>
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	$\dagger$
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	T
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	+

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS				
Examiner						
Initials	C346	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Office Action, Application No. 09/716,963, date mailed: March 18, 2005	T			
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005				
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006				
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007				
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002				
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003				
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004				
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004				
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005				
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006				
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007				
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007				
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007				
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008				
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002				
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002				
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003				
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004				
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004				
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005				
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006				
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006				
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007				
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002				
·	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002				
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003				
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003				
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004				

<b>EXAMINER</b>	
NYI-4088719v2	,

DATE CONSIDERED

Sheet 25 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	6274	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Office Action, Application No. 09/717,053, date mailed: May 3, 2005	Т
	C374	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	ļ
<del></del>	C375	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	-
	C376	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	ļ
<del></del>	C377		ļ
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	<u> </u>
	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	ļ
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	<u> </u>
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	<u> </u>
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	<del> </del>
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	-
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	<del>                                     </del>
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	-
<del> </del>	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	<del> </del>
<del></del>	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	ł
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	ļ
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	<del> </del> -
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	$\vdash$
	C397	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	_
	C398	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

EXAMINER	
NYI-4088719v2	2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 26 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т			
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912				
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008				

EXAMINER NYI-4088719v2

**DATE CONSIDERED** 

Sheet 1 of 26 of List of References

ATTY. DOCKET NO.

APPLICATION NO.

10165-042-999

10/573,905

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Coleman et al.

FILING DATE

ART UNIT

May 30, 2006

1647

#### **U.S. PATENT DOCUMENTS**

TRADEN	AARIT		0.5.1	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A01	4,343,782	8/10/982	Shapiro	FIGURES APPEAR
	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	All	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	Λ13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	Λ21	5,696,080	12/09/97	O' Brien	
	Λ22	5,700,909	12/23/97	O'Brien	
	A23	5,714,459	02/03/98	O'Brien	
	A24	5,750,376	5/12/98	Weiss et al.	
	125	5,756,349	05/26/98	Lin	
		5,763,198	6/09/98	Hirth et al	
		5,767.078	06/16/98	Johnson et al.	

<b>EXAMINER</b>
NVI-108871062

**DATE CONSIDERED** 

Sheet 2 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

			U.S. 1	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
	A28	5,773,569	06/30/98	Wrighton et al.	FIGURES APPEAR
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	Λ46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	Λ48	6,531,121	3/11/03	Brines et al.	
	Λ49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
	A51	7,214,532	5/08/07	Stern et al.	
	A52	7.309,687	12/18/07	Brines et al.	
		7,345,019	3/18/08	Brines et al.	
	154	2002/0031806	3/14/02	Lee	

EXAMINER
NYI-4088719v2

Sheet 3 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

				141ay 30, 2000	1047
			U.S.	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
	A55	2002/0052309	5/02/02	Anagnostou et al.	FIGURES APPEAR
	A56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	<u> </u>
	A72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	Λ74	2004/0009902	1/15/04	Boime	
	A75	2004/0018978	1/29/04	Campana et al.	
	Λ76	2004/0091961	5/13/04	Evans et al.	
	Λ77	2004/0096447	5/20/04	Yasuda et al.	
	A78	2004/0122216	6/24/04	Nielsen et al.	
	A79	2004/0209812	10/21/04	Farrell et al.	
	180	2004/0214236	10/28/04	Brines et al.	
		2005/0176627	8/11/05	Cerami et al.	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

*EXAMINER					PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
INITIAL	<del> </del>	DOCUMENT NUMBER	DATE	NAME	FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

FOREIGN PATENT DOCUMENTS						
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR		
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh	NECEVANT FIGURES APPEAR	$\vdash$	
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		-	
B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.			
B04	EP 0640619	1/03/95	Amgen Inc.		-	
B05	EP 0668 351	8/23/95	Amgen, Inc.			
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		_	
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)			
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)	•	_	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

ART UNIT

1647

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME.	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
B09		6/8/00	Eli Lilly & Co.	RELEVANT FIGURES APPEAR	T
B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		ļ
B11	WO 00/24893	5/4/00	Amgen, Inc.		
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)		
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		
B14	WO 01/81405	1/11/01	Amgen Inc.		<u> </u>
B15	WO 01/82952	11/08/01	Action Pharma APS		
B16	WO 01/82953	11/08/01	Action Pharma APS		
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		
B20	WO 02/14356	2/21/02	Althoff, Claudia		
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B32	WO 06/002646	1/12/06	Lundbeck A/S		
B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		$\dashv$

<b>EXAMINER</b>
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 6 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	REDEVANT FIGURES AFFEAR	1
B35	WO 91/05867	5/02/91	Amgen Inc.		†
B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		+
В37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		1
B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		t
B39	WO 95/05465	02/23/95	Amgen, Inc.		1
B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		ł
B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.	· · · · · · · · · · · · · · · · · · ·	ł
B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		ł
B43	WO 97/32895	9/12/97	Regents of the University of California		ŀ
B44	WO 98/10650	3/19/98	East Carolina University		ŀ
B45	WO 98/18926	05/07/98	G.D. Searle & Co.		ŀ
B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		-
B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		
B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		_
B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		-
B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		-
B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		_
B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		-
B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		-
B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		-
B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		-
B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		_

<b>EXAMINER</b> NYI-4088719v2
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 7 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ł	
ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS			
Examiner					
Initials	<b>-</b>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т		
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of			
	<del></del>	claims, and Ehrenreich clean copy of claims (10/02/06)			
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	Т		
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69			
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of			
·		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134			
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	Т		
		alpha-crystallins," Current Eye Research, Vol. 18:270-276			
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following			
		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	L		
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	Г		
	+ -	Natl. Acad. Sci. USA 91:3974-3978			
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	Ι		
·		for Bioassay," Bull. Org. mond. Sante, 47:99-112.	L		
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	Ι.		
	<del> </del>	der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)			
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated			
	<del></del>	Glycoproteins," Meth. Enzymol., 50:287-291.			
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	Γ		
	+	Cerebrovascular Disease, Vol. 9:131-135	L		
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in			
	<del> </del>	premature rabbits," Pediatric Res., Vol. 40(3):381-387			
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic			
	<del> </del>	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193			
	C13	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.			
·	╂	Cell. Biol. 14(10):6506-6514			
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-			
	<del></del>	function relationships," J. Biol. Chem. 272(8):4985-4992			
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in			
	<del>                                     </del>	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8			
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after			
	<del> </del>	traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36			
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-			
	<del> </del> -	12.			
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,			
		projectin, erythropoletin and IL-6 receptors, and the p75 IL-2 receptor beta-chain." Biochem Biophys Res			
	ļ	Commun. 164(2):788-795			
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral			
<del></del>	<u> </u>	artery occulsion in rats," Brain Research, Vol. 739:88-96			
	C20	BENIT et al., 1993, "The 'WS motif' common to <i>v-mpl</i> and members of the cytokine receptor superfamily is			
		dispensable for myeloproliferative leukemia virus pathogenicity." Oncogene 8787-790			

<b>EXAMINER</b>
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 8 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ARTUNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS					
Examiner			T		
Initials	_	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т		
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598			
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870			
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57			
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651			
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278			
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590			
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828			
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22			
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7			
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983- 15993			
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.			
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562			
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16			
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345			
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559			
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972			
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.			
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531			
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300			

<b>EXAMINER</b>
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 9 of 26 of List of References

LIST OF	<b>REFERENCES</b>	CITED	BY	APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			1
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597.	
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	1
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42	
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	Ī
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179	
	C'58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 10 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

	1
ATTY, DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the outbox (in CARITAL LETTERS) Title Day of the part of the outbox (in CARITAL LETTERS)	Τ_
initials	C60	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	Т
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 11 of 26 of List of References

1647

# ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905 APPLICANT (Use several sheets if necessary) Coleman et al. FILING DATE ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905 APPLICANT Coleman et al.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T_
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury,"	1
	<del> </del> -	Transplantation Proceedings, Vol. 36, pp. 2935-2938	↓_
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective	1
		activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	↓_
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury,"	
	<u> </u>	www.molmed.org. July 2006	L
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	1
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by	H
	C60	severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd	$\vdash$
	1007	Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	İ
	Coo	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine,	╁╌
	C88	path.upmc.edu/consult/ria/july 1995.html	
		FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007,	╁
	C89	http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	1
	+	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	╁
	C90		
	-	Curr. Opin. Neurol. 15(4):483-9	₽-
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl	
<del></del>	<del></del>	tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	┡
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology	
		and Metabolism, Vol. 78(3):753-756	_
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but	l
	<u> </u>	how?" Endocrinology 143(1):2-10	L
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY	
	<u> </u>	1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics	
		across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal	
		of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and	
	( )	erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of	$\vdash$
	C90	Carbohydrates," Blood, 73(1):84-89.	
	COO	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal	$\vdash$
	C99	transduction," Semin. Immunol. 2:119-128	l
<del></del>	-	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol.	⊢
	C100		l
		269(10):7224-7230	<u> </u>
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 12 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C102		
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	╙
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	t –
		Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,	T
		Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	T
		Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	1
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97(2):315-	
		323.	
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	Γ
		neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	L
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental	
		spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in	ĺ
		rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	CIII	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	
	<u> </u>	clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	_
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	İ
	<b>_</b>	therapy. J Sleep Res. 4(S1): 130-134	L
	C113	GREGORY et al., 1999, "GATA-I and erythropoietin cooperate to promote erythroid cell survival by regulating	
		bcl-x _L expression", Blood 94:87-96	L
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	
		Kidney Intl. 38:480-486	L
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal	
		degeneration," Nature Medicine, Vol. 8(7):718-724	L.
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.	
		1592:215-223	<u>L</u>
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	
		antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	
	ļ	granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II.	
	<b> </b>	Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	
		receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	
	$\downarrow$	Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	

EXAM	INER	
NYI-408	8719v2	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 13 of 26 of List of References

APPLICATION NO.

1647

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
TITICIAIS	<del> </del>	in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	ľ
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209	
	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
, ,	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	Ī
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462.	
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients, "Nephron, Vol. 72, pp. 30-36	
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179	
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER NYI-4088719v2	
NYI-4088719v2	

**DATE CONSIDERED** 

Sheet 14 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

I .	
ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			_
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene symmetric following	+
		I wanter of adenovital vectors to illouse liver and limb " Hilm Gene Ther 7/171/1555 22	١
	C142	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum personnes and in the human serum personnes and in the human serum personnes and in the human serum personnes and in the human serum personnes and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human serum personness and in the human ser	+
		1 Chem Blot interact, voj. [19-120:79-84	١
	C143		+
		I SIVUP SCICCULVE INDERHING MIN SHE-HITECTER MUTAGENESIS "C'hem Diol Intornat Val 110 100 31 50	l
	C144	JUDINSK I et al., 1996. The beta c component of the granulocyte magraphage as lawy at a 1 discount.	4
		CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence	
	1	proliferation and beta-globin mRNA expression," Mol. Med. 2(6):766-773	l
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the	Ļ
		1 cryunopoletin receptor. B100d 90(5):1867-1873	
	C146		Ļ
		injury", Proc. Natl. Acad. Sci. USA 99(16):10659-10664	
	C147	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous	L
	"	system", Pediatr. Res. 43(1):40-49	ı
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	L
		fetus", Early Human Devel. 52(3):235-249	l
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	L
	"	sheep", Soc. for Neuroscience Abstracts 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San	
		Diego, CA 1107, 10-13, 2001)	
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	L
-	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrior transport of bibliotics."	L
		of avidin and a monoclonal antibody to the transferrin receptor," Drug Metab Dispos. Vol. 22(1):99-105	
	C152	KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin,"	_
	0.52	Glycobiology, Vol. 11(12):1043-1049	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	
	0.55	therapy of heart failure-induced mitral regurgitation. Circulation 108:1795-1797	
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New	
		York Acad. Sci., 149:18-24.	
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"	
	0.55	Ann. Neurol. Vol. 56(6):815-826	
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3	_
	C130	activation," Blood 99(1):102-110	
	C157	KISHIMOTO et al. 1987 "Transcandathalial transcand (	
	(13/	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver," Am J Anat. Vol. 178:241-9.	
		1111 3 1111dt. 4 01, 1 / 0, 2 7 1 = 7.	
	C138	KITAJIMA et al., 1994, "Effective combination therapy by recombinant crythropoietin and cepharanthin in a girl	
	1	warrenacion dicina. Japanese i Cin Hematology Vol 35/7)/603/2000 //Em=P-L -1	
	C159	KITAMURA et al., 1989. "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1." Blood, Vol 73(2):375-80	

<b>EXAMINER</b>
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 15 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) Coleman et a

NON PATENT LITERATURE DOCUMENTS			
Examiner			T.,
nitials	<u> </u>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	r
	C160		
		Obstetrics and Gynecology, 96(5):826-828.	╀
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic	
		neurons in vitro and in vivo", Brain Res. 609:29-35	Ļ
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic	
		mechanism.", Behav. Neural Biol. 62:237-243	L
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in	
		patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following	
		neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle	
	0.05	cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	1
	C166	1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Π
	0.00	asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	l
	C167	1 A TONY 1 1 1000 (10 11 11 11 11 11 11 11 11 11 11 11 11 1	Τ
	(2107	and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J.	l
		Cardiovasc. Pharmacol. 31(4):601-608	l
	C168	1 T T T 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2	T
	1 0100	95:11371-11376	
	C169	Trick to control to the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state o	T
	10109	305, pp. 239-242	
	C170	1 D 1 C 1 1 C 1 C 1 C 1 C 1 C 1 C 1 C 1	T
	10170	93:75-80	
	10171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid	T
	C171	progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	+	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human	+
	C172	fetuses", Pediatr. Res. 40(3):376-380	1
	+	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing	╁
	C173	various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	1
	<del> </del> -	THE EVERYGRAN WOUND HEATING W. 1.C. d. 11 P.1 1	╁
	C174		ŀ
		http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	╁
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked	
	<del>                                     </del>	glycans," Anal. Biochem. 219:207-217	1
	C176	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats". Brain	
	<b></b>	Res. 692:143-153	╄
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the	
		Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	L
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol.	
		166:159-169	L
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct	
	10.,,	hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	1

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 16 of 26 of List of References

APPLICATION NO.

1647

	10165-042-999	10/573,905
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Coleman et al.	
	FILING DATE	ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
initiais	C180	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
-	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	T
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	T
<del> </del>	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll. Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 17 of 26 of List of References

	ATTY, DOCKET NO.	APPLICATION NO.	i
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Coleman et al.		
	FILING DATE May 30, 2006	ART UNIT	

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	Τ
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
· · · · · · · · · · · · · · · · · · ·	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	
-	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
•	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 18 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

NON PATENT LITERATURE DOCUMENTS					
Examiner		(Include name of the number (in CARITAL LETTERS) Title Date Restings Pages 54-)	T		
<u>Initials</u>	C221	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages. Etc.)  OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	'		
	C222	OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	T		
	C223	OVARA A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE AND A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE HAVE BY A LOOK WE	T		
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website <a href="http://cancerweb.ncl.ac.uk/omd">http://cancerweb.ncl.ac.uk/omd</a> . Published at the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB Project.			
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261			
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267			
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69			
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	T		
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60			
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92.			
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731			
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704			
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti- carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635			
_	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16			
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773			
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980			
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34			
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260(5 Pt 2): H1406-1414			
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131			

EXAMIN	ER
NY1-40887	19v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 19 of 26 of List of References

APPLICATION NO.

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al.

FILING DATE ART UNIT May 30, 2006 1647

ATTY. DOCKET NO.

# NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
tiitiais		16	+
	C240	Montvale, NJ), pp.1765-1769	
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-	T
	C241	related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717-720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
	C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8	
	C248		
.,	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	Ī
	C252	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 20 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C259	SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives	
		ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	L
	C260	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262	SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift für Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only)	
	C263		;
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464	
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin- dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29	
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	
	C274	STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C276	STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J. of Clinical Investigation, Vol. 35, pp. 711-717	

EXAMINER
EXAMINER NYI-4088719v2

**DATE CONSIDERED** 

Sheet 21 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10165-042-999 10/573,905

NON PATENT LITERATURE DOCUMENTS			
Examiner			T
Initials	<del></del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C279		
	ļ	blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	╁
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535	
	C282	SWISS ACCESSION No. P32927, October 1, 1993	-
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor	
		orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in	+
	C283	vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	1
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol.	+
	1 0280	81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood	1
	0207	flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on	+-
	0200	chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys.	T
	10207	Res. Commun. 148(1):443-448	
_	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis,"	t
	10270	Press Medicale, Vol. 31(11):505-514 (Abstract only)	1
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats	+-
	2271	with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced	<del>                                     </del>
	(2)2	anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1-β Immunoreactivity and microglia are enhanced in the rat hippocampus	$\vdash$
	102/3	by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol	
		19(12):5054-65	
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures	╁
	C274	but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological	
	1	assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	
	C295	VUKICEVIC et al., 1996. "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone	├-
	(293	morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins,"	<del> </del>
	(27/	Blut, 44:173-175.	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	$\vdash$
	C 298	1. 2225, 1777, 7824, 177, 31 matational effects in proteins, Diochemistry, vol. 27(37),0309-0317	1

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 22 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C299		† <u> </u>
· · · · · · · · · · · · · · · · · · ·	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	
···	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:1-32-1-42	
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83	
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
***	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 23 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

APPLICATION NO.

10/573,905

APPLICANT

ART UNIT

1647

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Oncologist 1(5):337-339	Т
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	1
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	T
<del>-</del>	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	T
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	T
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	T
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	T
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	T
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	_
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	T
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	T
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	T
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	$\top$
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	$\dagger$

EXAMINE	3
NYI-4088719	/2

DATE CONSIDERED

Sheet 24 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials	C346	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Office Action, Application No. 09/716,963, date mailed: March 18, 2005	<u>T</u>
	C346	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C347	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C348	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
	1	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C350	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C351	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C352	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
······································	C353	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C354	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C355		
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
<del> </del>	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717.053, date mailed: April 20, 2004	

<b>EXAMINER</b>
NYI-4088719v2

Sheet 25 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C374	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	_
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	┸
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	
•	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	1
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	╁
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	+
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	1
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	T
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	<u> </u>
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	T
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	†
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	<del> </del>
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	T
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	$\vdash$
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

<b>EXAMINER</b>
NIVI-1088719v2

DATE CONSIDERED

Sheet 26 of 26 of List of References

APPLICATION NO.

1647

	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Coleman et al.		
	FILING DATE	ART UNIT	

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912	
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008	

**EXAMINER** NYI-4088719v2

Express Mail No.: <u>EV 654 895 272 US</u> Express Mail No.: <u>EV 654 895 286 US</u> Express Mail No.: <u>EV 654 895 290 US</u>

Express Mail No.: <u>EV 654 895 309 US</u>

Sheet 1 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Esc several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999

APPLICATION NO. 10/573,905

APPLICANT

Coleman et al.

FILING DATE

ART UNIT

May 30, 2006

1647

U.S. PATENT DOCUMENTS

		TRADENAM!	U.S. I	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	4,343,782	8/10/982	Shapiro	FIGURES AFFEAR
	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	A11	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	λ13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	Λ21	5,696,080	12/09/97	O' Brien	
	Λ22	5,700,909	12/23/97	O'Brien	
	A23	5,714,459	02/03/98	O'Brien	
	Λ24	5,750.376	5/12/98	Weiss et al.	
		5,756,349	05/26/98	Lin	
		5,763,198	6/09/98	Hirth et al	
	_	5,767,078	06/16/98	Johnson et al.	

<b>EXAMINER</b>
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 2 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

10/573,905

APT UNIT

1647

			U.S. 1	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
/	128	5,773,569	06/30/98	Wrighton et al.	FIGURES APPEAR
1	129	5,824,672	10/20/98	Simpkins et al.	
F	130	5,830,851	11/03/98	Wrighton et al.	
A	١31	5,835,382	11/10/98	Wilson et al.	
Λ	32	5,856,298	01/05/99	Strickland	
A	.33	5,888,772	03/30/99	Okasinski et al.	
A	34	5,955,422	09/21/99	Lin	
A	35	5,997,865	12/7/99	Bennett et al.	
A	36	6,048,971	4/11/00	Sytkowski et al.	
A	37	6,071,970	6/06/00	Mueller et al.	
A	38	6,103,526	04/15/05	Smith et al.	
A	39	6,153,407	11/28/00	Sytkowski et al.	
A	40	6,165,783	12/26/00	Weiss et al.	
A	41	6,242,570	6/05/01	Sytkowski	
A	12	6,291,661	09/18/01	Graddis et al.	
A	13	6,340,742	1/22/02	Burg et al.	
A4	14	6,399,336	6/4/02	Paulson et al.	
A4	15	6,440,932	8/27/02	Lehmann et al.	
Λ4	6	6,489,293	12/3/02	Sytkowski et al.	
A4	7 (	6,521,245	2/18/03	Zaharia	
Λ4	8 6	5,531,121	3/11/03	Brines et al.	
Λ4	-	5,583,272	6/24/03	Bailon	
Λ5	+,	5,645,522	11/11/03	Naeff et al.	
Λ5		7,214,532	5/08/07	Stern et al.	
Λ5.		7,309,687	12/18/07	Brines et al.	
A5.		,345,019	3/18/08	Brines et al.	
Λ54	-	002/0031806	3/14/02	Lee	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

			U.S.	PATENT DOCUMENTS	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERI RELEVANT PASSAGES OR RELEVA
	A55	2002/0052309	5/02/02	Anagnostou et al.	FIGURES APPEAR
	A56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
,	A68	2003/0113871	6/19/03	Lee et al.	
/	469	2003/0118547	6/26/03	Vandenberg	
/	170	2003/0120045	6/26/03	Bailon	
F	171	2003/0124115	7/3/03	Lee et al.	
1	172	2003/0134798	7/17/03	Brines et al.	
Λ	73	2003/0166566	9/04/03	Kinstler et al.	
Λ	74	2004/0009902	1/15/04	Boime	
Λ	75	2004/0018978	1/29/04	Campana et al.	
Λ	76	2004/0091961	5/13/04	Evans et al.	
Α	77	2004/0096447	5/20/04	Yasuda et al.	
1	78 2	2004/0122216	6/24/04	Nielsen et al.	
Λ	79 2	004/0209812	10/21/04	Farrell et al.	
A	80 2	004/0214236	10/28/04	Brines et al.	
1	81 2	005/0176627	8/11/05	Cerami et al.	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

*EXAMINER					PAGES, COLUMNS, LINES, WHERE
INITIAL	ļ	DOCUMENT NUMBER	DATE	NAME	RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	TIGURES AFFEAR
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh	RELEVANT FIGURES APPEAR	L _T
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		
B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
B04	EP 0640619	1/03/95	Amgen Inc.		
B05	EP 0668 351	8/23/95	Amgen, Inc.		
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

:	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)			PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	T
B09		6/8/00	Eli Lilly & Co.	RELEVANT FIGURES APPEAR	╀
B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		+
B11	WO 00/24893	5/4/00	Amgen, Inc.		$\perp$
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)		$\vdash$
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		$\vdash$
B14	WO 01/81405	1/11/01	Amgen Inc.		┝
B15	WO 01/82952	11/08/01	Action Pharma APS		-
B16	WO 01/82953	11/08/01	Action Pharma APS		H
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		-
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		-
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		H
B20	WO 02/14356	2/21/02	Althoff, Claudia		_
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		_
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		_
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		_
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		_
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		_
B32	WO 06/002646	1/12/06	Lundbeck A/S		_

EXAMIN	ER
NYI-40887	19v2

**DATE CONSIDERED** 

Sheet 6 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

ART UNIT

1647

May 30, 2006

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
B34		2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	RELEVANT FIGURES APPEAR	T
B35	WO 91/05867	5/02/91	Amgen Inc.		
B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		<del> </del>
B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		
B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		
B39	WO 95/05465	02/23/95	Amgen, Inc.		
B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		
B41	WO 97/08307	3/6/97	II Dong Pharmaceutical Co. Ltd.		
B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		_
B43	WO 97/32895	9/12/97	Regents of the University of California		
B44	WO 98/10650	3/19/98	East Carolina University		
B45	WO 98/18926	05/07/98	G.D. Searle & Co.		
B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		
B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		
B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		
B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		
B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		
B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		
B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		
B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		
B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		
B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		

EXAMINER
NYI-4088719v2

Sheet 7 of 26 of List of References

### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	1		_
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper I. Declaration, Brines clean copy of	+
		claims, and Ehrenreich clean copy of claims (10/02/06)	
-	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	+
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	╁
		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	ı
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	╁
	00.	alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	╀
	005	Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	l
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	╀
	000	Natl. Acad. Sci. USA 91:3974-3978	
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	╀
	1007	for Bioassay," Bull. Org. mond. Sante, 47:99-112.	ı
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	╀
	1 000	der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	ı
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	╀
	100	Glycoproteins," Meth. Enzymol., 50:287-291.	
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	╀
	1010	Cerebrovascular Disease, Vol. 9:131-135	
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	⊢
	1011	premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	L
	1012	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	C13	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	L
	1013	Cell. Biol. 14(10):6506-6514	
	CIA	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	L
	C14	function relationships," J. Biol. Chem. 272(8):4985-4992	
	CIE	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	
	C15	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	C16	BASKAVA et al. 1907 "The higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the higheric company of the highe	_
	CIO	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after traumetic brain injury in rats." Neuroscience Letters, Vol. 226:33-36	
	61.5	BALIER 1005 "The Owners See The Co. The Co.	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-12.	
<del></del>	611.0		
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
		prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
		DELAYEV et al. 1004 (2).700-773	
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
	<del>                                     </del>	artery occulsion in rats," Brain Research, Vol. 739:88-96	
	C20	BENIT et al., 1993, "The 'WS motif common to v-mpl and members of the cytokine receptor superfamily is	
	L	dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	

<b>EXAMINER</b>
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 8 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

	NON PATENT LITERATURE DOCUMENTS					
Examiner			T			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T			
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598				
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870				
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	ļ			
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651				
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	1			
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590				
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828				
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22				
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7				
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-				
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.				
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562				
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16				
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345				
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559				
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	-			
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.				
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531				
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300				

EXAMIN	ER
NYI-40887	19v2

**DATE CONSIDERED** 

Sheet 9 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		Т
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597.	
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
•••	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	T
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	T
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	1
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	T
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42	
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	-
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960	-
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179	
	C58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 10 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
Initials	<del></del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation	
		to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem.	1
		Vol. 10(1):32-7	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist,	
		Vol. 3:314-318	1
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival - Modifications to the	П
		tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	l
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's	T
	005	disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley &	╁╌
	C04	Sons, p. 122, p. 508	
	CCE	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple	+-
	C65	sclerosis," Brain, Vol. 128, pp. 375-385	
		Sciences, Brain, vol. 126, pp. 575-365	╄
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and	1
	<del> </del>	platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	╙
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the	İ
		mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant	
		erythropoietin treatment", ASAIO J. 38:M477-M480	1
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation:	Ī
	. ]	prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global	$\vdash$
		ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	l
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	†-
	10/1		L
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	ļ
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New	$\vdash$
	C/3	York, 1993	
	074	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion,	<del>  -</del>
	C74	and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	<del>                                     </del>	and Biological Function, J. Biol. Crem., 203(33):17510-17521.	ļ
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance,"	
	<u> </u>	Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	_
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP),"	ľ
	<u> </u>	Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med.	
		8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular	
	''	Psychiatry, 9:42-54	
	C70	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C79		
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 11 of 26 of List of References

	ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Coleman et al.		
	FILING DATE May 30, 2006	ART UNIT	

		NON PATENT LITERATURE DOCUMENTS	
Examiner	1		T
<u>Initials</u>		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	T
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
W 174 .	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
· · · · · · ·	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

<b>EXAMINER</b> NYI-4088719v2
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C102	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and	
	<del></del>	Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	╙
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	T
		Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,	Τ
		Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	┪
		Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97(2):315-	Γ
		323.	ļ
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	
		neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental	Г
		spinal cord injury," PNAS, Vol. 102(45):16379-84	l
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in	Г
		rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	CHI	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	
		clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	
		therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating	
		bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	
		Kidney Intl. 38:480-486	
	C115		
		degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.	
		1592:215-223	
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	
	1	antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	
		granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II.	
		Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	
		receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	_
		Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	

<b>EXAMIN</b>	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 13 of 26 of List of References

	ATTY, DOCKET NO.	APPLICATION NO.		
	10165-042-999	10/573,905		
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT			
(Use several sheets if necessary)	Coleman et al.			
	FILING DATE	ART UNIT	:	
	May 30, 2006	1647		

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	T
			┺
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209	
-	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	<del> -</del>
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
•	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	ļ
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462.	
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients, "Nephron, Vol. 72, pp. 30-36	
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179	
• =	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER
EXAMINER NYI-4088719v2

DATE CONSIDERED

Sheet 14 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		_
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgens symmetric for the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement of the significant statement statement of the significant statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement statement sta	+
		Twenty of auchovital vectors to mouse liver and ling " Hum Gene Ther 7(12), 1555 22	1
	C142	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paragyonase active site."	+
		Chem Dioi interact, Vol. [19-120:79-84	l
	C143		╁
		group-scientive labelling and site-directed militagenesis." Chem Riol Internet. Vol. 110, 120-71, 70	
	C144	JUDINSK I et al., 1996, "The beta c component of the granulocyte magraphaga colony stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimulating and any stimula	╁
		1 Col / microcurin 5 (1L-5)/1L-5 receptor interacts with a hybrid (iM-CSF/erythropoietin recenter to indicate indicate in the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the	
		promeration and deta-globin mixing expression " Mol. Med. 2(6),766,772	
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 recentor functionally associates with the	H
	<b>_</b>	1 cryunopoleun receptor. Diood 90/31/18/7-18/3	
	C146		╁
	ļ	1 11 11 11 11 11 11 11 11 11 11 11 11 1	
	C147	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central persons	╀
	<del></del>	1 System , Pediatr. Res. 43(1):4()-49	
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	┞
	<b> </b>	1 10td5 ; Edity Human DCVCI, 32(3),233,•249	
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	┝
		slicep, soc. for Neuroscience Abstracts 2/(1):929 (31st Annual Meeting of the Society for Neuroscience Care	
	-	1 DIORO, CA 1909, 1971.). 2001.1	
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	H
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate	
	<del>                                     </del>	of arisin and a monoclottal allipout to the transferrin recentor "Thric Metab Diamos Val 22/1/20 106	
	C152	NA WASAKI et al., 2001, Structural analysis of sulfated N-linked oligosaccharides in anythronoistic "	
	-	Glycolology, vol. 1 ((2):1043-1049	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	_
<u></u> .		therapy of healt famile-induced mitral regulation ( ) regulation 100.1705 1707	
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoiatin" Apprels New	_
		1 OTK / 1000, DCI., 17/, 10-24.	
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"	_
	1 1	7 tim. (*edio). *01. 50(0).615-620	
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3	_
	, ,	4607400016 D1000 77(1), 102-110	
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	
		7 till 3 / tildt. 7 Oi, 1 / O.241=7.	
	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant crythropoietin and cepharanthin in a girl	
		The remarkory and man Japanese J. Chil. Piemanology Vol. 33771604.6089 (w/Emaliab abadas and	
	C159 L	KITANIONA et al., 1969. Identification and analysis of human erythropoletin recentors on a feature described	_
		line. TF-1." Blood, Vol 73(2):375-80	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 15 of 26 of List of References

# ATTY. DOCKET NO. | APPLICATION NO. | 10165-042-999 | 10/573,905 | LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) Coleman et al. | FILING DATE | ART UNIT | May 30, 2006 | 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(I. I. I. C. C. CADITAL LETTERS) Tide Day Buring San	Т
Initials	C160	(Include name of the author (in CAPITAL LETTERS), Title. Date, Pertinent Pages, Etc.)  KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis,"  Obstetrics and Gynecology, 96(5):826-828.	
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo", Brain Res. 609:29-35	
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31(4):601-608	
	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A. 95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol. 305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol. 93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	C172	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40(3):376-380	
	C173	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	C174	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund, http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," Anal. Biochem. 219:207-217	
-	C176	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	

EXAMINER
NY1-4088719v2

DATE CONSIDERED

Sheet 16 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner		CHARLES CONTRACTOR OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY	T
Initials	C180	(Include name of the author (in CAPITAL LETTERS). Title, Date, Pertinent Pages, Etc.)  LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	-
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
, , , <del></del> , , , , , ,	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll. Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 17 of 26 of List of References

APPLICATION NO.

1647

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
· · · · · · · · · · · · · · · · · · ·	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .	1
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	Ī
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	$\vdash$

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 18 of 26 of List of References

APPLICATION NO.

1647

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner	T		T,
Initials	┷	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Ļ
	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	
	1		+
	C222	chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	ŀ
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion	t
	C223	57:328-332	
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website <a href="http://cancerweb.ncl.ac.uk/omd">http://cancerweb.ncl.ac.uk/omd</a> . Published at	T
		the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB	
		Project.	L
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the	
		rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	$\perp$
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the	ı
		rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	┸
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development	
		factor or thrombopoietin," Cytokine 8(1):66-69	1
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the	İ
	ļ	introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	╀
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain	l
	<del></del>	barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	╀
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem.	
	<del> </del>	Vol. 70:1781-92.  PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	╁
	C231		$\perp$
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a	1
		recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	1
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti-	
···		carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	4
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major	
		histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta	
		2m," Eur. J. Immunol. 25:1609-16 PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked	╀
	C235	oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-	
		773	
	(1224	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics	t
	C236	11(4):974-980	ı
· <u></u> ·	C227	DETERMINE 1070 ME L. Alta Anthre Science de la contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra del Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra del la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de la Contra del la Contra de la Contra de la Contra de la Contra de la Contra de la Contra de	t
	C237	infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	
	C238	process at a 1001 p	T
	1 (238	260(5 Pt 2): H1406-1414	
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525	T
	6239	and 2125-2131	

EXAMIN	ER
NYI-40887	19v2

**DATE CONSIDERED** 

Sheet 19 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS			
Examiner			T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Ţ
	C240	PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company, Montvale, NJ), pp.1765-1769	
	-	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-	╁
	C241	related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
	C247		
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
	C252	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
<del></del>	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 20 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

NON PATENT LITERATURE DOCUMENTS			
Examiner	T		T_
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C259		
	<del></del>	ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	<u> </u>
	C260	74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262		
		Neonatologie (202)(2), pp 64-68 (Abstract Only)	
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain	
		and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for	
		erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	1
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent	
		growth in hematopoietic cell lines," Blood 88(2):455-464	l
	C265	GUIDANAIGH A 1004 40 CHAIL CO A CO A CO A CALL CO A CALL	
	0203	Vivo and in Vitro," Exp. Cell Res., 215:249-256.	l
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-	
		dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress",	
		Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270		
	1 0270	Ultrastruct Res. Vol. 88(1):18-29	
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood,	$\vdash$
	(2/1	73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J.	$\vdash$
	(2/2	Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	$\vdash$
		STEDMAN'S MEDICAL DICTIONARY, 27th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and	<u> </u>
	C274		
	<del> </del>	Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc.	
	-	Natl. Acad. Sci. U. S. A. 99(22):13972-4	L
	C276	STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin:	
		Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human	
		Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and	
		Biological Properties," British J. Haematology, 100:79-89.	
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J.	
	/	of Clinical Investigation, Vol. 35, pp. 711-717	

EX.	AMI	INE	ER
NYI	-408	871	9v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 21 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T	
initials	C279	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	† <u>*</u>	
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.		
	C281	73:1525-1535		
	C282	SWISS ACCESSION No. P32927, October 1, 1993		
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516		
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872		
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252		
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402		
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268		
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738		
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448		
	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale, Vol. 31(11):505-514 (Abstract only)		
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133		
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508		
	C293	VEZANNI et al., 1999, "Interleukin-1- $\beta$ Immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol 19(12):5054-65		
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63		
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026		
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.		
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," Blut, 44:173-175.		
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 22 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
intiais	C299		╁
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C303	Semin. Immunol. 5(5):337-344	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42	
	C306	utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83	
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	
	C312	Eur. J. Biochem. 239:494-500	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	Π

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 23 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
mitiais	<del> </del>	Oncologist 1(5):337-339	†
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
. , ,	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	Τ
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	Ť
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	T
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	1
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	1
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	†
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	$\top$
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	T
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	T
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	1
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	T
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	+
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	$\dagger$
	+	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	+

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 24 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.		
10165-042-999	10/573,905		
APPLICANT			
Coleman et al.			
FILING DATE	ART UNIT		
May 30, 2006	1647		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C346	Office Action, Application No. 09/716,963, date mailed: March 18, 2005	
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
-	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
•	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	

<b>EXAMIN</b>	ER
NVI-10887	1902

**DATE CONSIDERED** 

Sheet 25 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.	
10165-042-999	10/573,905	
APPLICANT		
Coleman et al.		
FILING DATE	ART UNIT	
May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
IIIIIIais	C374	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	† †
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	+
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	$\dagger$
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	$\dagger$
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	
	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	1
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	†
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	1
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	
-	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	T
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	
·····	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	†
<del></del> ,,	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	T
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	T
<u> </u>	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	
<del></del>	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	T
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

EXAMINE	R
NYI-4088719	v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 26 of 26 of List of References

APPLICATION NO.

1647

	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT Coleman et al.		
(Use several sheets if necessary)			
	FILING DATE	ARTUNIT	

ATTY. DOCKET NO.

May 30, 2006

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912	i	
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008		

EXAMINER NYI-4088719v2

Sheet 1 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

EXAMINER					PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
INITIAL	A01	DOCUMENT NUMBER 4,343,782	8/10/982	NAME	FIGURES APPEAR
		4,377,513		Shapiro	
	A02	4,658,019	03/22/83	Sugimoto et al.	
	A03		04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	All	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	Λ13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Podusio et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
,	A18	5,621,080	04/15/97	Lin	
/	419	5,625,035	04/29/97	Clemons	
,	120	5,661,125	08/26/97	Strickland	
/	121	5,696,080	12/09/97	O' Brien	
/	122	5,700,909	12/23/97	O'Brien	
1	123	5,714,459	02/03/98	O'Brien	
/	\24	5,750,376	5/12/98	Weiss et al.	
	125	5,756,349	05/26/98	Lin	
		5,763,198	6/09/98	Hirth et al	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 2 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

ART UNIT

1647

May 30, 2006

			U.S. I	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A28	5,773,569	06/30/98	Wrighton et al.	FIGURES APPEAR
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	A46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	Λ48	6,531,121	3/11/03	Brines et al.	
	Λ49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
	A51	7,214,532	5/08/07	Stern et al.	
	Λ52	7,309,687	12/18/07	Brines et al.	
	Λ53	7,345,019	3/18/08	Brines et al.	
	Λ54	2002/0031806	3/14/02	Lee	

<b>EXAMINER</b>
NYI-4088719v2

Sheet 3 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

### **U.S. PATENT DOCUMENTS** PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT *EXAMINER INITIAL DOCUMENT NUMBER DATE NAME FIGURES APPEAR 2002/0052309 A55 5/02/02 Anagnostou et al. 2002/0061849 A56 5/23/02 Nielsen et al. 2002/0077294 A57 6/20/02 Kay et al. A58 2002/0081734 6/27/02 Choi et al. A59 2002/0086816 7/04/02 Brines et al. 2002/0142370 A60 10/3/02 Paulson et al. 2002/0160460 A61 10/31/02 Paulson et al. A62 2003/0003529 1/2/03 Bayer 2003/0040037 2/27/03 A63 Bayer 2003/0072737 4/17/03 A64 Brines 2003/0077753 4/24/03 A65 Tischer 2003/0083251 5/01/03 A66 Westfenfelder 2003/0104988 6/5/03 A67 Brines 2003/0113871 A68 6/19/03 Lee et al. 2003/0118547 6/26/03 A69 Vandenberg 2003/0120045 6/26/03 A70 Bailon A71 2003/0124115 7/3/03 Lee et al. 2003/0134798 A72 7/17/03 Brines et al. 2003/0166566 A73 9/04/03 Kinstler et al. 2004/0009902 1/15/04 A74 Boime A75 2004/0018978 1/29/04 Campana et al. 2004/0091961 5/13/04 A76 Evans et al. 2004/0096447 5/20/04 A77 Yasuda et al. 2004/0122216 6/24/04 Λ78 Nielsen et al. 2004/0209812 10/21/04 Λ79 Farrell et al. 2004/0214236 10/28/04 A80 Brines et al. 2005/0176627 8/11/05 A81 Cerami et al.

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 4 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

10/573,905

ART UNIT

1647

*EXAMINER INITIAL		DOCUMENT NUMBER	D. 1770		PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
BATTIAL	A82	2006/0034799	2/16/06	NAME	FIGURES APPEAR
	//82		2/10/06	Brines et al.	
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh	RESEVANT FIGURES APPEAR	H
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		-
В03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		_
B04	EP 0640619	1/03/95	Amgen Inc.		<del> </del>
B05	EP 0668 351	8/23/95	Amgen, Inc.		_
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		_

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
B09		6/8/00	Eli Lilly & Co.	RELEVANT FIGURES APPEAR	+-
B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		-
BII	WO 00/24893	5/4/00	Amgen, Inc.		╁╌
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)		
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		╁
B14	WO 01/81405	1/11/01	Amgen Inc.		-
B15	WO 01/82952	11/08/01	Action Pharma APS		H
B16	WO 01/82953	11/08/01	Action Pharma APS		_
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		_
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		_
B20	WO 02/14356	2/21/02	Althoff, Claudia		
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		_
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		_
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		_
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		-
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B32	WO 06/002646	1/12/06	Lundbeck A/S		
B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		

<b>EXAMINER</b>
NYI-4088719v2

DATE CONSIDERED

Sheet 6 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

			FOREIG	EN PATENT DOCUMENTS		
		FÖREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	Т
	B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	RESEVANT TOURES AFFEAR	† • • • • • • • • • • • • • • • • • • •
	B35	WO 91/05867	5/02/91	Amgen Inc.		<u>†                                    </u>
	B36	WO 92/08493	5/29/92	Brigham & Women's Hospital	4-	<del>                                     </del>
	B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		
	B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		<del>                                     </del>
	B39	WO 95/05465	02/23/95	Amgen, Inc.		-
	B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		<u> </u>
	B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.		
	B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		
	B43	WO 97/32895	9/12/97	Regents of the University of California		
	B44	WO 98/10650	3/19/98	East Carolina University		
	B45	WO 98/18926	05/07/98	G.D. Searle & Co.		
	B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
	B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		
	B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		
	B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		
	B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		
	B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		
	B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		-
<u> </u>	B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		
	B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		
	B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		$\dashv$
	B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 7 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		<del>-</del>
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of	+:
		claims, and Ehrenreich clean copy of claims (10/02/06)	1
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	╁
	""	myocardial ischemia," Shock, Vol. 22(1), pp 63-69	1
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	╁
	005	experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	+
	1004	alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	╀
	1003	Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	ı
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	╀
	100	Natl. Acad. Sci. USA 91:3974-3978	į.
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	╂
	207	for Bioassay," Bull. Org. mond. Sante, 47:99-112.	!
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	╁
	1 008	der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	┞_
	109	Glycoproteins," Meth. Enzymol., 50:287-291.	
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	↓_
	CIU	Cerebrovascular Disease, Vol. 9:131-135	İ
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	L
	CII	premature rabbits," Pediatric Res., Vol. 40(3):381-387	1
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	_
	CIZ	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	1012	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	<u> </u>
	C13	Cell. Biol. 14(10):6506-6514	
<del>-                                    </del>	1014	RAPPONE et al. 1907 "Mutagenesis and in Calaba	L
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships," J. Biol. Chem. 272(8):4985-4992	
<del></del>	1000	PARRON et al. 1004 "Allowations in January 1971"	
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	
		murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	
		traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-12.	
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
	1018	prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
		Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
	1019	artery occulsion in rats," Brain Research, Vol. 739:88-96	
<del></del>	C20	BENIT et al. 1003 "The 'W's motif common to a ward and an action of the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and the common to a ward and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second an	
	C20	BENIT et al., 1993, "The 'WS motif common to v-mpl and members of the cytokine receptor superfamily is	
	<u> </u>	dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 8 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.	
10165-042-999	10/573,905	
APPLICANT		
Coleman et al.		
FILING DATE	ART UNIT	
May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	ַד
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	-
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER
EXAMINER NYI-4088719v2

DATE CONSIDERED

Sheet 9 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597.	
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	T
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	1
· · · · · · · · · · · · · · · · · · ·	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	
-	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	T
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42	
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	T
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179	
	C58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 10 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.		
10165-042-999	10/573,905		
APPLICANT			
Coleman et al.			
FILING DATE	ART UNIT		
May 30, 2006	1647		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	1	(Include name of the outbox (in CADITAL LETTEDS) Title Date Portions Degree Fts.)	T
initiais	C60	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem.  Vol. 10(1):32-7	1
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277.	
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	1
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	

<b>EXAMINER</b>	
NYI-4088719v2	

DATE CONSIDERED

Sheet 11 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	<u> </u>		
Initials	<del></del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury,"	
		Transplantation Proceedings, Vol. 36, pp. 2935-2938	-
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective	
		activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	├-
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury,"	i
	-	www.molmed.org. July 2006	⊢
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by	
		severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd	
		Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine,	
		path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007,	
		http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
		Curr. Opin. Neurol. 15(4):483-9	İ
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl	
	<u> </u>	tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	<u> </u>
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology	
	<u> </u>	and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but	
		how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY	
		1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics	
		across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal	
		of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and	
		erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	L
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of	
	<u> </u>	Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal	
		transduction," Semin. Immunol. 2:119-128	
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol.	
		269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

EXAM	IN	ER
NYI-408	387	19v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		Π
Initials		(Include name of the author (in CAPITAL LETTERS). Title, Date, Pertinent Pages, Etc.)	T
	C102		1
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	<u> </u>
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	
	0.0.	Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,	T
		Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	
	0.00	Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	ļ
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97(2):315-	
	10107	323.	
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	
	0.00	neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental	
	10.07	spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in	1
	10110	rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	CHI	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	T
	" "	clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	
	0112	therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating	t
	10113	bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	
	10114	Kidney Intl. 38:480-486	
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal	
	10113	degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.	Т
	10110	1592:215-223	
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	$\vdash$
	(117	antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	<del>                                     </del>
	(.116	granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II.	_
	City	Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
<del></del>	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	$\vdash$
	C120	receptor." Biochem. Biophys. Res. Comm. 208(3):1060-1066	
_	(333)	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	<del> </del>
	C121	Bioengineering, Vol. 16:1069-1079	
	1,110	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	_
	C122	TANSEN, et al., 2000, A failuoinized, binded placebo contioned, phase II, dose-inding study of ARANESP	

<b>EXAM</b>	INI	ER
NYI-408	871	942

DATE CONSIDERED

Sheet 13 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS). Title, Date, Pertinent Pages, Etc.) in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	Т
<u></u>	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain	
	C124	expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209  HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an	-
	C125	erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366  HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a	<del> </del>
	C126	specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319  HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database,	
· - · · · · · · · · · · · · · · · · · ·	C127	FRP 03-05, ID No. 136456, Comp & Dist. By NTIS  HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	that a lace well is a lace to the lace to the second with the lace to the second will be a lace to the second with the lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the second will be a lace to the s	
	C136	Nephron, Vol. 72, pp. 30-36	
	C137	Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179	
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER
EXAMINER NYI-4088719v2

DATE CONSIDERED

Sheet 14 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICA	ANT
-------------------------------------	-----

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following	+-
		I derivery of adenovital vectors to mouse liver and ling "Hum Gene Ther 7(13),1555 22	
	C142	JUSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paragyonase active site."	╀
		1 Chem Dioi interact. Vol. 119-120:79-84	
	C143	JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino acid residues by	┿
		group-sciective labelling and site-directed mulagenesis." (Them Riol Interact. Vol. 110, 120.71, 70	
	C144	JOBINSK F et al., 1990, "The beta c component of the granulocyte-macrophage colony stimulating forter (CA)	╀
	ł	1 Col / Interiourn 5 (12-5)/12-5 receptor interacts with a hybrid (iM-CSF/erythropoietin recentor to influence	ı
		prometation and beta-globin mkNA expression "Mol Med 2(6)-766,772	l
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 recentor functionally associates with the	╁
		Crymropotetiii receptor,   Dioon 90(3):1867-1873	
	C146	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute inchamic recording."	╀
		1 mjury , 1 toc. Nati. Acau. Sci. USA 99(16):10639-10664	
	C147	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central name and	╁
	<b>_</b>	5ystem   , redian   Res. 45(1):40-49	l
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	┝
		1 icius ; Larry Turrian Dever, 32(3):233-249	
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	⊢
		siecp, soc. for Neuroscience Abstracts 2/(1):929 (31st Annual Meeting of the Society for Neuroscience Co. 1	
		Diego, CA (10), 10-13, 2001)	
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	-
	1		
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate	_
	-	or a vietn and a monocional antibody to the transferrin recentor "Thrug Metah Dispos. Vol. 22(1).00, 105	
	C152	NA WASAKI et al., 2001, Structural analysis of sulfated N-linked oligosaccharides in another mainting v	
		Glycolology, vol. 11(12):1043-1049	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	
	LI	therapy of heart familie-induced filling registration ( ironiation 100-1705 1707	
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Engthropoietin." Appels New	_
	<u> </u>	1 OTK / 1 Cud. 3 Cl., 177, 10 - 24.	
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"	
	<u> </u>	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3	
		4401440014 D1004 77(1),102-110	
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	_
	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant crythropoietin and cepharanthin in a girl	
		The remarked another Japanese J. Chil. Hematology Vol. (\$77)-kua kogo (111/Emaliak akasa-ak	
	C159 I	KITAWOKA et al., 1969. Identification and analysis of human grythronoistin recentors on a Control of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the stat	
		line. TF-1," Blood, Vol 73(2):375-80	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 15 of 26 of List of References

	ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT  Coleman et al.	
	FILING DATE May 30, 2006	ART UNIT

		NON PATENT LITERATURE DOCUMENTS	
Examiner		Control of Capital Interpret Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Control of Capital Capital Control of Capital Control of Capital Control of Capital Capital Control of Capital Control of Capital Capital Control of Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capital Capit	
Initials	<del></del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis,"	T
	C160	Obstetrics and Gynecology, 96(5):826-828.	
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic	<del> </del>
	CIGI	neurons in vitro and in vivo", Brain Res. 609:29-35	
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic	1
	10102	mechanism.", Behav. Neural Biol. 62:237-243	
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in	
		patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following	1
		neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle	i
	<b>_</b>	cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	╁
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
		LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive	+
	C167	and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J.	
		Cardiovasc. Pharmacol. 31(4):601-608	
	C168	The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	†
	100	95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol.	
	[,	305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol.	
		93:75-80	ļ
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid	
		progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	-
	C172	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human	
		fetuses", Pediatr. Res. 40(3):376-380  LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing	<del> </del>
	C173	various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
		LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund,	┼─
	C174	http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked	†
	C175	glycans," Anal. Biochem. 219:207-217	
	C176		<b>T</b>
	10170	Res. 692:143-153	
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the	1
		Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol.	
		166:159-169	
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct	
		hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 16 of 26 of List of References

1647

## ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) Coleman et al. FILING DATE ART UNIT

May 30, 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner		(I. I. I. C. C. C. CADITAL I ETTERO), Till D. D. C. C. D. C.	Т
Initials	C180		
	C181	272(51):32395-32400  LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	-
	C183		
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
· · · · · · · · · · · · · · · · · · ·	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
• •	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll." Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990. "Extravastatin of albumin in ischaemia brain oedema." Acta Neurochirurgica, Suppl.	_

<b>EXAMINER</b>	
NYI-4088719v2	2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 17 of 26 of List of References

ATTY. DOCKET NO. APPLICATION NO.

10165-042-999 10/573,905

APPLICANT
(Use several sheets if necessary)

Coleman et al.

FILING DATE
May 30, 2006 1647

NON PATENT LITERATURE DOCUMENTS				
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
············		Vol. 51:220-222		
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465		
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994		
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229		
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.		
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390		
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.		
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116		
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260		
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7		
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353		
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26th ed. pp. 524-526, McGraw-Hill Co., .		
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897		
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201		
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302		
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35		
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21		
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7		
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416		
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31		
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556		

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 18 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages. Etc.)	Т
mittais	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	Ť
	C222	OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332	
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website <a href="http://cancerweb.ncl.ac.uk/omd">http://cancerweb.ncl.ac.uk/omd</a> . Published at the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB Project.	
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69	
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92.	
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti- carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773	
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980	
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260(5 Pt 2): H1406-1414	
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 19 of 26 of List of References

APPLICATION NO.

## LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al.

FILING DATE ART UNIT
May 30, 2006 1647

ATTY. DOCKET NO.

		NON PATENT LITERATURE DOCUMENTS	
Examiner	_		Τ_
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C240	PHYSICIANS' DESK REFERENCE, 1995, 49th Edition (Medical Economics Data Production Company,	
	<u> </u>	Montvale, NJ), pp.1765-1769	ļ
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717-720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
	C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8	
***************************************	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
	C252	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
···	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER NYI-4088719v2
NYI-4088719v2

DATE CONSIDERED

Sheet 20 of 26 of List of References

APPLICATION NO.

## 

FILING DATE ART UNIT
May 30, 2006 1647

ATTY. DOCKET NO.

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ_
nitials	<b>_</b>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C259	SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives	
	ļ	ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	L
	C260	74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262		
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464	
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin- dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
· · · · · · · · · · · · · · · · · · ·	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29	
.,,	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	
	C274	STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C276	STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J. of Clinical Investigation, Vol. 35, pp. 711-717	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 21 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ARTUNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C279	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral	
		blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	_
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol.	
		73:1525-1535	
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283		
		orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by	
		inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in	
		vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol.	
		81:395-402	١.
	C287		
		flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on	
		chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys.	
		Res. Commun. 148(1):443-448	
	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis,"	
		Press Medicale, Vol. 31(11):505-514 (Abstract only)	
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats	
		with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced	
		anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- $\beta$ Immunoreactivity and microglia are enhanced in the rat hippocampus	
		by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol	
		19(12):5054-65	
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures	
		but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological	
		assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone	_
		morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins,"	-
	(2)	Blut, 44:173-175.	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	
	(270	2.5.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 22 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10/573,905 ART UNIT May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C299		†
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C303	Semin. Immunol. 5(5):337-344	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42	
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	
	C308	Thromb. Haemost. 78:1505-1509	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83	
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	Π
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	

EXAMINER NYI-4088719v2
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 23 of 26 of List of References

APPLICATION NO.

1647

## LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Oncologist 1(5):337-339	Т
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	-
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
,	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	1
-	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	Ī
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	T
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	T
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	T
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	T
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	T
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	
<del></del>	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	1-
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	T
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	T
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	t
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	T

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 24 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the outbox (in CADITAL LETTERS) Title Date Partinent Record Etc.)	Т
muais	C346	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Office Action, Application No. 09/716,963, date mailed: March 18, 2005	
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
····	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
<u>.</u> .	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717.053, date mailed: April 20, 2004	

EXA	MINER	
NYI-	1088719v2	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 25 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ARTUNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C374	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	
•	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	†
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	<b>†</b>
- ·	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	†
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	+
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	+
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	T
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	†
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	1
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	$\vdash$
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	
•	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	†
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	_
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	$\vdash$
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

EXA	ΜI	N	ER
NYI-4	088	37	19v2

**DATE CONSIDERED** 

Sheet 26 of 26 of List of References

APPLICATION NO.

1647

## LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title. Date. Pertinent Pages, Etc.)	Т				
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912					
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008					

EXAMINER NYI-4088719v2

Express Mail No.: <u>EV 654 895 309 US</u> Sheet I of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

ART LINIT

FILING DATE

May 30, 2006

ART UNIT

1647

S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN FIGURES APPEAR
	A01	4,343,782	8/10/982	Shapiro	TIOOKESTITEAK
	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	All	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	A21	5,696,080	12/09/97	O' Brien	
		5,700,909	12/23/97	O'Brien	
		5,714,459	02/03/98	O'Brien	
		5,750,376	5/12/98	Weiss et al.	
		5,756,349	05/26/98	Lin	
		5,763,198	6/09/98	Hirth et al	
		5,767,078	06/16/98	Johnson et al.	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>EV 654 895 272 US</u> Express Mail No.: <u>EV 654 895 286 US</u> Express Mail No.: <u>EV 654 895 290 US</u>

Express Mail No.: EV 654 895 309 US

Sheet 2 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

			U.S. I	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN
	A28	5,773,569	06/30/98	Wrighton et al.	FIGURES APPEAR
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	Λ46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	Λ48	6,531,121	3/11/03	Brines et al.	
	Λ49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
	Λ51	7,214,532	5/08/07	Stern et al.	
	Λ52	7,309,687	12/18/07	Brines et al.	
	A53	7,345,019	3/18/08	Brines et al.	
		2002/0031806	3/14/02	Lee	

<b>EXAMINER</b>
NYI-4088719v2

DATE CONSIDERED

Sheet 3 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

			U.S.	PATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
	A55		5/02/02	Anagnostou et al.	FIGURES APPEAR
	A56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	Λ72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	Λ74	2004/0009902	1/15/04	Boime	
	A75	2004/0018978	1/29/04	Campana et al.	
	A76	2004/0091961	5/13/04	Evans et al.	
		2004/0096447	5/20/04	Yasuda et al.	
		2004/0122216	6/24/04	Nielsen et al.	
		2004/0209812	10/21/04	Farrell et al.	
<del></del>		2004/0214236	10/28/04	Brines et al.	
		2005/0176627	8/11/05	Cerami et al.	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

*EXAMINER INITIAL		DOCUMENTALINADED			PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
IMITIAL	100	DOCUMENT NUMBER 2006/0034799	DATE	NAME	FIGURES APPEAR
	A82	2000/0034/99	2/16/06	Brines et al.	
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

i i	FOREIGN PATENT	T			
	DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh	RECEVALIT FIGURES AFFEAR	t
B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		
B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
B04	EP 0640619	1/03/95	Amgen Inc.		_
B05	EP 0668 351	8/23/95	Amgen, Inc.		
B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		_
B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		-

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>EV 654 895 309 US</u>
Sheet 5 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

ART UNIT

1647

May 30, 2006

	FOREIGN PATENT	<u> </u>		T
	DOCUMENT COUNTRY CODE, NUMBER,			PAGES, COLUMNS, LINES, WHERE
	KIND CODE (IF KNOWN)	DATE	NAME	RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
B09		6/8/00	Eli Lilly & Co.	NECEVANT FIGURES APPEAR
B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories	
B11	WO 00/24893	5/4/00	Amgen, Inc.	
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)	
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG	
B14	WO 01/81405	1/11/01	Amgen Inc.	
B15	WO 01/82952	11/08/01	Action Pharma APS	
B16	WO 01/82953	11/08/01	Action Pharma APS	
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG	
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.	
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.	
B20	WO 02/14356	2/21/02	Althoff, Claudia	
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG	
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG	
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.	
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.	
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.	-
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.	
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.	
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.	
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S	
B32	WO 06/002646	1/12/06	Lundbeck A/S	
B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc.,	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 6 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

			FOREIG	N PATENT DOCUMENTS		
		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
	B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	RELEVANT FIGURES AFFEAR	$\dagger$
	B35	WO 91/05867	5/02/91	Amgen Inc.		╁
	B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		t
	B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		H
	B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		H
	B39	WO 95/05465	02/23/95	Amgen, Inc.		$\vdash$
· · · · · · · · · · · · · · · · · · ·	B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		H
	B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.	·.	H
	B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		
	B43	WO 97/32895	9/12/97	Regents of the University of California		H
	B44	WO 98/10650	3/19/98	East Carolina University		Г
	B45	WO 98/18926	05/07/98	G.D. Searle & Co.		_
	B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
	B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		
	B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		_
	B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		
	B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		_
	B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV		
	B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		
	B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		_
	B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		
	B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		_
	B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		_

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 7 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Т
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	$ _{T}$
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper I. Declaration, Brines clean copy of	†÷
		claims, and Ehrenreich clean copy of claims (10/02/06)	
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	T
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	1
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	T
		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	
		alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	1
		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	i
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	T
		Natl. Acad. Sci. USA 91:3974-3978	
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	
		for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	
	<b>-</b>	der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	
		Glycoproteins," Meth. Enzymol., 50:287-291.	
	C10	AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	
	ļ	Cerebrovascular Disease, Vol. 9:131-135	
	CH	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	
		premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	
	<u> </u>	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	C13	BARBER et al.,1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	
	<b></b>	Cell. Biol. 14(10):6506-6514	
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	
	<b> </b>	function relationships," J. Biol. Chem. 272(8):4985-4992	
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	
	<del> </del>	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	
	ļ	traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	
<del> </del>	L	12.	
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
		prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain." Biochem Biophys Res	
	L	Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	_
		artery occulsion in rats," Brain Research, Vol. 739:88-96	
	C20	BENIT et al., 1993, "The 'WS motif common to v-mpl and members of the cytokine recentor superfamily is	
	L	dispensable for myeloproliferative leukemia virus pathogenicity." Oncogene 8787-790	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 8 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

10/573,905

ART UNIT

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(lealed a serve felt and a C. CARVITAL I EXTERNOL THE SERVE III	T
muais		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	17
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	T
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	T
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
···	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

Sheet 9 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials	<del></del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With	
	<del></del> -	Erythrocytosis," Blood, 81(6):1593-1597.	$oldsymbol{\perp}$
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat	1
	-	model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	$\perp$
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding	
	-	to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	┸
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci.,	1
		149:40-45.	
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-	
		241	
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	Т
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure:	╁
	C40	angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	1
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through	╄
	(47	separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res,	╀
	C48	Vol. 81, pp. 29-42	i
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil.,	╀
	1 (49	65:370-374.	
	CEO	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a	<b>├</b>
	C50	Reduced Pressure," Nature, 191:1065-1067.	
·	1051	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante,	╀
	C51	35:751-760.	
	050	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of	⊢
	C52	Erythropoietin, Annals New York Acad. Sci., 149:12-17.	l
	+	CUMINGLA Motor 1 1080 SHEEt and Line 1 1080 SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SHEET AND SH	<u> </u>
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-	
	<del>↓</del>	scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the	
		mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	_
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors:	
	<del>                                     </del>	insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by	ŀ
	ŀ	expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest.	
	<u> </u>	102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the	
		cell surface," Nature, Vol. 415, pp. 175-179	
	C58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and	
		neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest.	
		86(3):681-687	

<b>EXAMINER</b>
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 10 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	1		T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
_	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	
-	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	

EXAMIN	ŁR.
NYI-408871	19v2

^{*}ENAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 11 of 26 of List of References

APPLICATION NO.

1647

## LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Indiana Charles Capital I ETTERS) Till Die Deiler Des Est	
Initials	C81	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)   EMIR, 2004, "Erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury,"   Transplantation Proceedings, Vol. 36, pp. 2935-2938	T
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org. July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	T
,	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	1
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10	
•	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.	
10165-042-999	10/573,905	
APPLICANT		
Coleman et al.		
FILING DATE	ARTUNIT	
May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include completely makes (in CADITAL LETTERS). Title Date Butters Butters Butters	
muais		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C102		
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711 GENBANK No. M59941, 1994	-
	C103	GENBANK No. M39941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	
		Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,	$\vdash$
		Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	COLDUIT CODD	1
	0.00	Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	
	C107		T
	`.,,	323.	
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances	T
	03	neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental	H
	10.07	spinal cord injury," PNAS, Vol. 102(45):16379-84	ļ
	C110	GD + GGO + 1 - GGO - //D - GT + 1 - GG G	
	10110	rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	
	CIII	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	-
		clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	┢
	C112	therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating	-
	10113	bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	-
	C114	Kidney Intl. 38:480-486	
	CILE	CD V A C . L COCC (VVID C L L L L L L L L L L L L L L L L L L	-
	C115	degeneration," Nature Medicine, Vol. 8(7):718-724	
<del></del>		GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta.	
	C116	1592:215-223	
		GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	
	C117	antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
		GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	
	C118	granule cells," Toxicological Sciences, Vol. 64:83-89	
	<del> </del>		_
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II.	
<del></del>	+	Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	
	<del> </del> -	receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	
	ļ	Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 13 of 26 of List of References

APPLICATION NO.

1647

	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		
	Coleman et al.		
	FILING DATE	ART UNIT	

ATTY, DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(I. I. I. C. CADITAL LETTERS) Title Date Particular Pages (Inc.)	Т
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	+-
	<b>_</b>		1
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain	
	<u> </u>	expressed in Escherichia coli," J. Biol. Chem. 267(21):15205-15209	+
	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	G100	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a	╁
	C125	specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database,	+
	C126	FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human	t
	10127	megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit	╁
	1 (129	and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	İ
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction	
	10130	with recombinant human EPO", Am. J. Physiol. 262:F737-F743	1
CI31	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin	
		in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
· · · · · · · · · · · · · · · · · · ·	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal	ı
	_	fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	╄
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes:	
		pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	┼
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in	
	j	ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun.	-
		188(1):352-357 IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem.,	╁┈
	C135	194:457-462.	1
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients,"	1
	C136	Nephron, Vol. 72, pp. 30-36	1
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family,"	T
	(137	Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human	Т
	(3.130	granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires	1
		the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	$\perp$
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces	
		infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol.	
		139:173-179	↓
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood	}
	1	76(1):31-35	1

EXAMINER
EXAMINER NYI-4088719v2

Sheet 14 of 26 of List of References

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Т
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgens our receipt C-U.	+
		delivery of authovital vectors to mouse liver and ling "Hum Gene Ther 7/12)-1555 66	1
	C142	JOSSE et al., 1999, "Tryptopnan residue(s) as major components of the human serum paragyonase active site."	+
		Chem Dioi interact, voi. 119-120:79-84	1
	C143	JOSSE et al., 1999, "Human serum paraoxanase (PONI): Identification of essential amino acid residues by	+
		1 Stoup Scientiff and Sile-directed militagenesis "Them Riol Interest Vol. 110 120.71 70	ı
	C144	JUDINON I Ct al., 1990. The Deta C component of the granulocyte-macrophogo colony stimulating C. A. (O) 4	+
	l l	Col // intericular 5 (1L-5)/1L-5 receptor interacts with a hybrid GM-CSF/erythronoistin recenter to the first	١
		promeration and deta-globin mixing expression." Mol. Med. 2(6)-766-773	l
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 recentor functionally associates with the	╀
<del></del>		crymopoleum receptor,   Diood 30(2);   XP/-1X/(	l
	C146	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute inchamic reprofession	t
		111111 1 100. Nati. Acad. 301. USA 99(16):10639-10664	١
	C147	JUUL et al., 1998, "Erythropoietin and erythropoietin recentor in the developing human central newspapers."	┞
	.l	System   Pediatr   Res. 43(1):4()=49	ı
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	H
	<b>_</b>	retus, carry riunian Devel, 32131233-749	l
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	H
		sheep, soc. for Neuroscience Abstracts 2/(1):929 (31st Annual Meeting of the Society for Neuroscience, Sen. 1	
	ļ	Diego, CA 1404, 10-13, 2001)	
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	-
	ļ	duringe, Acta i actuall, 3000, v(), 43x nn (6.4)	
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate	-
	<b> </b>	of a vietn and a monocional antibody to the transferrin recentor "Thing Metab Dispos. Vol. 22(1).00, 105	
	C152	NA WASAKI et al., 2001, Structural analysis of sulfated N-linked oligosaccharidas in another mainting	-
	L	Glycoolology, vol. 11(12):1043-1049	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	_
	ļļ	merupy of near family-induced initial replication 1 irollation 100-1705 1707	
	C154	NEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards of Englishment Standards	
		1 OTK 11 Cdd. 3C1., 177,10-24.	
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"	_
		7 mm. 14earon, 401, 50(0),815-820	
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3	-
		4017411011, D1004 77(1), 1(/2+1)()	
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	
	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and beautiful and	
	C159 L	KITANIONA Ct al., 1969. Identification and analysis of human grythropolatin recent and the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state	_
		line. TF-1." Blood. Vol 73(2):375-80	

<b>EXAMINER</b>
NYI-4088719v2

DATE CONSIDERED

Sheet 15 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	1
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		
	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C160		
	<del>-</del>	Obstetrics and Gynecology, 96(5):826-828.	╁
	C161 KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinerg		
		neurons in vitro and in vivo", Brain Res. 609:29-35	+
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic	
	<del>-  </del>	mechanism.", Behav. Neural Biol. 62:237-243  GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in	╁
	C163	patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	<del></del>	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following	+
	C164	neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	1
	6145	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle	+-
	C165	cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	CICC	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional	t
	C166	asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive	1
	(107	and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J.	
		Cardiovasc. Pharmacol. 31(4):601-608	
	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A.	1
	100	95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol.	T
	0.07	305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol.	Π
		93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid	
		progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	$\perp$
	C172	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human	
		fetuses", Pediatr. Res. 40(3):376-380	$\perp$
	C173	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing	
		various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	1
	C174	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund,	1
		http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	╄
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked	
		glycans," Anal. Biochem. 219:207-217	₩
	C176	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain	
		Res. 692:143-153	↓_
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the	
		Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol.	1
		166:159-169	$\vdash$
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct	
		hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	1

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 16 of 26 of List of References

1647

APPLICATION NO.

### LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
initiais	C180	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	†
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	1	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
-·	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	
	C198		
	C199		
	C200	A CENTRE CONTROL AND A CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF THE CONTROL OF TH	

<b>EXAMINER</b>
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 17 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Vol. 51:220-222	Т
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	ļ
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26 th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

<b>EXAMINER</b>	
NYI-4088719v2	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 18 of 26 of List of References

### LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al.

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Include come of the earth of CADITAL LETTERS) Title Date Regions Recognition	Т
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	-
	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	
	C222	OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	ļ
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332	
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website <a href="http://cancerweb.ncl.ac.uk/omd">http://cancerweb.ncl.ac.uk/omd</a> . Published at the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB Project.	
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69	
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	
·	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92.	
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti- carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773	
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980	
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260(5 Pt 2): H1406-1414	
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131	

EXAMINER NYI-4088719v2	DATE CONSIDERED	
	1	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 19 of 26 of List of References

APPLICATION NO.

1647

### LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T_
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C240	PHYSICIANS' DESK REFERENCE, 1995, 49th Edition (Medical Economics Data Production Company,	
<del></del>	<del>-</del>	Montvale, NJ), pp.1765-1769	-
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone- related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
	C247		
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
·	C252	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
/= N	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER NYI-4088719v2	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 20 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Τ
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C259		
		ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	L
	C260	74(1):103-109	İ
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262	0.0000000000000000000000000000000000000	
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464	
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	Ī
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29	
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	
	C274	STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C276	STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	-
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J. of Clinical Investigation, Vol. 35, pp. 711-717	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 21 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C279	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral	
	<del></del>	blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	1
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535	1
	C282		-
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516	T
	C284	07.100	T
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in	┼┈
	C283	vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	[ m. v v. c. v c	╄
	C280	81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood	┼
	0207	flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on	$\vdash$
	0200	chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys.	$\vdash$
	10207	Res. Commun. 148(1):443-448	
	C290		
		Press Medicale, Vol. 31(11):505-514 (Abstract only)	
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced	-
	C292	anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- $\beta$ Immunoreactivity and microglia are enhanced in the rat hippocampus	
		by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol 19(12):5054-65	
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures	$\vdash$
		but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological	
		assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	İ
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein I (bone	
		morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," Blut, 44:173-175.	
	<del> </del>	WELLS 1000 "Additivity of mutational officers in a series " P. 1 1 1 2027 2027	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	

EXAMINE	₹
NYI-4088719v	/2

**DATE CONSIDERED** 

Sheet 22 of 26 of List of References

APPLICATION NO.

### LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al.

FILING DATE ART UNIT May 30, 2006 1647

ATTY. DOCKET NO.

NON PATENT LITERATURE DOCUMENTS				
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T	
intiais	C299	WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	+	
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	1	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	T	
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	T	
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	1	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30		
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42		
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958		
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485		
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509		
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83		
-	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	T	
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194		
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500		
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	I	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	ľ	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	T	
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	T	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	T	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	T	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	Ť	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 23 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) Oncologist 1(5):337-339	Т	
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7		
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51		
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7		
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002		
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002		
···	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002		
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003		
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	1	
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	1	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	T	
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	T	
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	1	
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	T	
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002		
····	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003		
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004		
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	†	
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	<u> </u>	
<del> </del>	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	1	
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	$\top$	
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	T	
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	+	
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	+	
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	+-	
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	+	
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	+	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 24 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

<u> </u>	
ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
Tititais	C346	Office Action, Application No. 09/716,963, date mailed: March 18, 2005	
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
· · · · · · · · · · · · · · · · · · ·	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
-	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	

EXAMINER
NY1-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 25 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include normal of the market (in CADITAL LETTERS). Title Date Date on Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of Date of	T	
muais	C374	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Office Action, Application No. 09/717,053, date mailed: May 3, 2005	Т	
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	+	
	C376		+	
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	+	
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	+	
	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	+	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	<del> </del>	
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	+	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	+-	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	+-	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	+	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	$\dagger$	
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	╁╌	
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	+	
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	+-	
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	╁╌	
• .	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	╁	
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	$\vdash$	
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	+-	
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	+	
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	†	
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	$\top$	
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	†	
·	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007		
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007		
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL		
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	Ī	

EXAMINER
NYI-4088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 26 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T	
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912		
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008		

EXAMINER NYI-4088719v2

Sheet 1 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE
May 30, 2006

ART UNIT

1647

JUL 2 9 2008

#### **U.S. PATENT DOCUMENTS** PAGES, COLUMNS, LINES, WHERE *EXAMINER RELEVANT PASSAGES OR RELEVANT INITIAL DOCUMENT NUMBER DATE NAME FIGURES APPEAR 8/10/982 4,343,782 A01 Shapiro 4,377,513 03/22/83 A02 Sugimoto et al. 4,658,019 04/14/87 Kung et al. A03 4,703,008 10/27/87 Lin A04 4,806,524 02/21/89 Kawaguchi et al. A05 4,835,260 05/30/89 Shoemaker A06 4,992,419 2/12/91 Woog et al. A07 5,194,596 3/16/93 Tischer et al A08 5,278,065 6/11/94 D'Andrea A09 5,292,654 3/08/94 Yoshimura A10 5,350,836 9/27/94 Kopchick et al. ALL 5,457,089 10/10/95 Fibi et al. A12 5,547,933 08/20/96 Lin Λ13-5,571,787 11/05/96 O'Brien et al. A14 5,604,198 2/18/97 Poduslo et al. A15 03/25/97 5,614,184 Sytkowski et al. Å16 5,618,698 04/08/97 Lin A17 5,621,080 04/15/97 A18 Lin 5,625,035 04/29/97 Clemons λ19 5,661,125 08/26/97 Strickland Λ20 O' Brien 5,696,080 12/09/97 Λ21 5,700,909 12/23/97 O'Brien ΛŻŹ 5,714,459 02/03/98 O'Brien A23 5,750,376 5/12/98 Weiss et al. A24 5,756,349 05/26/98 Lin Λ25 5,763,198 6/09/98 Hirth et al A26 5,767,078 06/16/98 Johnson et al. Λ27

EXAMINER NYI-4088719v2

**DATE CONSIDERED** 

Sheet 2 of 26 of List of References

APPLICATION NO.

1647

### LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) APPLICANT Coleman et al. FILING DATE ART UNIT

ATTY. DOCKET NO.

May 30, 2006

			U.S. P	ATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A28	5,773,569	06/30/98	Wrighton et al.	
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
.=-	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	A46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	Λ48	6,531,121	3/11/03	Brines et al.	
	Λ49	6,583,272	6/24/03	Bailon	
	Λ50	6,645,522	11/11/03	Naeff et al.	
<u> </u>	A51	7,214,532	5/08/07	Stern et al.	
	Λ52	7,309,687	12/18/07	Brines et al.	
	A53	7,345.019	3/18/08	Brines et al.	
	Λ54	2002/0031806	3/14/02	Lee	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 3 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

			U.S. P	ATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A55	2002/0052309	5/02/02	Anagnostou et al.	FIGURES AFFEAR
	Λ56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	A72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	A74	2004/0009902	1/15/04	Boime	
	Λ75	2004/0018978	1/29/04	Campana et al.	
	A76	2004/0091961	5/13/04	Evans et al.	
	Λ77	2004/0096447	5/20/04	Yasuda et al.	
	Α78	2004/0122216	6/24/04	Nielsen et al.	
	Λ79	2004/0209812	10/21/04	Farrell et al.	
	A80	2004/0214236	10/28/04	Brines et al.	
	Α81	2005/0176627	8/11/05	Cerami et al.	

EXAM	IN	ER
NYI-408	87	19v2

**DATE CONSIDERED** 

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
TIEING BRIE	711(1 0141)
May 30, 2006	1647

	U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
	A82	2006/0034799	2/16/06	Brines et al.		
	A83	2006/0216757	9/28/06	Brines et al.		
	A84	2007/0298031	12/27/07	Brines et al.		
	A85	2008/0045412	02/21/08	Brines et al.		
	A86	09/290,938	4/13/99	Brines et al		
	A87	09/547,220	4/11/00	Brines et al.		
	A88	09/718,829	11/21/00	Brines et al.		
	A89	09/716,963	11/21/00	Brines et al.		
	A90	09/716,960	11/21/00	Brines et al.		
	A91	10/554,517	10/25/05	Brines et al.		
	A92	11/283,024	11/18/05	Cerami et al.		
	A93	11/631,458	7/01/05	Brines et al.		
	A94	11/880,275	7/19/07	Brines et al.		

	FOREIGN PATENT DOCUMENTS						
		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	Т	
1	B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh			
1	B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)			
1	B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.			
1	B04	EP 0640619	1/03/95	Amgen Inc.			
1	B05	EP 0668 351	8/23/95	Amgen, Inc.			
1	B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG			
I	B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)			
I	B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)			

EXAMIN	ER
NYI-40887	19v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

APPLICATION NO.

APPLICATION NO.

10/573,905

ART UNIT

1647

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B09	WO 00/032772	6/8/00	Eli Lilly & Co.	RELEVANT FIGURES AFFEAR	H
B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		
B11	WO 00/24893	5/4/00	Amgen, Inc.		<del> </del>
B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)		
B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		<del>                                     </del>
B14	WO 01/81405	1/11/01	Amgen Inc.		
B15	WO 01/82952	11/08/01	Action Pharma APS		
B16	WO 01/82953	11/08/01	Action Pharma APS		
B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		
B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		
B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		
B20	WO 02/14356	2/21/02	Althoff, Claudia		
B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		
B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		
B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
· B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		
B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		
B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
B32	WO 06/002646	1/12/06	Lundbeck A/S		
В33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute. Inc., et al.	/	

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 6 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		FOREIG	N PATENT DOCUMENTS		
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S		
B35	WO 91/05867	5/02/91	Amgen Inc.		Γ
B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		Г
B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		
B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		T
B39	WO 95/05465	02/23/95	Amgen, Inc.		r
B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		H
B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.		H
B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		Ī
B43	WO 97/32895	9/12/97	Regents of the University of California		Γ
B44	WO 98/10650	3/19/98	East Carolina University		Γ
B45	WO 98/18926	05/07/98	G.D. Searle & Co.		Γ
B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		_
B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		-
B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		
B50	WO 93/25221	12/23/93	Alkerms Controlled Therapeutics		_
B51	WO 91/09955	7/11/91	Applied Research Systens, ARS Holding MV	· · · · · · · · · · · · · · · · · · ·	_
B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		_
B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		_
B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		_
B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		_
B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		
		11			

<b>EXAMINER</b>
NYI-4088719v2

Sheet 7 of 26 of List of References

1647

## LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE ART UNIT

May 30, 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner			
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of	
		claims, and Ehrenreich clean copy of claims (10/02/06)	_
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an	
		myocardial ischemia," Shock, Vol. 22(1), pp 63-69	ļ
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of	
		experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	<u> </u>
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant	
-		alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following	
		Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	ـــ
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc.	İ
	+	Natl. Acad. Sci. USA 91:3974-3978  ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary,	⊢
	C07		
	-	for Bioassay," Bull. Org. mond. Sante, 47:99-112.  ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie	-
	C08		
	+	der Demenz," Arzneiverordrung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)  ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated	├-
	C09	Glycoproteins," Meth. Enzymol., 50:287-291.	
		AY et al., 1999, "Potential usefullness of basic fibroblast growth factor a a treatment for stroke,"	-
	C10	Cerebrovascular Disease, Vol. 9:131-135	
	1011	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in	-
	CH	premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic	-
	CIZ	activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193	
	C12	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol.	-
	C13	Cell. Biol. 14(10):6506-6514	
-	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-	_
	C14	function relationships," J. Biol. Chem. 272(8):4985-4992	ŀ
	C15	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in	
	1013	murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood—brain barrier in the cortex and hippocampus after	_
	1010	traumetic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-	_
	1017	12.	
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone,	
	C 18	prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res.	
	1	Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996, "Quantative evaluation of blood-brain barrier permeability following middle cerebral	
	1019	artery occulsion in rats," Brain Research, Vol. 739:88-96	
	(:20	BENIT et al., 1993, "The 'WS motif' common to <i>v-mpl</i> and members of the cytokine receptor superfamily is	
	C20	dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	

EXAMINER	
NYI-4088719v2	
}	

DATE CONSIDERED

Sheet 8 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
Initials	<b>_</b>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-15993	
	C31	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)." J. Biol. Chem. 274(48):33966-33972	
. <del></del>	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER	
NYI-4088719v2	

DATE CONSIDERED

Sheet 9 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	· · · · · · · · · · · · · · · · · · ·
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T	
mitais	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597.		
	C41	BUEMI et al., 2002, "Recombinant human erythropoietein influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417		
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331		
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.		
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241		
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401		
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325		
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58.		
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42		
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.		
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.		
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.		
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.		
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085		
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950		
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243		
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960		
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179		
	C58	DAME et al., 2001, "The biology of crythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35		
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687		

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 10 of 26 of List of References

# ATTY. DOCKET NO. | APPLICATION NO. | 10165-042-999 | 10/573,905 | LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) Coleman et al. | ART UNIT | May 30, 2006 | 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(A. I. I. C. CAPITALI ETTERO) Til D. D. C. D. C.	
Initials	<b>-</b>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	<u> </u>
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immul Methods, Vol. 89:271-277	
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolne and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAOLO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	-
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.	Ì
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	Γ

EXAMINE	R
NYI-4088719	v2

**DATE CONSIDERED** 

Sheet 11 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner			T
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	
	G02	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective	╁
	C82	activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury,"	1
	005	www.molmed.org. July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	Τ
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	t
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by	t
	1 000	severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	ļ
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd	T
		Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine,	Π
		path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007,	Γ
	<u> </u>	http://www,FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htp	L
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics,"	
		Curr. Opin. Neurol. 15(4):483-9	L
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl	
	<del>                                     </del>	tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	<del> </del>
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	Ì
	-	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin actionit takes two to tango, but	┝
	C93	how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY	┢
	C94	1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics	┢
	(7)	across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal	
		of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and	
	L	erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of	
		Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal	
	<b>_</b>	transduction," Semin. Immunol. 2:119-128	L
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol.	
		269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 12 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	· · · · · · · · · · · · · · · · · · ·
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			I
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
	C102		
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	L
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer.	T
		Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology,	T
		Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of	T
		Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	l
	C107		1
		323.	-
	C108		T
		neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	COD10 . 1 400	T
		spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in	Г
		rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 998):5627-5631	ĺ
	CHI	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and	Г
		clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP	r
	"	therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating	┢
	0.15	bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin",	
	"	Kidney Intl. 38:480-486	
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal	Н
	(11)	degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim, Biophys, Acta.	
		1592:215-223	
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and	
	"	antithrombotic effects in vivo," J. Biol. Chem. Vol.\ 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar	-
	10110	granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II.	
		Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF	
	10120	receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and	
	[ [ [ ]	Bioengineering, Vol. 16:1069-1079	
	10122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	
	C122	A failed fraceto controlled, phase II, dose-finding study of ARANESP	

EXAMIN	ER
NYI-40887	19v2

**DATE CONSIDERED** 

Sheet 13 of 26 of List of References

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 10/573,905 APPLICANT Coleman et al. FILING DATE May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials	<del></del>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	T
····	<b>↓</b>		<del> </del>
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain	
	+	expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209  HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an	<del> </del>
	C124	erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a	+
	(.123	specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database,	
	]	FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human	
		megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit	†
	(0.2)	and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction	
		with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin	
	ļ	in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	ــــــ
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal	
	-	fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	╄
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
		IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in	
	C134	ELM-1-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun.	
		188(1):352-357	İ
	C135	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem.,	1
	10133	194:457-462.	
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients, "	
		Nephron, Vol. 72, pp. 30-36	İ
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family,"	
		Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human	1
		granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires	
	<del> </del>	the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	<del>                                     </del>
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol.	
		139:173-179	
	GLIG	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood	+
	C140	76(1):31-35	

EXA	MIN	NER
NYI-	40881	719v2

DATE CONSIDERED

Sheet 14 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	T		T_
nitials	<b></b>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C141		
	<u> </u>	delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	╄
	C142		
	<del>.  </del> .	Chem Biol Interact, Vol. 119-120:79-84	1
	C143	JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino acid residues by	
	<u> </u>	group-selective labelling and site-directed mutagenesis," Chem Biol Interact, Vol. 119-120:71-78	+-
	C144		
		CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence	
	<del>                                     </del>	proliferation and beta-globin mRNA expression," Mol. Med. 2(6):766-773	╀
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the	
	+	erythropoietin receptor," Blood 90(5):1867-1873	+
	C146		
	<del> </del>	injury", Proc. Natl. Acad. Sci. USA 99(16):10659-10664	+-
	C147		ł
	+	system", Pediatr. Res. 43(1):40-49	+
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human	1
	<del> </del>	fetus", Early Human Devel. 52(3):235-249	╄
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal	
		sheep", Soc. for Neuroscience Abstracts 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San	
		Diego, CA Nov. 10-15, 2001)	╀
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain	1
	+	damage," Acta Paediatr. Supp. Vol. 438, pp. 36-42	╀
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate	
	<del>                                     </del>	of avidin and a monoclonal antibody to the transferrin receptor," Drug Metab Dispos. Vol. 22(1):99-105	╁
	C152	KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin,"	
	<del> </del>	Glycobiology, Vol. 11(12):1043-1049	╀
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the	
	-	therapy of heart failure-induced mitral regurgitation. Circulation 108:1795-1797	╀
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New	
	-	York Acad. Sci., 149:18-24.	╀
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration,"	
	<del> </del>	Ann. Neurol. Vol. 56(6):815-826	⊢
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3	l
	-	activation," Blood 99(1):102-110	┞
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver,"	
	<del> </del>	Am J Anat. Vol. 178:241-9.	$\vdash$
	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant crythropoietin and cepharanthin in a girl	
	<u> </u>	with refractory anemia," Japanese J. Clin. Hematology, Vol. 35(7):694-6988 (w/English abstract)	ــــ
	C159	KITAMURA et al., 1989, "Identification and analysis of human crythropoietin receptors on a factor-dependent cell line, TF-1," Blood, Vol 73(2):375-80	l

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 15 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.	<del></del>	
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

		NON PATENT LITERATURE DOCUMENTS	
xaminer	T	(I I I I CA CA CADITAL I ETTERS) Till Des Business Press Press	T
nitials	C160	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis,"	T
		Obstetrics and Gynecology, 96(5):826-828.	
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo", Brain Res. 609:29-35	
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	<del> </del>
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle cerebral artery occlusion," Acta Neurophotalogica, Vol. 68:122-129	
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31(4):601-608	
	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A. 95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol. 305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol. 93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32:36-44	
	C172	Ll et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40(3):376-380	
	C173	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	C174	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund, http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," Anal. Biochem. 219:207-217	
	C176	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454	T

EXAMINER NYI-4088719v2  DATE CONSIDERED	EXAMINER NYI-4088719v2	DATE CONSIDERED
-----------------------------------------	---------------------------	-----------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 16 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner	I		
Initials	ļ	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C180	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	
	C181	Blood, Vol. 110(7):2408-2413	
	C182	activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll. Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 17 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ł				
ATTY. DOCKET NO.	APPLICATION NO.			
10165-042-999	10/573,905			
APPLICANT				
Coleman et al.				
FILING DATE	ART UNIT			
May 30, 2006	1647			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Vol. 51:220-222	Т
<del> </del>	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	Π
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid- Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26 th ed. pp. 524-526, McGraw-Hill Co., .	$\vdash$
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	_
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
·	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethrane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoeitin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
*	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

EXAMIN	ER
NYI-40887	19v2

DATE CONSIDERED

Sheet 18 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Т
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Ľ
	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	
	C222	OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332	T
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website <a href="http://cancerweb.ncl.ac.uk/omd">http://cancerweb.ncl.ac.uk/omd</a> . Published at the Dept. of Medical Oncology, University of Newcastle upon Type. Copyright 1997-2004. The CancerWEB Project.	
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	T
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69	T
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	T
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92.	T
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	T
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti- carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773	
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980	
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-34	
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260(5 Pt 2): H1406-1414	
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131	

EXAMIN	ER
NYI-40887	19v2

**DATE CONSIDERED** 

Sheet 19 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
mitiais	C240	the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone- related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717- 720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352	
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
	C247	Pharmaceutical Design, Vol. 9, pp. 1-8	
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
	C252	DOOR ID A LINE A LINE OF A CONTROL OF A LINE AND A CONTROL OF A LINE AND A CONTROL OF A LINE AND A CONTROL OF A LINE AND A CONTROL OF A LINE AND A CONTROL OF A LINE AND A CONTROL OF A LINE AND A CONTROL OF A LINE AND A CONTROL OF A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A LINE AND A	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER NYI-4088719v2
NYI-4088719v2

DATE CONSIDERED

Sheet 20 of 26 of List of References

# ATTY. DOCKET NO. | APPLICATION NO. | 10165-042-999 | 10/573,905 | LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) Coleman et al. | FILING DATE | ART UNIT | May 30, 2006 | 1647 |

		NON PATENT LITERATURE DOCUMENTS	
Examiner			Ī_
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C259	SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives	
		ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	L
	C260	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262	SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift für Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only)	
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464	
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin- dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29	
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	T
	C274	STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C276	STORRING et al.,1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J. of Clinical Investigation, Vol. 35, pp. 711-717	

EXAMINER NYI-4088719v2
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 21 of 26 of List of References

## LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. 10165-042-999 APPLICANT Coleman et al. FILING DATE May 30, 2006 APPLICATION NO. 10/573,905 APPLICANT Coleman et al.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
initials	C279	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neurophatologica (Berl), Vol. 60:207-216	
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535	
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448	
	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale, Vol. 31(11):505-514 (Abstract only)	
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- $\beta$ Immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol 19(12):5054-65	
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	1
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," Blut, 44:173-175.	
<del></del>	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	Ī

EXAMINER NYI-4088719v2	DATE CONSIDERED

Sheet 22 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

	NON PATENT LITERATURE DOCUMENTS				
Examiner	T		Τ		
nitials		(Include name of the author (in CAPITAL LETTERS). Title, Date, Pertinent Pages, Etc.)  WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	T		
	C299				
	C300	receptors", Kidney Intl. 55:808-820			
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70			
·	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244			
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	Ť		
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30			
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-1-42			
	C306				
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485			
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509			
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83			
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259			
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194			
	C312	11.1.1.11	T		
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915			
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665			
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38			
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719			
·	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826			
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063			
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"			

EX.	AM	IN	ER
NYI	-408	387	19v2

**DATE CONSIDERED** 

Sheet 23 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 10165-042-999 10/573,905

APPLICANT

Coleman et al.

FILING DATE ART UNIT

May 30, 2006 1647

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Oncologist 1(5):337-339	T
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	T
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	Γ
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	T
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	Γ
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	T
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	T
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	T
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	T
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	T
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	T
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	T
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	T
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	T
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	T
· · · · · · · · · · · · · · · · · · ·	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	T
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	T
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	T
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	T
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	T
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	T
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	T
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	$\vdash$
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	$\vdash$
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	H

<b>EXAMINER</b>
NYI-1088719v2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 24 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

APPLICATION NO.

10/573,905

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Ť
mittuis	C346	Office Action, Application No. 09/716,963, date mailed: March 18, 2005	
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C356	Office Action, Application No. 09/716,960, date mailed: February 1,2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
·	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
****	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	

EXAM	IN	ER
NYI-408	387	19v2

**DATE CONSIDERED** 

Sheet 25 of 26 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10165-042-999	10/573,905
APPLICANT	
Coleman et al.	
FILING DATE	ART UNIT
May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS			
Examiner		(Include name of the outbox (in CADITAL LETTEDS) Title Date Destinant Bases Etc.)	Т
Initials	C374	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  Office Action, Application No. 09/717,053, date mailed: May 3, 2005	+-
·	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	╁
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	+
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	╁╌
·	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	+
	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	╁
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	+
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	$\vdash$
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	$\vdash$
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	十
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	T
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	-
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	+
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	-
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	ļ
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	$\vdash$
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	-
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	$\vdash$
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	$\vdash$
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	$\vdash$
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	$\vdash$
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	$\vdash$
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	$t^-$
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	<del>                                     </del>
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

EXAMINER
NYI-4088719v2

**DATE CONSIDERED** 

Sheet 26 of 26 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	10165-042-999	10/573,905	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Coleman et al.		
	FILING DATE	ART UNIT	
	May 30, 2006	1647	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912		
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008		

EXAMINER NYI-4088719v2